<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523416300897</prism:url><dc:identifier>doi:10.1016/j.ejmech.2016.02.018</dc:identifier><eid>1-s2.0-S0223523416300897</eid><prism:doi>10.1016/j.ejmech.2016.02.018</prism:doi><pii>S0223-5234(16)30089-7</pii><dc:title>Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>02235234</prism:issn><prism:volume>112</prism:volume><prism:startingPage>298</prism:startingpage><prism:endingPage>346</prism:endingpage><prism:pageRange>298-346</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2016-04-13</prism:coverdate><prism:coverDisplayDate>13 April 2016</prism:coverdisplaydate><prism:copyright>Copyright Â© 2016 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Sharma, Sahil</dc:creator><dc:creator>Singh, Jagjeet</dc:creator><dc:creator>Ojha, Ritu</dc:creator><dc:creator>Singh, Harbinder</dc:creator><dc:creator>Kaur, Manpreet</dc:creator><dc:creator>Bedi, P.M.S.</dc:creator><dc:creator>Nepali, Kunal</dc:creator><dc:description>
                  Kinases control a diverse set of cellular processes comprising of reversible phosphorylation of proteins. Protein kinases play a pivotal role in human tumor cell proliferation, migration and survival of neoplasia. In the recent past, purine based molecules have emerged as significantly potent kinase inhibitors. In view of their promising potential for the inhibition of kinases, this review article focuses on purines which have progressed as kinase inhibitors during the last five years. A detailed account of the design strategies employed for the synthesis of purine analogs exerting inhibitory effects on diverse kinases has been presented. Apart from presenting the design strategies, the article also highlights the structure activity relationship along with mechanistic insights revealed during the biological evaluation of the purine analogs for kinase inhibition. The interactions with the amino acid residues responsible for kinase inhibitory potential of purine based molecules have also been discussed. In this assemblage, purine based protein kinase inhibitors patented in the past have also been summarized in the tabular form. This compilation will be of great interest for the researchers working in the area of protein kinase inhibitors.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Purine</dcterms:subject><dcterms:subject>Cancer</dcterms:subject><dcterms:subject>Kinases</dcterms:subject><dcterms:subject>Cell lines</dcterms:subject><dcterms:subject>Structure activity relationship</dcterms:subject><dcterms:subject>Design strategies</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523416300897" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523416300897" rel="scidir"/></link></coredata><objects><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="187" height="164" size="20769">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="146" height="164" size="10475">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="151" height="164" size="11237">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="183" height="163" size="10830">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="199" height="164" size="9900">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="208" height="164" size="9967">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="211" height="164" size="9570">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="fx16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="151" size="9498">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx16.sml?httpAccept=%2A%2F%2A</object><object ref="fx17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="146" size="9634">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx17.sml?httpAccept=%2A%2F%2A</object><object ref="fx18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="207" height="164" size="11515">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx18.sml?httpAccept=%2A%2F%2A</object><object ref="fx19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="199" height="164" size="12096">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx19.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="149" height="164" size="10120">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="206" height="164" size="10810">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx20.sml?httpAccept=%2A%2F%2A</object><object ref="fx21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="140" size="10243">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx21.sml?httpAccept=%2A%2F%2A</object><object ref="fx22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="203" height="164" size="11350">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx22.sml?httpAccept=%2A%2F%2A</object><object ref="fx23" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="111" height="164" size="10197">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx23.sml?httpAccept=%2A%2F%2A</object><object ref="fx24" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="134" height="163" size="10901">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx24.sml?httpAccept=%2A%2F%2A</object><object ref="fx25" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="83" height="162" size="7863">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx25.sml?httpAccept=%2A%2F%2A</object><object ref="fx26" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="141" height="163" size="11263">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx26.sml?httpAccept=%2A%2F%2A</object><object ref="fx27" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="131" height="163" size="10757">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx27.sml?httpAccept=%2A%2F%2A</object><object ref="fx28" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="148" size="9778">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx28.sml?httpAccept=%2A%2F%2A</object><object ref="fx29" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="148" size="9802">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx29.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="128" height="164" size="10075">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="fx30" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="138" size="9564">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx30.sml?httpAccept=%2A%2F%2A</object><object ref="fx31" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="139" size="9671">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx31.sml?httpAccept=%2A%2F%2A</object><object ref="fx32" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="203" height="164" size="10114">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx32.sml?httpAccept=%2A%2F%2A</object><object ref="fx33" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="146" size="9946">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx33.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="148" height="164" size="10999">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="148" height="164" size="11235">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="128" height="164" size="10283">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="145" height="164" size="11532">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="178" height="164" size="10350">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="183" height="164" size="10303">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="211" height="164" size="14189">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="103" size="10966">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="gr12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="114" height="164" size="20333">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr12.sml?httpAccept=%2A%2F%2A</object><object ref="gr13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="102" height="164" size="10604">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr13.sml?httpAccept=%2A%2F%2A</object><object ref="gr14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="217" height="164" size="10910">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr14.sml?httpAccept=%2A%2F%2A</object><object ref="gr15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="122" height="163" size="8787">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr15.sml?httpAccept=%2A%2F%2A</object><object ref="gr16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="187" height="164" size="13523">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr16.sml?httpAccept=%2A%2F%2A</object><object ref="gr17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="158" height="164" size="16518">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr17.sml?httpAccept=%2A%2F%2A</object><object ref="gr18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="129" height="163" size="12413">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr18.sml?httpAccept=%2A%2F%2A</object><object ref="gr19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="156" height="164" size="15890">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr19.sml?httpAccept=%2A%2F%2A</object><object ref="gr1a" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="133" height="164" size="13973">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr1a.sml?httpAccept=%2A%2F%2A</object><object ref="gr1b" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="138" height="163" size="14286">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr1b.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="200" height="164" size="11683">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="146" height="164" size="12209">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr20.sml?httpAccept=%2A%2F%2A</object><object ref="gr21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="114" height="164" size="11707">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr21.sml?httpAccept=%2A%2F%2A</object><object ref="gr22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="180" height="163" size="13784">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr22.sml?httpAccept=%2A%2F%2A</object><object ref="gr23" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="101" height="164" size="13084">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr23.sml?httpAccept=%2A%2F%2A</object><object ref="gr24" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="126" height="164" size="12464">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr24.sml?httpAccept=%2A%2F%2A</object><object ref="gr25" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="164" size="17170">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr25.sml?httpAccept=%2A%2F%2A</object><object ref="gr26" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="121" size="11234">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr26.sml?httpAccept=%2A%2F%2A</object><object ref="gr27" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="176" height="163" size="11952">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr27.sml?httpAccept=%2A%2F%2A</object><object ref="gr28" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="138" size="14775">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr28.sml?httpAccept=%2A%2F%2A</object><object ref="gr29" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="105" height="163" size="11065">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr29.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="164" size="14106">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr30" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="122" size="9506">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr30.sml?httpAccept=%2A%2F%2A</object><object ref="gr31" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="123" height="163" size="12557">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr31.sml?httpAccept=%2A%2F%2A</object><object ref="gr32" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="139" height="164" size="14759">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr32.sml?httpAccept=%2A%2F%2A</object><object ref="gr33" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="137" height="163" size="13976">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr33.sml?httpAccept=%2A%2F%2A</object><object ref="gr34" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="206" height="164" size="11766">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr34.sml?httpAccept=%2A%2F%2A</object><object ref="gr35" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="99" height="164" size="8671">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr35.sml?httpAccept=%2A%2F%2A</object><object ref="gr36" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="117" size="13944">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr36.sml?httpAccept=%2A%2F%2A</object><object ref="gr37" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="160" height="164" size="17034">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr37.sml?httpAccept=%2A%2F%2A</object><object ref="gr38" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="164" size="12538">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr38.sml?httpAccept=%2A%2F%2A</object><object ref="gr39" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="114" height="163" size="11652">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr39.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="145" height="163" size="15865">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr40" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="214" height="164" size="16515">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr40.sml?httpAccept=%2A%2F%2A</object><object ref="gr41" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="158" height="164" size="17458">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr41.sml?httpAccept=%2A%2F%2A</object><object ref="gr42" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="126" size="12775">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr42.sml?httpAccept=%2A%2F%2A</object><object ref="gr43" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="135" height="164" size="13446">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr43.sml?httpAccept=%2A%2F%2A</object><object ref="gr44" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="154" size="12415">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr44.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="139" height="164" size="14613">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="154" height="164" size="10481">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="155" size="13990">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="137" height="164" size="15694">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="95" height="164" size="12182">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="280" height="245" size="42312">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="116" height="130" size="32984">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="116" height="126" size="34043">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="122" height="109" size="32461">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="120" size="31337">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="115" size="31475">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="143" height="111" size="30078">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="147" height="101" size="30169">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx16.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="147" height="98" size="30200">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx17.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="140" height="111" size="22703">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx18.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="144" height="119" size="34470">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx19.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="112" height="123" size="32232">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="116" size="32579">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx20.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="94" size="31448">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx21.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="118" size="33351">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx22.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="96" height="142" size="22165">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx23.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="108" height="131" size="33448">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx24.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="96" height="188" size="29933">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx25.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="115" height="133" size="34120">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx26.jpg?httpAccept=%2A%2F%2A</object><object ref="fx27" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="107" height="133" size="33319">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx27.jpg?httpAccept=%2A%2F%2A</object><object ref="fx28" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="99" size="19909">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx28.jpg?httpAccept=%2A%2F%2A</object><object ref="fx29" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="99" size="30621">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx29.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="115" height="147" size="33210">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx30" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="148" height="93" size="30365">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx30.jpg?httpAccept=%2A%2F%2A</object><object ref="fx31" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="147" height="93" size="30430">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx31.jpg?httpAccept=%2A%2F%2A</object><object ref="fx32" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="118" size="31624">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx32.jpg?httpAccept=%2A%2F%2A</object><object ref="fx33" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="97" size="20056">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx33.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="115" height="127" size="34103">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="115" height="127" size="34493">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="115" height="147" size="33550">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="115" height="130" size="34708">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="117" height="108" size="31941">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="117" height="105" size="31571">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="681" height="528" size="107787">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="711" height="336" size="80060">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="495" height="710" size="227026">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr12.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="645" height="1038" size="184361">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr13.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="556" height="420" size="55914">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr14.jpg?httpAccept=%2A%2F%2A</object><object ref="gr15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="542" height="724" size="70248">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr15.jpg?httpAccept=%2A%2F%2A</object><object ref="gr16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="603" size="107617">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr16.jpg?httpAccept=%2A%2F%2A</object><object ref="gr17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="715" size="186087">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr17.jpg?httpAccept=%2A%2F%2A</object><object ref="gr18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="543" height="687" size="98832">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr18.jpg?httpAccept=%2A%2F%2A</object><object ref="gr19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="556" height="583" size="107642">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr19.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1a" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="729" height="899" size="151952">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr1a.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1b" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="782" height="924" size="171214">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr1b.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="550" height="451" size="60315">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="494" height="555" size="81807">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr20.jpg?httpAccept=%2A%2F%2A</object><object ref="gr21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="600" height="864" size="161363">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr21.jpg?httpAccept=%2A%2F%2A</object><object ref="gr22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="625" size="98048">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr22.jpg?httpAccept=%2A%2F%2A</object><object ref="gr23" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="543" height="880" size="167399">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr23.jpg?httpAccept=%2A%2F%2A</object><object ref="gr24" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="752" size="113191">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr24.jpg?httpAccept=%2A%2F%2A</object><object ref="gr25" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="587" height="594" size="133667">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr25.jpg?httpAccept=%2A%2F%2A</object><object ref="gr26" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="779" height="432" size="90385">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr26.jpg?httpAccept=%2A%2F%2A</object><object ref="gr27" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="534" height="496" size="56109">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr27.jpg?httpAccept=%2A%2F%2A</object><object ref="gr28" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="556" height="351" size="77148">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr28.jpg?httpAccept=%2A%2F%2A</object><object ref="gr29" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="436" height="677" size="101099">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr29.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="625" height="632" size="112847">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr30" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="445" height="248" size="36947">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr30.jpg?httpAccept=%2A%2F%2A</object><object ref="gr31" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="493" height="653" size="102969">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr31.jpg?httpAccept=%2A%2F%2A</object><object ref="gr32" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="525" height="619" size="110044">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr32.jpg?httpAccept=%2A%2F%2A</object><object ref="gr33" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="534" height="636" size="123644">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr33.jpg?httpAccept=%2A%2F%2A</object><object ref="gr34" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="756" height="601" size="107236">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr34.jpg?httpAccept=%2A%2F%2A</object><object ref="gr35" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="311" height="515" size="47676">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr35.jpg?httpAccept=%2A%2F%2A</object><object ref="gr36" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="756" height="404" size="95395">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr36.jpg?httpAccept=%2A%2F%2A</object><object ref="gr37" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="494" height="506" size="122768">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr37.jpg?httpAccept=%2A%2F%2A</object><object ref="gr38" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="311" height="236" size="37000">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr38.jpg?httpAccept=%2A%2F%2A</object><object ref="gr39" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="675" height="968" size="151765">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr39.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="567" height="639" size="141078">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr40" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="705" height="539" size="124896">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr40.jpg?httpAccept=%2A%2F%2A</object><object ref="gr41" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="756" height="784" size="188121">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr41.jpg?httpAccept=%2A%2F%2A</object><object ref="gr42" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="579" height="333" size="80649">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr42.jpg?httpAccept=%2A%2F%2A</object><object ref="gr43" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="445" height="541" size="90110">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr43.jpg?httpAccept=%2A%2F%2A</object><object ref="gr44" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="231" height="163" size="27836">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr44.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="541" height="637" size="129091">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="477" height="507" size="49835">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="756" height="536" size="111917">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="602" height="719" size="164758">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="614" height="1057" size="214155">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1239" height="1085" size="198032">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="517" height="579" size="57861">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="514" height="558" size="59781">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="544" height="486" size="54178">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="648" height="533" size="55566">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="648" height="511" size="54238">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="636" height="493" size="51150">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="653" height="449" size="52135">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="654" height="435" size="52482">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="492" size="50099">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="641" height="528" size="66026">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="499" height="550" size="53391">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="650" height="518" size="58751">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="647" height="415" size="54069">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="647" height="522" size="61974">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="429" height="633" size="48288">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx23_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="479" height="583" size="59857">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx24_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="429" height="839" size="56451">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx25_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="512" height="593" size="63263">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx26_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx27" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="476" height="593" size="60245">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx27_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx28" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="650" height="439" size="41983">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx28_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx29" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="650" height="439" size="53068">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx29_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="509" height="651" size="60718">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx30" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="659" height="414" size="52365">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx30_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx31" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="651" height="414" size="52342">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx31_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx32" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="650" height="525" size="56306">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx32_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx33" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="648" height="431" size="42940">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx33_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="509" height="563" size="59371">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="509" height="563" size="60435">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="509" height="651" size="61731">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="509" height="574" size="63029">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="520" height="479" size="51275">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="522" height="468" size="50574">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3015" height="2339" size="743676">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3150" height="1488" size="619632">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2193" height="3147" size="2118108">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2856" height="4594" size="1498597">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2463" height="1860" size="351703">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2402" height="3208" size="490612">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3053" height="2673" size="814387">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3053" height="3169" size="1642399">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2403" height="3040" size="751914">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2462" height="2582" size="842566">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1a" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3229" height="3981" size="1233236">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr1a_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1b" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3463" height="4093" size="1372000">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr1b_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2436" height="1999" size="373059">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2186" height="2457" size="591791">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2659" height="3829" size="1333794">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3051" height="2769" size="729515">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr23" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2403" height="3895" size="1398796">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr23_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr24" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2561" height="3330" size="836340">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr24_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr25" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2600" height="2630" size="1016581">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr25_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr26" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3448" height="1911" size="638569">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr26_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr27" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2364" height="2196" size="338095">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr27_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr28" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2463" height="1557" size="559844">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr28_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr29" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1932" height="2999" size="792347">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr29_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2767" height="2799" size="826384">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr30" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1971" height="1097" size="220375">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr30_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr31" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2185" height="2896" size="752144">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr31_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr32" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2326" height="2743" size="837736">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr32_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr33" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2364" height="2816" size="878666">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr33_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr34" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3348" height="2661" size="853554">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr34_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr35" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1378" height="2283" size="300484">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr35_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr36" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3348" height="1789" size="728833">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr36_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr37" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2188" height="2243" size="890368">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr37_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr38" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1379" height="1046" size="164717">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr38_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr39" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2991" height="4288" size="1247298">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr39_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2510" height="2830" size="1084376">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr40" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3121" height="2385" size="1024428">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr40_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr41" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3349" height="3473" size="1616090">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr41_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr42" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2562" height="1474" size="566048">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr42_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr43" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1971" height="2395" size="616282">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr43_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr44" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1024" height="722" size="100793">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr44_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2395" height="2822" size="1076551">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2115" height="2249" size="299487">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3347" height="2371" size="781593">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2664" height="3181" size="1283894">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2717" height="4677" size="1902290">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416300897-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>84978793212</scopus-id><scopus-eid>2-s2.0-84978793212</scopus-eid><pubmed-id>26907156</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/84978793212" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20160211">2016-02-11</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20160211">2016-02-11</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20160221">2016-02-21</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20160221">2016-02-21</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2019-04-26T21:36:24</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523416300897</xocs:eid>
      <xocs:pii-formatted>S0223-5234(16)30089-7</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523416300897</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2016.02.018</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.4</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523416X00049</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20190427">2019-04-27T02:23:59.33188Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20160413</xocs:date-search-begin>
      <xocs:year-nav>2016</xocs:year-nav>
      <xocs:indexeddate epoch="1455161119">2016-02-11T03:25:19.345995Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body affil appendices articletitle auth authfirstini authfull authkeywords authlast highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>112</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>112</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 112</xocs:vol-iss-suppl-text>
      <xocs:sort-order>3</xocs:sort-order>
      <xocs:first-fp>298</xocs:first-fp>
      <xocs:last-lp>346</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>298</xocs:first-page>
         <xocs:last-page>346</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20160413</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>13 April 2016</xocs:cover-date-text>
      <xocs:cover-date-start>2016-04-13</xocs:cover-date-start>
      <xocs:cover-date-year>2016</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Review articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>Copyright Â© 2016 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DESIGNSTRATEGIESSTRUCTUREACTIVITYRELATIONSHIPMECHANISTICINSIGHTSFORPURINESKINASEINHIBITORS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>SHARMA</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>S</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Tyrosine specific protein kinase inhibitors</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Non-receptor tyrosine kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Receptor associated tyrosine kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Lipid associated tyrosine specific protein kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Other tyrosine specific protein kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Specific protein kinase inhibitors</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Serine/threonine specific protein kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cyclin-dependent specific protein kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Other specific protein kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Dual specificity (tyrosine/specific protein) protein kinase inhibitors</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>5</xocs:item-toc-label>
            <xocs:item-toc-section-title>Miscellaneous kinase inhibitors</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>6</xocs:item-toc-label>
            <xocs:item-toc-section-title>Patent summary</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>7</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-section-title>Index of applied abbreviations and acronyms</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>COHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>309</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>GRANT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1163</xocs:ref-first-fp>
            <xocs:ref-last-lp>1177</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>KNOCKAERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>417</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>DAUB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1001</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>DAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>769</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>NOBLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1800</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>KNIGHT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>621</xocs:ref-first-fp>
            <xocs:ref-last-lp>637</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>MEIJER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>417</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>GRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>533</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>SORBERA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>674</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>153</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>ALIGAYER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>344</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>BELSCHESJABLONSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>1465</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>MACMILLANCROW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>350</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>RUCCI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>342</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>MISSBACH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>541</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>AZAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>9244</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>VERONES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5678</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>MARTIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>467</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>YEATMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>470</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>FINN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1379</xocs:ref-first-fp>
            <xocs:ref-last-lp>1386</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>SUMMY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>337</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>FRAME</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>114</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>SUMMY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1398</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>RUCCI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>342</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>HILBIG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>179</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>BOYCE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>6291</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>LOMBARDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>6658</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>DAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>6819</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>SERRELS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>249</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4743</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>DALGARNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>46</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>3067</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>LEGRAVEREND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>3987</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>CHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>4497</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>4615</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>CHESON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1992</xocs:ref-pub-year>
            <xocs:ref-first-fp>695</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>ELGEMEIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>2627</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>GALMARINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>415</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>DAVIES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>745</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>BURNSTOCK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>58</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>295</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>825</xocs:ref-first-fp>
            <xocs:ref-last-lp>833</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>CHUNG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>1803</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>MANDAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>3</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>SHAHANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>5618</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>MOHAMED</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>58</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>SHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2206</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>CAPPELLEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>18</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>CHESI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>260</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>HERNANDEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>848</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>SONVILLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1145</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>TRAXLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>195</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>LEGRAVEREND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>3987</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>TAKTAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1254</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>ROBINSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>5548</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>LINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>35</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>358</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>CHOI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5439</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>OKRAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>779</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>SUAREZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>VANHAESEBROECK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>535</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>627</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>SAAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>2554</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>SHE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>4340</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>AMERIKS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>738</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>GILBERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>636</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>627</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>YAP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>393</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>BELLACOSA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>29</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>MANNING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1261</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-normalized-surname>ENGELMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>606</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref73">
            <xocs:ref-normalized-surname>HENNESSY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>988</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref74">
            <xocs:ref-normalized-surname>VENKATESAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>653</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref75">
            <xocs:ref-normalized-surname>VANHAESEBROECK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>535</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref76">
            <xocs:ref-normalized-surname>HONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>7212</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref77">
            <xocs:ref-normalized-surname>OBRIEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>3670</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref78">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2508</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref79">
            <xocs:ref-normalized-surname>OKKENHAUG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>270</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref80">
            <xocs:ref-normalized-surname>OKKENHAUG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>317</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref81">
            <xocs:ref-normalized-surname>SADHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>2647</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref82">
            <xocs:ref-normalized-surname>MURRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>7686</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref83">
            <xocs:ref-normalized-surname>ROMMEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>191</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref84">
            <xocs:ref-normalized-surname>HERZOG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>195</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref85">
            <xocs:ref-normalized-surname>ALI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1007</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref86">
            <xocs:ref-normalized-surname>SAFINA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>5887</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref87">
            <xocs:ref-normalized-surname>MURRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>7686</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref88">
            <xocs:ref-normalized-surname>SAFINA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4953</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref89">
            <xocs:ref-normalized-surname>ELION</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1977</xocs:ref-pub-year>
            <xocs:ref-first-fp>5716</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref90">
            <xocs:ref-normalized-surname>BROWN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>876</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref91">
            <xocs:ref-normalized-surname>BENCI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>221</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib92a">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2333</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib92b">
            <xocs:ref-normalized-surname>GAIKWAD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref92">
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>243</xocs:ref-first-fp>
            <xocs:ref-normalized-srctitle>ADISINTERNATIONALLTDERLOTINIBCP358774NSC718781OSI774R1415DRUGSRD4</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref93">
            <xocs:ref-normalized-surname>SMITH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1513</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref94">
            <xocs:ref-normalized-surname>AMINE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1042</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref95">
            <xocs:ref-normalized-surname>BURCHAT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1687</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref96">
            <xocs:ref-normalized-surname>BORHANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>2613</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref97">
            <xocs:ref-normalized-surname>PEAT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>2127</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref98">
            <xocs:ref-normalized-surname>REVESZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>262</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref99">
            <xocs:ref-normalized-surname>ANGELUCCI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>2838</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref100">
            <xocs:ref-normalized-surname>GILBERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>636</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref101">
            <xocs:ref-normalized-surname>CURRAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1440</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref102">
            <xocs:ref-normalized-surname>BAKR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>27</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref103">
            <xocs:ref-normalized-surname>SIEGEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>10</xocs:ref-first-fp>
            <xocs:ref-last-lp>29</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref104">
            <xocs:ref-normalized-surname>KOBAYASHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>786</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref105">
            <xocs:ref-normalized-surname>PAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>73</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref106">
            <xocs:ref-normalized-surname>KWAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>7665</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref107">
            <xocs:ref-normalized-surname>YUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2070</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref108">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>10685</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref109">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>9</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref110">
            <xocs:ref-normalized-surname>BAKAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>32</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref111">
            <xocs:ref-normalized-surname>ULRICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>52</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref112">
            <xocs:ref-normalized-surname>SZEKELY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>225</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref113">
            <xocs:ref-normalized-surname>DONAT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4056</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref114">
            <xocs:ref-normalized-surname>DEBARBOUILLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4070</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref115">
            <xocs:ref-normalized-surname>BELTRAMINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1406</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref116">
            <xocs:ref-normalized-surname>KRISTICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>3508</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref117">
            <xocs:ref-normalized-surname>HONGJIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1351</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref118">
            <xocs:ref-normalized-surname>RAJAGOPAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1329</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref119">
            <xocs:ref-normalized-surname>GILBERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>636</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref120">
            <xocs:ref-normalized-surname>OXOBY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>3486</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref121">
            <xocs:ref-normalized-surname>COHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>479</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref122">
            <xocs:ref-normalized-surname>IBRAHIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>3389</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref123">
            <xocs:ref-normalized-surname>FLAHERTY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>809</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref124">
            <xocs:ref-normalized-surname>SINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>484</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref125">
            <xocs:ref-normalized-surname>TOL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>98</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref126">
            <xocs:ref-normalized-surname>COHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>625</xocs:ref-first-fp>
            <xocs:ref-last-lp>627</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref127">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>5753</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref128">
            <xocs:ref-normalized-surname>FLAHERTY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>809</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref129">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1027</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref130">
            <xocs:ref-normalized-surname>HAUBER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>158</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref131">
            <xocs:ref-normalized-surname>KRENITSKY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1427</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref132">
            <xocs:ref-normalized-surname>KRENITSKY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1433</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref133">
            <xocs:ref-normalized-surname>BOGOYEVITCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>463</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref134">
            <xocs:ref-normalized-surname>SIDDIQUI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>3005</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref135">
            <xocs:ref-normalized-surname>KRENITSKY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1427</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref136">
            <xocs:ref-normalized-surname>CHEONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>465</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref137">
            <xocs:ref-normalized-surname>GALLEGO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>139</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref138">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>4401</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref139">
            <xocs:ref-normalized-surname>KNIPPSCHILD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>675</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref140">
            <xocs:ref-normalized-surname>FLAJOLET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>4159</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref141">
            <xocs:ref-normalized-surname>KNIPPSCHILD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>508</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref142">
            <xocs:ref-normalized-surname>BIBIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4374</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref143">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1487</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref144">
            <xocs:ref-normalized-surname>STAAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1987</xocs:ref-pub-year>
            <xocs:ref-first-fp>5034</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref145">
            <xocs:ref-normalized-surname>CHENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>3636</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref146">
            <xocs:ref-normalized-surname>JOSEPH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>10983</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref147">
            <xocs:ref-normalized-surname>CANTLEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1655</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref148">
            <xocs:ref-normalized-surname>NICHOLSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>381</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref149">
            <xocs:ref-normalized-surname>CHENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>7482</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref150">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>167</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref151">
            <xocs:ref-normalized-surname>MURRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref152">
            <xocs:ref-normalized-surname>MADER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1993</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>CELLBIOLOGY</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref153">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>2134</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref154">
            <xocs:ref-normalized-surname>ALSHAER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>4316</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref155">
            <xocs:ref-normalized-surname>DAVIES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>PLANTHORMONES</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref156">
            <xocs:ref-normalized-surname>MEIJER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>527</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref157">
            <xocs:ref-normalized-surname>BENSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>7</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref158">
            <xocs:ref-normalized-surname>TRAVNICEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>4609</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref159">
            <xocs:ref-normalized-surname>CASTANEDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1716</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref160">
            <xocs:ref-normalized-surname>TANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>2985</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref161">
            <xocs:ref-normalized-surname>SENDEROWICZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>2986</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref162">
            <xocs:ref-normalized-surname>ELGAZWY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>7639</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref163">
            <xocs:ref-normalized-surname>DEHAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>438</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref164">
            <xocs:ref-normalized-surname>MALUMBRES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>630</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref165">
            <xocs:ref-normalized-surname>SIELECKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref166">
            <xocs:ref-normalized-surname>KNOCKAERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>417</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref167">
            <xocs:ref-normalized-surname>SENDEROWICZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>313</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref168">
            <xocs:ref-normalized-surname>DEAZEVEDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>51</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref169">
            <xocs:ref-normalized-surname>WYATT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>4986</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref170">
            <xocs:ref-normalized-surname>WONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>2457</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref171">
            <xocs:ref-normalized-surname>GOLSTEYN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>129</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref172">
            <xocs:ref-normalized-surname>RUDOLPH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>202</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref173">
            <xocs:ref-normalized-surname>WILSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>6949</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref174">
            <xocs:ref-normalized-surname>ALDOSS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1957</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref175">
            <xocs:ref-normalized-surname>GUZI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1311</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref176">
            <xocs:ref-normalized-surname>LIEBL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>281</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref177">
            <xocs:ref-normalized-surname>GRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>533</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref178">
            <xocs:ref-normalized-surname>SENDEROWICZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>376</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref179">
            <xocs:ref-normalized-surname>YENUGONDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2714</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref180">
            <xocs:ref-normalized-surname>CHRISTIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>573</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref181">
            <xocs:ref-normalized-surname>BETTAYEB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5797</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref182">
            <xocs:ref-normalized-surname>NGOMPAZADIARRA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>210</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref183">
            <xocs:ref-normalized-surname>GRANVILLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>679</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref184">
            <xocs:ref-normalized-surname>POULSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>305</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref185">
            <xocs:ref-normalized-surname>HAVLICEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>408</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref186">
            <xocs:ref-normalized-surname>MCCLUE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>463</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref187">
            <xocs:ref-normalized-surname>LE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>3243</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref188">
            <xocs:ref-normalized-surname>MAHADEVAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2137</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref189">
            <xocs:ref-normalized-surname>ZATLOUKAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>61</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref190">
            <xocs:ref-normalized-surname>KNOCKAERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>417</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref191">
            <xocs:ref-normalized-surname>DOLECKOVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>443</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref192">
            <xocs:ref-normalized-surname>BACH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>31208</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref193">
            <xocs:ref-normalized-surname>BECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>246</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref194">
            <xocs:ref-normalized-surname>BETTAYEB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5797</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref195">
            <xocs:ref-normalized-surname>BISCHOF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1577</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref196">
            <xocs:ref-normalized-surname>DEMANGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3247</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref197">
            <xocs:ref-normalized-surname>ENGELMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>550</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref198">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>4023</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref199">
            <xocs:ref-normalized-surname>BLANCHARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2880</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref200">
            <xocs:ref-normalized-surname>AOYAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>266</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref201">
            <xocs:ref-normalized-surname>MILANESE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1216</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref202">
            <xocs:ref-normalized-surname>PEISACH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>703</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref203">
            <xocs:ref-normalized-surname>RUBIORUIZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>154</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref204">
            <xocs:ref-normalized-surname>KANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>15359</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref205">
            <xocs:ref-normalized-surname>TARDIFF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2267</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref206">
            <xocs:ref-normalized-surname>KUMAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>4377</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref207">
            <xocs:ref-normalized-surname>SHARMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>414</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref208">
            <xocs:ref-normalized-surname>CONEJOGARCIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3795</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref209">
            <xocs:ref-normalized-surname>NUNEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2614</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref210">
            <xocs:ref-normalized-surname>MARCHAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1301</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref211">
            <xocs:ref-normalized-surname>SHARMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>308</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>SHARMAX2016X298</xocs:refkey3>
         <xocs:refkey4lp>SHARMAX2016X298X346</xocs:refkey4lp>
         <xocs:refkey4ai>SHARMAX2016X298XS</xocs:refkey4ai>
         <xocs:refkey5>SHARMAX2016X298X346XS</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:self-archiving>
         <xocs:sa-start-date>2018-02-21T00:00:00Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(16)30089-7</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523416300897</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523416300897</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2016.02.018</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2019-04-27T02:23:59.33188Z</xocs:timestamp>
         <xocs:cover-date-start>2016-04-13</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/MAIN/application/pdf/56c22c600e79caa8af339ddf4ebae8cf/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>5326052</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>49</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523416300897-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/PREVIEW/image/png/d7fa781bc2a25ebdd57f6a90139a40cd/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>40838</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx1/THUMBNAIL/image/gif/df45a0c8d14452c0e3273931b49f0292/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>20769</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>187</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx10/THUMBNAIL/image/gif/6ee8fe4a8e3d6f138a3454eb19b3efc0/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10475</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx11/THUMBNAIL/image/gif/1aca51a4c369ae6fb96d84db478e5f10/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11237</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>151</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx12/THUMBNAIL/image/gif/0f3bc95dedf5601483cd3877345de4ce/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10830</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>183</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx13/THUMBNAIL/image/gif/c4b32561aefb3435f6885e51b71713f6/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9900</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>199</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx14/THUMBNAIL/image/gif/b07e6e8425b3bd4b0af56a9b559bcc3c/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9967</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>208</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx15/THUMBNAIL/image/gif/78162c466f11a796fdda0d0124b3a3be/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9570</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>211</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx16/THUMBNAIL/image/gif/10bdacd0449ea67644b69e9929590022/fx16.sml</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9498</xocs:filesize>
               <xocs:pixel-height>151</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx17/THUMBNAIL/image/gif/7c988012b08a713e01ca863b092f6f5c/fx17.sml</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9634</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx18/THUMBNAIL/image/gif/a4c724d897ef0acddede865a39b74d63/fx18.sml</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11515</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx19/THUMBNAIL/image/gif/00f0b8b8b80147d1a169cbe99a5178b3/fx19.sml</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12096</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>199</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx2/THUMBNAIL/image/gif/70b012ae165434f2022ed2efdd9065e8/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10120</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>149</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx20/THUMBNAIL/image/gif/2c350ced468d3ef15c49fdd27171bfc7/fx20.sml</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10810</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>206</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx21/THUMBNAIL/image/gif/c0ed1478ea3ae40c8b86b877d86323d8/fx21.sml</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10243</xocs:filesize>
               <xocs:pixel-height>140</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx22/THUMBNAIL/image/gif/54efb114b5165d706be67b6e685b36c3/fx22.sml</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11350</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx23.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx23/THUMBNAIL/image/gif/c536d603e74e66259f0b42983ede7e68/fx23.sml</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10197</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>111</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx24.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx24/THUMBNAIL/image/gif/6486d419c46438da24a931c2d465cb64/fx24.sml</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10901</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>134</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx25.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx25/THUMBNAIL/image/gif/24ba840ce7a12c3307e7aae26eff48d0/fx25.sml</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7863</xocs:filesize>
               <xocs:pixel-height>162</xocs:pixel-height>
               <xocs:pixel-width>83</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx26.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx26/THUMBNAIL/image/gif/6df30e9b9017d4814784b91c4842df9f/fx26.sml</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11263</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>141</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx27.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx27/THUMBNAIL/image/gif/9d9ef95335014a652be44c0fc2e34aa4/fx27.sml</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10757</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>131</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx28.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx28/THUMBNAIL/image/gif/98ab96de215f4dcfbce983eb8de1df1c/fx28.sml</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9778</xocs:filesize>
               <xocs:pixel-height>148</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx29.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx29/THUMBNAIL/image/gif/444d61a326392f8d8010f03eb4c14b0e/fx29.sml</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9802</xocs:filesize>
               <xocs:pixel-height>148</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx3/THUMBNAIL/image/gif/8e68c61737367af367bfc91b7a91eb56/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10075</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>128</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx30.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx30/THUMBNAIL/image/gif/ee4bc7cf21ee9440673e23c48a077f89/fx30.sml</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9564</xocs:filesize>
               <xocs:pixel-height>138</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx31.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx31/THUMBNAIL/image/gif/6b6f680489d47b77fec0990acdcefa78/fx31.sml</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9671</xocs:filesize>
               <xocs:pixel-height>139</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx32.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx32/THUMBNAIL/image/gif/6a401e2c01fab9fb0d2fb4a5c57e074d/fx32.sml</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10114</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx33.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx33/THUMBNAIL/image/gif/231580512b6b6afc7425138e9abb34bf/fx33.sml</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9946</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx4/THUMBNAIL/image/gif/616a08caf1c06aba618637b27b7dd629/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10999</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>148</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx5/THUMBNAIL/image/gif/b07a151c191a323e30ab04fdd3ca22d5/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11235</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>148</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx6/THUMBNAIL/image/gif/724e1aea9feafc945ceeaa363667c8d5/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10283</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>128</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx7/THUMBNAIL/image/gif/cfc44ce30b51af3ff40a06332ac22dc6/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11532</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>145</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx8/THUMBNAIL/image/gif/2ba5971b4408377baa10e3ccfef4644f/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10350</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>178</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx9/THUMBNAIL/image/gif/095993ba0f3a745b92795b4682591851/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10303</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>183</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr10/THUMBNAIL/image/gif/810d5e6307ba5f512d3a110725e53daf/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14189</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>211</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr11/THUMBNAIL/image/gif/c818e629ae4c0e57c46cc71c34d2f140/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10966</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr12/THUMBNAIL/image/gif/9580776ea6de4d75023b62e8fa942e74/gr12.sml</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>20333</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>114</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr13/THUMBNAIL/image/gif/95343ba3545f38328e526d46fb7d0a14/gr13.sml</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10604</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>102</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr14/THUMBNAIL/image/gif/1ce80608d79581831e61d52b86e0f0d0/gr14.sml</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10910</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>217</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr15/THUMBNAIL/image/gif/8de2abb5deedf0475912d1314eb282e1/gr15.sml</xocs:ucs-locator>
               <xocs:file-basename>gr15</xocs:file-basename>
               <xocs:filename>gr15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8787</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>122</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr16/THUMBNAIL/image/gif/f5f6685cb8a44b771cf2c323731e3ec6/gr16.sml</xocs:ucs-locator>
               <xocs:file-basename>gr16</xocs:file-basename>
               <xocs:filename>gr16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13523</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>187</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr17/THUMBNAIL/image/gif/0fe25e49e2b3eeb7eccbe5aee4dce874/gr17.sml</xocs:ucs-locator>
               <xocs:file-basename>gr17</xocs:file-basename>
               <xocs:filename>gr17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16518</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr18/THUMBNAIL/image/gif/405fbcb587ac258de77c22ba039ee73d/gr18.sml</xocs:ucs-locator>
               <xocs:file-basename>gr18</xocs:file-basename>
               <xocs:filename>gr18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12413</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>129</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr19/THUMBNAIL/image/gif/1d85fe3df08ef9523cf5075bcee7524d/gr19.sml</xocs:ucs-locator>
               <xocs:file-basename>gr19</xocs:file-basename>
               <xocs:filename>gr19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15890</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>156</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr1a.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr1a/THUMBNAIL/image/gif/0d93c0dfeb412c87695d8c23ee98daea/gr1a.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1a</xocs:file-basename>
               <xocs:filename>gr1a.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13973</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>133</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr1b.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr1b/THUMBNAIL/image/gif/850ec51acac5ff450eb431a3320cb3a2/gr1b.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1b</xocs:file-basename>
               <xocs:filename>gr1b.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14286</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>138</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr2/THUMBNAIL/image/gif/5d4f298078e5fbf7b273de18c8f73f38/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11683</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>200</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr20/THUMBNAIL/image/gif/f235a9a7becf5f34c58ce89bf2c11ce3/gr20.sml</xocs:ucs-locator>
               <xocs:file-basename>gr20</xocs:file-basename>
               <xocs:filename>gr20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12209</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr21/THUMBNAIL/image/gif/6a39053592bb16bb1cb4290da1cbd631/gr21.sml</xocs:ucs-locator>
               <xocs:file-basename>gr21</xocs:file-basename>
               <xocs:filename>gr21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11707</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>114</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr22/THUMBNAIL/image/gif/f70ecb6808459e3474467cae28d28b30/gr22.sml</xocs:ucs-locator>
               <xocs:file-basename>gr22</xocs:file-basename>
               <xocs:filename>gr22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13784</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr23.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr23/THUMBNAIL/image/gif/d56406df6dc28751cb24b4f7d23ece58/gr23.sml</xocs:ucs-locator>
               <xocs:file-basename>gr23</xocs:file-basename>
               <xocs:filename>gr23.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13084</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>101</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr24.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr24/THUMBNAIL/image/gif/d1f4e2193b4e5c841552c137f9d9bff6/gr24.sml</xocs:ucs-locator>
               <xocs:file-basename>gr24</xocs:file-basename>
               <xocs:filename>gr24.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12464</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>126</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr25.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr25/THUMBNAIL/image/gif/d5235462ca4dbe1cfb357c71adaa8f63/gr25.sml</xocs:ucs-locator>
               <xocs:file-basename>gr25</xocs:file-basename>
               <xocs:filename>gr25.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17170</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr26.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr26/THUMBNAIL/image/gif/650c0b0536a3cbc88912f7da73f75ba4/gr26.sml</xocs:ucs-locator>
               <xocs:file-basename>gr26</xocs:file-basename>
               <xocs:filename>gr26.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11234</xocs:filesize>
               <xocs:pixel-height>121</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr27.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr27/THUMBNAIL/image/gif/3fa414a7c88648b42ec3af9764ba7a6c/gr27.sml</xocs:ucs-locator>
               <xocs:file-basename>gr27</xocs:file-basename>
               <xocs:filename>gr27.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11952</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr28.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr28/THUMBNAIL/image/gif/3abec690271bb5bfc8a4d97f7623be8c/gr28.sml</xocs:ucs-locator>
               <xocs:file-basename>gr28</xocs:file-basename>
               <xocs:filename>gr28.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14775</xocs:filesize>
               <xocs:pixel-height>138</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr29.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr29/THUMBNAIL/image/gif/ea01e30e27bf1beccc3754daf69cc1a4/gr29.sml</xocs:ucs-locator>
               <xocs:file-basename>gr29</xocs:file-basename>
               <xocs:filename>gr29.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11065</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>105</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr3/THUMBNAIL/image/gif/1035a1f28eddd5d47a1d380b5d0d8395/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14106</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr30.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr30/THUMBNAIL/image/gif/9b52427eeeb4070feb4ce1843c4d0f10/gr30.sml</xocs:ucs-locator>
               <xocs:file-basename>gr30</xocs:file-basename>
               <xocs:filename>gr30.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9506</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr31.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr31/THUMBNAIL/image/gif/5315877a47df779c74071a917b74cfd4/gr31.sml</xocs:ucs-locator>
               <xocs:file-basename>gr31</xocs:file-basename>
               <xocs:filename>gr31.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12557</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>123</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr32.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr32/THUMBNAIL/image/gif/2aea63227569a559f201bd70b7ff7c75/gr32.sml</xocs:ucs-locator>
               <xocs:file-basename>gr32</xocs:file-basename>
               <xocs:filename>gr32.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14759</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>139</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr33.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr33/THUMBNAIL/image/gif/1b35be84fd2cbef1511df327efd1c6aa/gr33.sml</xocs:ucs-locator>
               <xocs:file-basename>gr33</xocs:file-basename>
               <xocs:filename>gr33.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13976</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>137</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr34.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr34/THUMBNAIL/image/gif/eeb67484f7b79de364d6478e0891e488/gr34.sml</xocs:ucs-locator>
               <xocs:file-basename>gr34</xocs:file-basename>
               <xocs:filename>gr34.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11766</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>206</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr35.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr35/THUMBNAIL/image/gif/aaa3d4ffdd85a5321ed9f4fb22938cc0/gr35.sml</xocs:ucs-locator>
               <xocs:file-basename>gr35</xocs:file-basename>
               <xocs:filename>gr35.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8671</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>99</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr36.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr36/THUMBNAIL/image/gif/973dacfd117deb0aac6ba2001e2832eb/gr36.sml</xocs:ucs-locator>
               <xocs:file-basename>gr36</xocs:file-basename>
               <xocs:filename>gr36.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13944</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr37.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr37/THUMBNAIL/image/gif/64b5a62a5a877cb506a6488b7c2fa2ab/gr37.sml</xocs:ucs-locator>
               <xocs:file-basename>gr37</xocs:file-basename>
               <xocs:filename>gr37.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17034</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>160</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr38.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr38/THUMBNAIL/image/gif/4c0eb7627764a1df7c94afc895af989a/gr38.sml</xocs:ucs-locator>
               <xocs:file-basename>gr38</xocs:file-basename>
               <xocs:filename>gr38.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12538</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr39.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr39/THUMBNAIL/image/gif/0b0ee605a8524fb227927041d165c3b0/gr39.sml</xocs:ucs-locator>
               <xocs:file-basename>gr39</xocs:file-basename>
               <xocs:filename>gr39.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11652</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>114</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr4/THUMBNAIL/image/gif/38eab986095e940b8f530952387b4cb0/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15865</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>145</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr40.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr40/THUMBNAIL/image/gif/b3fa1aeca5344e50565c6fd4c29906a1/gr40.sml</xocs:ucs-locator>
               <xocs:file-basename>gr40</xocs:file-basename>
               <xocs:filename>gr40.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16515</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>214</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr41.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr41/THUMBNAIL/image/gif/fc1e525c64e23295f433da7dea68ceca/gr41.sml</xocs:ucs-locator>
               <xocs:file-basename>gr41</xocs:file-basename>
               <xocs:filename>gr41.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17458</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr42.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr42/THUMBNAIL/image/gif/b5abb5353c4fab1d5327f2bb81d80dd2/gr42.sml</xocs:ucs-locator>
               <xocs:file-basename>gr42</xocs:file-basename>
               <xocs:filename>gr42.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12775</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr43.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr43/THUMBNAIL/image/gif/0bbda734fbb7f4dbb67e3a8d4dd7f271/gr43.sml</xocs:ucs-locator>
               <xocs:file-basename>gr43</xocs:file-basename>
               <xocs:filename>gr43.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13446</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>135</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr44.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr44/THUMBNAIL/image/gif/22e097987e96660284f61a0aefdbe60b/gr44.sml</xocs:ucs-locator>
               <xocs:file-basename>gr44</xocs:file-basename>
               <xocs:filename>gr44.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12415</xocs:filesize>
               <xocs:pixel-height>154</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr5/THUMBNAIL/image/gif/c96b267a0a1cbaa5d1f6c38fdcfa82a5/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14613</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>139</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr6/THUMBNAIL/image/gif/03133de1c0c5badb4a6d32ef211f9f9a/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10481</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>154</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr7/THUMBNAIL/image/gif/7601f3402cb2f50f8ae418e3c2ddaba3/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13990</xocs:filesize>
               <xocs:pixel-height>155</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr8/THUMBNAIL/image/gif/531f83c69be047e071834dce1ab4d453/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15694</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>137</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr9/THUMBNAIL/image/gif/6e95012ef79eee15ae6585ef84a77891/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12182</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>95</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx1/DOWNSAMPLED/image/jpeg/bedb0975fae6340c008c688157d4412c/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>42312</xocs:filesize>
               <xocs:pixel-height>245</xocs:pixel-height>
               <xocs:pixel-width>280</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx10/DOWNSAMPLED/image/jpeg/2f5dacc72f179d7db1f7a165949655a3/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32984</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>116</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx11/DOWNSAMPLED/image/jpeg/4cff628c70c716ed2892cbd9ea32a9fc/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34043</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>116</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx12/DOWNSAMPLED/image/jpeg/0b3d18d837b14b65afa4a5e95a3681d5/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32461</xocs:filesize>
               <xocs:pixel-height>109</xocs:pixel-height>
               <xocs:pixel-width>122</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx13/DOWNSAMPLED/image/jpeg/742428d9688bc56a746ce49b98efe557/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31337</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx14/DOWNSAMPLED/image/jpeg/9e5eb8f9e9c529f013fb71cb949c13a8/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31475</xocs:filesize>
               <xocs:pixel-height>115</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx15/DOWNSAMPLED/image/jpeg/1e7e46e53216a35828a5848c7f6d7ca2/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30078</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>143</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx16/DOWNSAMPLED/image/jpeg/096fbca146cda2889d208b783d76fe36/fx16.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30169</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>147</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx17/DOWNSAMPLED/image/jpeg/b1fdcef4d099ee499f36c0a8fa9a136e/fx17.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30200</xocs:filesize>
               <xocs:pixel-height>98</xocs:pixel-height>
               <xocs:pixel-width>147</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx18/DOWNSAMPLED/image/jpeg/3c12268847b40e51307bddd980d4d629/fx18.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22703</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>140</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx19/DOWNSAMPLED/image/jpeg/8acde1014253df26b3ba02b6766b0024/fx19.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34470</xocs:filesize>
               <xocs:pixel-height>119</xocs:pixel-height>
               <xocs:pixel-width>144</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx2/DOWNSAMPLED/image/jpeg/5cf0c5fd09853df3a839ab23fb21cf1d/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32232</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>112</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx20/DOWNSAMPLED/image/jpeg/8103a5b16d06f82d96aba9200c4cfc05/fx20.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32579</xocs:filesize>
               <xocs:pixel-height>116</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx21/DOWNSAMPLED/image/jpeg/0eec99239d5f4b00712d0c4772782de9/fx21.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31448</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx22/DOWNSAMPLED/image/jpeg/878f2523c1030579b1c055779bc6c881/fx22.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33351</xocs:filesize>
               <xocs:pixel-height>118</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx23.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx23/DOWNSAMPLED/image/jpeg/c1bead91c41d7cf592adfe9ae1d8670c/fx23.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22165</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>96</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx24.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx24/DOWNSAMPLED/image/jpeg/bc72e157529182653266b4dda4b4a287/fx24.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33448</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>108</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx25.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx25/DOWNSAMPLED/image/jpeg/21f7808db329fc5fe47913769d1d741e/fx25.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29933</xocs:filesize>
               <xocs:pixel-height>188</xocs:pixel-height>
               <xocs:pixel-width>96</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx26.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx26/DOWNSAMPLED/image/jpeg/6a3e98e6383aa548465585d8ba5c6b68/fx26.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34120</xocs:filesize>
               <xocs:pixel-height>133</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx27.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx27/DOWNSAMPLED/image/jpeg/cb147bb718dcae6fc8c3d2d7294e6647/fx27.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33319</xocs:filesize>
               <xocs:pixel-height>133</xocs:pixel-height>
               <xocs:pixel-width>107</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx28.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx28/DOWNSAMPLED/image/jpeg/9e79885e241282f6df78b0d3a0b6c216/fx28.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19909</xocs:filesize>
               <xocs:pixel-height>99</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx29.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx29/DOWNSAMPLED/image/jpeg/8d49d712b4c86460290c4c030f6cd268/fx29.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30621</xocs:filesize>
               <xocs:pixel-height>99</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx3/DOWNSAMPLED/image/jpeg/bc812d5c5fc21b91b188d540d668a1c6/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33210</xocs:filesize>
               <xocs:pixel-height>147</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx30.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx30/DOWNSAMPLED/image/jpeg/e8936f931454137c1a3a5b156c189323/fx30.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30365</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>148</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx31.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx31/DOWNSAMPLED/image/jpeg/a14430694afd86ac54695d6cc3118d70/fx31.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30430</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>147</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx32.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx32/DOWNSAMPLED/image/jpeg/14f11c8c5dac1c3dbd34a15dca8dd256/fx32.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31624</xocs:filesize>
               <xocs:pixel-height>118</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx33.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx33/DOWNSAMPLED/image/jpeg/8a69e6a2c984ee3f64c6d41c640f9392/fx33.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20056</xocs:filesize>
               <xocs:pixel-height>97</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx4/DOWNSAMPLED/image/jpeg/629cfeed4474cb5e19624f35ba202f50/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34103</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx5/DOWNSAMPLED/image/jpeg/c7af4b446bea57425e509967ae7f2783/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34493</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx6/DOWNSAMPLED/image/jpeg/0955a54a6fddc393db3afe7ed62efdaa/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33550</xocs:filesize>
               <xocs:pixel-height>147</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx7/DOWNSAMPLED/image/jpeg/0e0896ba253ac3a46a99d4a2b8a830fc/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34708</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx8/DOWNSAMPLED/image/jpeg/710d9a3465b8ab5383efd17796c764b4/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31941</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>117</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx9/DOWNSAMPLED/image/jpeg/e15dee54354c79312bca3ed446fa0b53/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31571</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>117</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr10/DOWNSAMPLED/image/jpeg/a6fbf8d1e56565e95205d971b608b86c/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>107787</xocs:filesize>
               <xocs:pixel-height>528</xocs:pixel-height>
               <xocs:pixel-width>681</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr11/DOWNSAMPLED/image/jpeg/8f5e1b8956b565d88f7959741bceeeb5/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>80060</xocs:filesize>
               <xocs:pixel-height>336</xocs:pixel-height>
               <xocs:pixel-width>711</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr12/DOWNSAMPLED/image/jpeg/5c9580cb92793b40a1fbef590660fedd/gr12.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>227026</xocs:filesize>
               <xocs:pixel-height>710</xocs:pixel-height>
               <xocs:pixel-width>495</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr13/DOWNSAMPLED/image/jpeg/423583ec78a48b78d1f899e18222ea14/gr13.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>184361</xocs:filesize>
               <xocs:pixel-height>1038</xocs:pixel-height>
               <xocs:pixel-width>645</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr14/DOWNSAMPLED/image/jpeg/d4d25d421af80e0b243051bf1668ac1f/gr14.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>55914</xocs:filesize>
               <xocs:pixel-height>420</xocs:pixel-height>
               <xocs:pixel-width>556</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr15/DOWNSAMPLED/image/jpeg/1b96ec2fb8374add00ea9b886bd7ef6f/gr15.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr15</xocs:file-basename>
               <xocs:filename>gr15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>70248</xocs:filesize>
               <xocs:pixel-height>724</xocs:pixel-height>
               <xocs:pixel-width>542</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr16/DOWNSAMPLED/image/jpeg/3300d8ccc652997436583446fae16e33/gr16.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr16</xocs:file-basename>
               <xocs:filename>gr16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>107617</xocs:filesize>
               <xocs:pixel-height>603</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr17/DOWNSAMPLED/image/jpeg/8688ad2894ac316b8a2c12c654d93711/gr17.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr17</xocs:file-basename>
               <xocs:filename>gr17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>186087</xocs:filesize>
               <xocs:pixel-height>715</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr18/DOWNSAMPLED/image/jpeg/88d72bb08e27b75f4beb64ab8e7190f5/gr18.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr18</xocs:file-basename>
               <xocs:filename>gr18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>98832</xocs:filesize>
               <xocs:pixel-height>687</xocs:pixel-height>
               <xocs:pixel-width>543</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr19/DOWNSAMPLED/image/jpeg/1632938cd0f70e47eb9bc9391142adf9/gr19.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr19</xocs:file-basename>
               <xocs:filename>gr19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>107642</xocs:filesize>
               <xocs:pixel-height>583</xocs:pixel-height>
               <xocs:pixel-width>556</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr1a.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr1a/DOWNSAMPLED/image/jpeg/e0b8a3a2c0d0b9df494a118ec1c2f94b/gr1a.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1a</xocs:file-basename>
               <xocs:filename>gr1a.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>151952</xocs:filesize>
               <xocs:pixel-height>899</xocs:pixel-height>
               <xocs:pixel-width>729</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr1b.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr1b/DOWNSAMPLED/image/jpeg/d3218930d60bfb40924b62f6ca4c0810/gr1b.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1b</xocs:file-basename>
               <xocs:filename>gr1b.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>171214</xocs:filesize>
               <xocs:pixel-height>924</xocs:pixel-height>
               <xocs:pixel-width>782</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr2/DOWNSAMPLED/image/jpeg/5d090391736cc43af4a89e5442f39ed6/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>60315</xocs:filesize>
               <xocs:pixel-height>451</xocs:pixel-height>
               <xocs:pixel-width>550</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr20/DOWNSAMPLED/image/jpeg/70f9d8961e9d837f5c693c27289c2a5a/gr20.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr20</xocs:file-basename>
               <xocs:filename>gr20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>81807</xocs:filesize>
               <xocs:pixel-height>555</xocs:pixel-height>
               <xocs:pixel-width>494</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr21/DOWNSAMPLED/image/jpeg/5ae9b139115fda7fcbd88a86cf0539bd/gr21.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr21</xocs:file-basename>
               <xocs:filename>gr21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>161363</xocs:filesize>
               <xocs:pixel-height>864</xocs:pixel-height>
               <xocs:pixel-width>600</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr22/DOWNSAMPLED/image/jpeg/cff0b914a0d6abc505bd4f83ddc7a5d2/gr22.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr22</xocs:file-basename>
               <xocs:filename>gr22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>98048</xocs:filesize>
               <xocs:pixel-height>625</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr23.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr23/DOWNSAMPLED/image/jpeg/62d52e9e303c3d04a9fd71661923be50/gr23.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr23</xocs:file-basename>
               <xocs:filename>gr23.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>167399</xocs:filesize>
               <xocs:pixel-height>880</xocs:pixel-height>
               <xocs:pixel-width>543</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr24.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr24/DOWNSAMPLED/image/jpeg/d15939117e9e0d4a2a059b2b649d6576/gr24.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr24</xocs:file-basename>
               <xocs:filename>gr24.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>113191</xocs:filesize>
               <xocs:pixel-height>752</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr25.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr25/DOWNSAMPLED/image/jpeg/acb5cf97d05918332ff99ef05da7c2f5/gr25.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr25</xocs:file-basename>
               <xocs:filename>gr25.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>133667</xocs:filesize>
               <xocs:pixel-height>594</xocs:pixel-height>
               <xocs:pixel-width>587</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr26.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr26/DOWNSAMPLED/image/jpeg/b4fb8c312a5710265abf9babcfc4e3ce/gr26.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr26</xocs:file-basename>
               <xocs:filename>gr26.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>90385</xocs:filesize>
               <xocs:pixel-height>432</xocs:pixel-height>
               <xocs:pixel-width>779</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr27.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr27/DOWNSAMPLED/image/jpeg/049ced1a04b61173be2c55c7336a1c9d/gr27.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr27</xocs:file-basename>
               <xocs:filename>gr27.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56109</xocs:filesize>
               <xocs:pixel-height>496</xocs:pixel-height>
               <xocs:pixel-width>534</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr28.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr28/DOWNSAMPLED/image/jpeg/6d40b357bbc0a0afc4a73790aad2fad7/gr28.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr28</xocs:file-basename>
               <xocs:filename>gr28.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>77148</xocs:filesize>
               <xocs:pixel-height>351</xocs:pixel-height>
               <xocs:pixel-width>556</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr29.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr29/DOWNSAMPLED/image/jpeg/f9c6546e592b58d3553645d1744114d6/gr29.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr29</xocs:file-basename>
               <xocs:filename>gr29.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>101099</xocs:filesize>
               <xocs:pixel-height>677</xocs:pixel-height>
               <xocs:pixel-width>436</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr3/DOWNSAMPLED/image/jpeg/b7f91e93440d430af9159da1d0c09430/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>112847</xocs:filesize>
               <xocs:pixel-height>632</xocs:pixel-height>
               <xocs:pixel-width>625</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr30.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr30/DOWNSAMPLED/image/jpeg/a839ad7e83afedbd9200f12128ad9036/gr30.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr30</xocs:file-basename>
               <xocs:filename>gr30.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36947</xocs:filesize>
               <xocs:pixel-height>248</xocs:pixel-height>
               <xocs:pixel-width>445</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr31.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr31/DOWNSAMPLED/image/jpeg/aca436da1c7910ed97391ca0a7d136df/gr31.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr31</xocs:file-basename>
               <xocs:filename>gr31.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>102969</xocs:filesize>
               <xocs:pixel-height>653</xocs:pixel-height>
               <xocs:pixel-width>493</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr32.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr32/DOWNSAMPLED/image/jpeg/8acbd5b4c7bf12c0c40740bdfaade7d4/gr32.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr32</xocs:file-basename>
               <xocs:filename>gr32.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>110044</xocs:filesize>
               <xocs:pixel-height>619</xocs:pixel-height>
               <xocs:pixel-width>525</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr33.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr33/DOWNSAMPLED/image/jpeg/e70b23d8953fc84c08a87ace1a53e2a6/gr33.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr33</xocs:file-basename>
               <xocs:filename>gr33.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>123644</xocs:filesize>
               <xocs:pixel-height>636</xocs:pixel-height>
               <xocs:pixel-width>534</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr34.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr34/DOWNSAMPLED/image/jpeg/3c31f4e2fca6ce8f6d060880185759b2/gr34.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr34</xocs:file-basename>
               <xocs:filename>gr34.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>107236</xocs:filesize>
               <xocs:pixel-height>601</xocs:pixel-height>
               <xocs:pixel-width>756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr35.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr35/DOWNSAMPLED/image/jpeg/6841510451bd4ebe7b9ff1cf1a949610/gr35.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr35</xocs:file-basename>
               <xocs:filename>gr35.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>47676</xocs:filesize>
               <xocs:pixel-height>515</xocs:pixel-height>
               <xocs:pixel-width>311</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr36.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr36/DOWNSAMPLED/image/jpeg/e4d82d3e8d792fcdab573201ea417278/gr36.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr36</xocs:file-basename>
               <xocs:filename>gr36.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>95395</xocs:filesize>
               <xocs:pixel-height>404</xocs:pixel-height>
               <xocs:pixel-width>756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr37.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr37/DOWNSAMPLED/image/jpeg/b157fffde2f06cf821a00cd33cda7a43/gr37.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr37</xocs:file-basename>
               <xocs:filename>gr37.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>122768</xocs:filesize>
               <xocs:pixel-height>506</xocs:pixel-height>
               <xocs:pixel-width>494</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr38.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr38/DOWNSAMPLED/image/jpeg/d9518d0078c18a3885c0fbf650968717/gr38.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr38</xocs:file-basename>
               <xocs:filename>gr38.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37000</xocs:filesize>
               <xocs:pixel-height>236</xocs:pixel-height>
               <xocs:pixel-width>311</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr39.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr39/DOWNSAMPLED/image/jpeg/55db688271af75d6f010d0bb93622fd0/gr39.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr39</xocs:file-basename>
               <xocs:filename>gr39.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>151765</xocs:filesize>
               <xocs:pixel-height>968</xocs:pixel-height>
               <xocs:pixel-width>675</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr4/DOWNSAMPLED/image/jpeg/ebaf7f75f9587e51c779da1c6252ee43/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>141078</xocs:filesize>
               <xocs:pixel-height>639</xocs:pixel-height>
               <xocs:pixel-width>567</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr40.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr40/DOWNSAMPLED/image/jpeg/85fba9cadce6bd185365c48dfb1d68a6/gr40.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr40</xocs:file-basename>
               <xocs:filename>gr40.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>124896</xocs:filesize>
               <xocs:pixel-height>539</xocs:pixel-height>
               <xocs:pixel-width>705</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr41.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr41/DOWNSAMPLED/image/jpeg/eff33622d723e2e5f47cb64c488e5f78/gr41.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr41</xocs:file-basename>
               <xocs:filename>gr41.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>188121</xocs:filesize>
               <xocs:pixel-height>784</xocs:pixel-height>
               <xocs:pixel-width>756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr42.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr42/DOWNSAMPLED/image/jpeg/30a46889702f6a628bfa122d63227b7b/gr42.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr42</xocs:file-basename>
               <xocs:filename>gr42.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>80649</xocs:filesize>
               <xocs:pixel-height>333</xocs:pixel-height>
               <xocs:pixel-width>579</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr43.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr43/DOWNSAMPLED/image/jpeg/e2be0bc80571e50b289988de29b91f8e/gr43.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr43</xocs:file-basename>
               <xocs:filename>gr43.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>90110</xocs:filesize>
               <xocs:pixel-height>541</xocs:pixel-height>
               <xocs:pixel-width>445</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr44.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr44/DOWNSAMPLED/image/jpeg/fc7f32fd00e4bac5a8080dd6c4948203/gr44.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr44</xocs:file-basename>
               <xocs:filename>gr44.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27836</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>231</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr5/DOWNSAMPLED/image/jpeg/620e611b6d21652ddea17416bdbb2102/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>129091</xocs:filesize>
               <xocs:pixel-height>637</xocs:pixel-height>
               <xocs:pixel-width>541</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr6/DOWNSAMPLED/image/jpeg/e995c307d516b24090573f141a06a487/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>49835</xocs:filesize>
               <xocs:pixel-height>507</xocs:pixel-height>
               <xocs:pixel-width>477</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr7/DOWNSAMPLED/image/jpeg/e655bd991acf7e0de9be087685cc5b6a/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>111917</xocs:filesize>
               <xocs:pixel-height>536</xocs:pixel-height>
               <xocs:pixel-width>756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr8/DOWNSAMPLED/image/jpeg/e58bad8743aba17b1b235a57959705c0/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>164758</xocs:filesize>
               <xocs:pixel-height>719</xocs:pixel-height>
               <xocs:pixel-width>602</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr9/DOWNSAMPLED/image/jpeg/bcfdf60fe35ef20fb90c513b93394a67/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>214155</xocs:filesize>
               <xocs:pixel-height>1057</xocs:pixel-height>
               <xocs:pixel-width>614</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx1/HIGHRES/image/jpeg/c734bb00a8a883e3f38d73a544e444b4/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>198032</xocs:filesize>
               <xocs:pixel-height>1085</xocs:pixel-height>
               <xocs:pixel-width>1239</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx10/HIGHRES/image/jpeg/45f90d003e889f7ce1a4a9d55b7e7dcb/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>57861</xocs:filesize>
               <xocs:pixel-height>579</xocs:pixel-height>
               <xocs:pixel-width>517</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx11/HIGHRES/image/jpeg/9efd343385fc930264f08a53025d406b/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59781</xocs:filesize>
               <xocs:pixel-height>558</xocs:pixel-height>
               <xocs:pixel-width>514</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx12/HIGHRES/image/jpeg/a284812f7eec5770d8ad7f0f61876669/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>54178</xocs:filesize>
               <xocs:pixel-height>486</xocs:pixel-height>
               <xocs:pixel-width>544</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx13/HIGHRES/image/jpeg/9c599979ad23c206b40be4cc7a903eb8/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>55566</xocs:filesize>
               <xocs:pixel-height>533</xocs:pixel-height>
               <xocs:pixel-width>648</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx14/HIGHRES/image/jpeg/f56acfa14e28f9d9839775b2840a6528/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>54238</xocs:filesize>
               <xocs:pixel-height>511</xocs:pixel-height>
               <xocs:pixel-width>648</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx15/HIGHRES/image/jpeg/9e68f9b843eb670247fa35a00a73631f/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>51150</xocs:filesize>
               <xocs:pixel-height>493</xocs:pixel-height>
               <xocs:pixel-width>636</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx16/HIGHRES/image/jpeg/9267dcce39655daa62214d458a9341f3/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>52135</xocs:filesize>
               <xocs:pixel-height>449</xocs:pixel-height>
               <xocs:pixel-width>653</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx17/HIGHRES/image/jpeg/907068f34c3003f4cf1a81390276ccf4/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>52482</xocs:filesize>
               <xocs:pixel-height>435</xocs:pixel-height>
               <xocs:pixel-width>654</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx18/HIGHRES/image/jpeg/e80245a2ab00550f38eb6aad70f1b8f8/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>50099</xocs:filesize>
               <xocs:pixel-height>492</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx19/HIGHRES/image/jpeg/7e05aec580052d152d1facd4cda6132a/fx19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>66026</xocs:filesize>
               <xocs:pixel-height>528</xocs:pixel-height>
               <xocs:pixel-width>641</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx2/HIGHRES/image/jpeg/e77d809dc6547378897be010a478a444/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>53391</xocs:filesize>
               <xocs:pixel-height>550</xocs:pixel-height>
               <xocs:pixel-width>499</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx20/HIGHRES/image/jpeg/c0bf9e0af9bcce456cc23cf29fc21ca7/fx20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>58751</xocs:filesize>
               <xocs:pixel-height>518</xocs:pixel-height>
               <xocs:pixel-width>650</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx21/HIGHRES/image/jpeg/0bf7399eb0a35568f3a83a2e4bf20dde/fx21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>54069</xocs:filesize>
               <xocs:pixel-height>415</xocs:pixel-height>
               <xocs:pixel-width>647</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx22/HIGHRES/image/jpeg/ff0c2395e1d6a589da59b3a87d2d95ba/fx22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>61974</xocs:filesize>
               <xocs:pixel-height>522</xocs:pixel-height>
               <xocs:pixel-width>647</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx23_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx23/HIGHRES/image/jpeg/b0ab4f510eaaca7359c876deed13c147/fx23_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>48288</xocs:filesize>
               <xocs:pixel-height>633</xocs:pixel-height>
               <xocs:pixel-width>429</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx24_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx24/HIGHRES/image/jpeg/62be8f4aacff13fe8f1d03b9fc64a327/fx24_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59857</xocs:filesize>
               <xocs:pixel-height>583</xocs:pixel-height>
               <xocs:pixel-width>479</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx25_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx25/HIGHRES/image/jpeg/ecd66f56739793dcffa9faa73577e4a3/fx25_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56451</xocs:filesize>
               <xocs:pixel-height>839</xocs:pixel-height>
               <xocs:pixel-width>429</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx26_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx26/HIGHRES/image/jpeg/7833ca7bdc74831c3a9169e8c4caf89b/fx26_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>63263</xocs:filesize>
               <xocs:pixel-height>593</xocs:pixel-height>
               <xocs:pixel-width>512</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx27_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx27/HIGHRES/image/jpeg/5cf35ebd0b845877d5d398e26e163c47/fx27_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>60245</xocs:filesize>
               <xocs:pixel-height>593</xocs:pixel-height>
               <xocs:pixel-width>476</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx28_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx28/HIGHRES/image/jpeg/3ae5ee77b6efcb0f8ccd0eedb95356ee/fx28_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>41983</xocs:filesize>
               <xocs:pixel-height>439</xocs:pixel-height>
               <xocs:pixel-width>650</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx29_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx29/HIGHRES/image/jpeg/aba8dfdbd6009648d82d4fffb3a70dfd/fx29_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>53068</xocs:filesize>
               <xocs:pixel-height>439</xocs:pixel-height>
               <xocs:pixel-width>650</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx3/HIGHRES/image/jpeg/b89bfeac4bb5e5ee9289dc061bf1e3aa/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>60718</xocs:filesize>
               <xocs:pixel-height>651</xocs:pixel-height>
               <xocs:pixel-width>509</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx30_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx30/HIGHRES/image/jpeg/32c108329bb97fbdd329817894e4fb23/fx30_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>52365</xocs:filesize>
               <xocs:pixel-height>414</xocs:pixel-height>
               <xocs:pixel-width>659</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx31_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx31/HIGHRES/image/jpeg/0276bd74c487f7f6ba7463727b7cabaf/fx31_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>52342</xocs:filesize>
               <xocs:pixel-height>414</xocs:pixel-height>
               <xocs:pixel-width>651</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx32_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx32/HIGHRES/image/jpeg/560f6d1da548a0c2ac13e72afa97a8aa/fx32_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56306</xocs:filesize>
               <xocs:pixel-height>525</xocs:pixel-height>
               <xocs:pixel-width>650</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx33_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx33/HIGHRES/image/jpeg/e73d1f614412decf2778fd692e1d4efc/fx33_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>42940</xocs:filesize>
               <xocs:pixel-height>431</xocs:pixel-height>
               <xocs:pixel-width>648</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx4/HIGHRES/image/jpeg/2f820b9d2d4eccf9a4aff5ef3df9fe84/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59371</xocs:filesize>
               <xocs:pixel-height>563</xocs:pixel-height>
               <xocs:pixel-width>509</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx5/HIGHRES/image/jpeg/7c2e58b5d54357d6b6a743c2b4019ae2/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>60435</xocs:filesize>
               <xocs:pixel-height>563</xocs:pixel-height>
               <xocs:pixel-width>509</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx6/HIGHRES/image/jpeg/7bed8d8290385beff3241529e5f0c9b3/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>61731</xocs:filesize>
               <xocs:pixel-height>651</xocs:pixel-height>
               <xocs:pixel-width>509</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx7/HIGHRES/image/jpeg/30daf664ab7b442d73c7aa6ba3101827/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>63029</xocs:filesize>
               <xocs:pixel-height>574</xocs:pixel-height>
               <xocs:pixel-width>509</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx8/HIGHRES/image/jpeg/7a279411157f9dda99e3323823abaf2d/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>51275</xocs:filesize>
               <xocs:pixel-height>479</xocs:pixel-height>
               <xocs:pixel-width>520</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/fx9/HIGHRES/image/jpeg/58d09289ea9fd5e145850501d714bceb/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>50574</xocs:filesize>
               <xocs:pixel-height>468</xocs:pixel-height>
               <xocs:pixel-width>522</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr10/HIGHRES/image/jpeg/140a408c3c5513e9a6c456c5db90a543/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>743676</xocs:filesize>
               <xocs:pixel-height>2339</xocs:pixel-height>
               <xocs:pixel-width>3015</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr11/HIGHRES/image/jpeg/512d55eb1848d23ead043ae6a9ac07d3/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>619632</xocs:filesize>
               <xocs:pixel-height>1488</xocs:pixel-height>
               <xocs:pixel-width>3150</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr12/HIGHRES/image/jpeg/e8dfdc22933e6da0844aa054f7f5007e/gr12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2118108</xocs:filesize>
               <xocs:pixel-height>3147</xocs:pixel-height>
               <xocs:pixel-width>2193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr13/HIGHRES/image/jpeg/4f1039f6889d467b29f9c61a30ab37c1/gr13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1498597</xocs:filesize>
               <xocs:pixel-height>4594</xocs:pixel-height>
               <xocs:pixel-width>2856</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr14/HIGHRES/image/jpeg/d28a04991815bc8c0a7b66925e2e3611/gr14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>351703</xocs:filesize>
               <xocs:pixel-height>1860</xocs:pixel-height>
               <xocs:pixel-width>2463</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr15/HIGHRES/image/jpeg/6ec84741b263ef92dc0c2aeb19b885eb/gr15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr15</xocs:file-basename>
               <xocs:filename>gr15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>490612</xocs:filesize>
               <xocs:pixel-height>3208</xocs:pixel-height>
               <xocs:pixel-width>2402</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr16/HIGHRES/image/jpeg/e0a45b254e5623d165f303924218b83a/gr16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr16</xocs:file-basename>
               <xocs:filename>gr16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>814387</xocs:filesize>
               <xocs:pixel-height>2673</xocs:pixel-height>
               <xocs:pixel-width>3053</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr17/HIGHRES/image/jpeg/b6b8c2a98288b2f7d0a54d80e7a06046/gr17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr17</xocs:file-basename>
               <xocs:filename>gr17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1642399</xocs:filesize>
               <xocs:pixel-height>3169</xocs:pixel-height>
               <xocs:pixel-width>3053</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr18/HIGHRES/image/jpeg/445966ff8fccedb2e06e9d94b6011e2f/gr18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr18</xocs:file-basename>
               <xocs:filename>gr18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>751914</xocs:filesize>
               <xocs:pixel-height>3040</xocs:pixel-height>
               <xocs:pixel-width>2403</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr19/HIGHRES/image/jpeg/302889583e9d7f842bf70ca2b09be3fe/gr19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr19</xocs:file-basename>
               <xocs:filename>gr19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>842566</xocs:filesize>
               <xocs:pixel-height>2582</xocs:pixel-height>
               <xocs:pixel-width>2462</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr1a_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr1a/HIGHRES/image/jpeg/f981962fadc6a554faca659b5cc8b4fa/gr1a_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1a</xocs:file-basename>
               <xocs:filename>gr1a_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1233236</xocs:filesize>
               <xocs:pixel-height>3981</xocs:pixel-height>
               <xocs:pixel-width>3229</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr1b_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr1b/HIGHRES/image/jpeg/b40f2f317cbbdba7e0a81b683c21cde0/gr1b_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1b</xocs:file-basename>
               <xocs:filename>gr1b_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1372000</xocs:filesize>
               <xocs:pixel-height>4093</xocs:pixel-height>
               <xocs:pixel-width>3463</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr2/HIGHRES/image/jpeg/aa8fcaaf36bdf30b1086180799009c04/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>373059</xocs:filesize>
               <xocs:pixel-height>1999</xocs:pixel-height>
               <xocs:pixel-width>2436</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr20/HIGHRES/image/jpeg/02a41e1ef8c09e7055b5dacbc42e83c5/gr20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr20</xocs:file-basename>
               <xocs:filename>gr20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>591791</xocs:filesize>
               <xocs:pixel-height>2457</xocs:pixel-height>
               <xocs:pixel-width>2186</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr21/HIGHRES/image/jpeg/8b32f2cef5cd0cc66747258ca18a5617/gr21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr21</xocs:file-basename>
               <xocs:filename>gr21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1333794</xocs:filesize>
               <xocs:pixel-height>3829</xocs:pixel-height>
               <xocs:pixel-width>2659</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr22/HIGHRES/image/jpeg/41e9e3a2ac0dd70abe64e9c1ef532928/gr22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr22</xocs:file-basename>
               <xocs:filename>gr22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>729515</xocs:filesize>
               <xocs:pixel-height>2769</xocs:pixel-height>
               <xocs:pixel-width>3051</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr23_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr23/HIGHRES/image/jpeg/9cbe744a40a273c1403800f86286769b/gr23_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr23</xocs:file-basename>
               <xocs:filename>gr23_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1398796</xocs:filesize>
               <xocs:pixel-height>3895</xocs:pixel-height>
               <xocs:pixel-width>2403</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr24_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr24/HIGHRES/image/jpeg/8251fdeb2cb51a4cbda09dc8c983fbe4/gr24_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr24</xocs:file-basename>
               <xocs:filename>gr24_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>836340</xocs:filesize>
               <xocs:pixel-height>3330</xocs:pixel-height>
               <xocs:pixel-width>2561</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr25_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr25/HIGHRES/image/jpeg/a8f4d7ed360b4706711be21040a35921/gr25_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr25</xocs:file-basename>
               <xocs:filename>gr25_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1016581</xocs:filesize>
               <xocs:pixel-height>2630</xocs:pixel-height>
               <xocs:pixel-width>2600</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr26_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr26/HIGHRES/image/jpeg/2171cf0aa5c9af1a5c20d1ad6eb5e7b0/gr26_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr26</xocs:file-basename>
               <xocs:filename>gr26_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>638569</xocs:filesize>
               <xocs:pixel-height>1911</xocs:pixel-height>
               <xocs:pixel-width>3448</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr27_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr27/HIGHRES/image/jpeg/f0079fd3c0e43d93f57a0b20ef9a18a2/gr27_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr27</xocs:file-basename>
               <xocs:filename>gr27_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>338095</xocs:filesize>
               <xocs:pixel-height>2196</xocs:pixel-height>
               <xocs:pixel-width>2364</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr28_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr28/HIGHRES/image/jpeg/f24828ea4a94a7c31231e4ab3870a537/gr28_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr28</xocs:file-basename>
               <xocs:filename>gr28_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>559844</xocs:filesize>
               <xocs:pixel-height>1557</xocs:pixel-height>
               <xocs:pixel-width>2463</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr29_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr29/HIGHRES/image/jpeg/e02b0cdfa9549862a9f28b92ea1db30a/gr29_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr29</xocs:file-basename>
               <xocs:filename>gr29_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>792347</xocs:filesize>
               <xocs:pixel-height>2999</xocs:pixel-height>
               <xocs:pixel-width>1932</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr3/HIGHRES/image/jpeg/c34bd257eef5e6ec0b5bfd49e6613c18/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>826384</xocs:filesize>
               <xocs:pixel-height>2799</xocs:pixel-height>
               <xocs:pixel-width>2767</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr30_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr30/HIGHRES/image/jpeg/b50c8a591dabc145896e06869a4afbfd/gr30_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr30</xocs:file-basename>
               <xocs:filename>gr30_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>220375</xocs:filesize>
               <xocs:pixel-height>1097</xocs:pixel-height>
               <xocs:pixel-width>1971</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr31_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr31/HIGHRES/image/jpeg/00dad17139981431353cb2faee11a0a8/gr31_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr31</xocs:file-basename>
               <xocs:filename>gr31_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>752144</xocs:filesize>
               <xocs:pixel-height>2896</xocs:pixel-height>
               <xocs:pixel-width>2185</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr32_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr32/HIGHRES/image/jpeg/093145cd53808d7829ed2970c260fd3e/gr32_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr32</xocs:file-basename>
               <xocs:filename>gr32_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>837736</xocs:filesize>
               <xocs:pixel-height>2743</xocs:pixel-height>
               <xocs:pixel-width>2326</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr33_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr33/HIGHRES/image/jpeg/9553845d7e4a2e1ed45fa06d30f54008/gr33_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr33</xocs:file-basename>
               <xocs:filename>gr33_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>878666</xocs:filesize>
               <xocs:pixel-height>2816</xocs:pixel-height>
               <xocs:pixel-width>2364</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr34_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr34/HIGHRES/image/jpeg/e40d09fde5b4f0f9fe5581b2a9fafdb2/gr34_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr34</xocs:file-basename>
               <xocs:filename>gr34_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>853554</xocs:filesize>
               <xocs:pixel-height>2661</xocs:pixel-height>
               <xocs:pixel-width>3348</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr35_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr35/HIGHRES/image/jpeg/3dd4591faf9ea144bbbbd7725b1d5c3c/gr35_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr35</xocs:file-basename>
               <xocs:filename>gr35_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>300484</xocs:filesize>
               <xocs:pixel-height>2283</xocs:pixel-height>
               <xocs:pixel-width>1378</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr36_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr36/HIGHRES/image/jpeg/367a3548292b42683e3c4601c6812d4b/gr36_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr36</xocs:file-basename>
               <xocs:filename>gr36_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>728833</xocs:filesize>
               <xocs:pixel-height>1789</xocs:pixel-height>
               <xocs:pixel-width>3348</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr37_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr37/HIGHRES/image/jpeg/f962cf3399cb71c6a8402fb6796956ef/gr37_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr37</xocs:file-basename>
               <xocs:filename>gr37_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>890368</xocs:filesize>
               <xocs:pixel-height>2243</xocs:pixel-height>
               <xocs:pixel-width>2188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr38_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr38/HIGHRES/image/jpeg/f2285f7328b8c495321525cd6d15c541/gr38_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr38</xocs:file-basename>
               <xocs:filename>gr38_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>164717</xocs:filesize>
               <xocs:pixel-height>1046</xocs:pixel-height>
               <xocs:pixel-width>1379</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr39_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr39/HIGHRES/image/jpeg/f9c431467bedb252a76c4127327a1015/gr39_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr39</xocs:file-basename>
               <xocs:filename>gr39_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1247298</xocs:filesize>
               <xocs:pixel-height>4288</xocs:pixel-height>
               <xocs:pixel-width>2991</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr4/HIGHRES/image/jpeg/4ca2d55a73950a30182d743b0c3cf7e3/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1084376</xocs:filesize>
               <xocs:pixel-height>2830</xocs:pixel-height>
               <xocs:pixel-width>2510</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr40_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr40/HIGHRES/image/jpeg/bdadf72383c6d6c35a36b3a0fa247a2f/gr40_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr40</xocs:file-basename>
               <xocs:filename>gr40_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1024428</xocs:filesize>
               <xocs:pixel-height>2385</xocs:pixel-height>
               <xocs:pixel-width>3121</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr41_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr41/HIGHRES/image/jpeg/5b5566cd86e48c527537ac4d2543e362/gr41_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr41</xocs:file-basename>
               <xocs:filename>gr41_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1616090</xocs:filesize>
               <xocs:pixel-height>3473</xocs:pixel-height>
               <xocs:pixel-width>3349</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr42_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr42/HIGHRES/image/jpeg/dfb4f3cdb2e0a33e3a83ea0188935f5d/gr42_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr42</xocs:file-basename>
               <xocs:filename>gr42_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>566048</xocs:filesize>
               <xocs:pixel-height>1474</xocs:pixel-height>
               <xocs:pixel-width>2562</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr43_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr43/HIGHRES/image/jpeg/dbcc6998bfc3f1292093dd7da7969e81/gr43_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr43</xocs:file-basename>
               <xocs:filename>gr43_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>616282</xocs:filesize>
               <xocs:pixel-height>2395</xocs:pixel-height>
               <xocs:pixel-width>1971</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr44_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr44/HIGHRES/image/jpeg/cc376d1f195332b0641fdae7718ce7d5/gr44_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr44</xocs:file-basename>
               <xocs:filename>gr44_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>100793</xocs:filesize>
               <xocs:pixel-height>722</xocs:pixel-height>
               <xocs:pixel-width>1024</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr5/HIGHRES/image/jpeg/3955e0346221d953bef14cb20a7f9a00/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1076551</xocs:filesize>
               <xocs:pixel-height>2822</xocs:pixel-height>
               <xocs:pixel-width>2395</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr6/HIGHRES/image/jpeg/cd2d1eefa8a2e249588b9d441fe5b5d2/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>299487</xocs:filesize>
               <xocs:pixel-height>2249</xocs:pixel-height>
               <xocs:pixel-width>2115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr7/HIGHRES/image/jpeg/c9f6f5906811fae63d86139978618cb5/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>781593</xocs:filesize>
               <xocs:pixel-height>2371</xocs:pixel-height>
               <xocs:pixel-width>3347</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr8/HIGHRES/image/jpeg/a71910c5cc468d86d6041098149fb7aa/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1283894</xocs:filesize>
               <xocs:pixel-height>3181</xocs:pixel-height>
               <xocs:pixel-width>2664</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416300897-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416300897/gr9/HIGHRES/image/jpeg/8fd142900c45a982fabe95bb0fae857b/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1902290</xocs:filesize>
               <xocs:pixel-height>4677</xocs:pixel-height>
               <xocs:pixel-width>2717</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.4" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>8369</aid>
            <ce:pii>S0223-5234(16)30089-7</ce:pii>
            <ce:doi>10.1016/j.ejmech.2016.02.018</ce:doi>
            <ce:copyright type="full-transfer" year="2016">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig.Â 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Protein kinase inhibitors approved by FDA.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr1a" xlink:type="simple" xlink:href="pii:S0223523416300897/gr1a"/></ce:link>
               <ce:link locator="gr1b" xlink:type="simple" xlink:href="pii:S0223523416300897/gr1b"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig.Â 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Purine based protein kinase inhibitors in pre-clinical/clinical trials.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr2" xlink:type="simple" xlink:href="pii:S0223523416300897/gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig.Â 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">3,4-ring fused azaindoles and deazapurines as JAK2 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr3" xlink:type="simple" xlink:href="pii:S0223523416300897/gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig.Â 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">4-aminotetrahydroquinazolino[3,2-<ce:italic>e</ce:italic>]purine analogs as Src tyrosine kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr4" xlink:type="simple" xlink:href="pii:S0223523416300897/gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig.Â 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">2,6-disubstituted purine analogs as Src tyrosine kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr5" xlink:type="simple" xlink:href="pii:S0223523416300897/gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig.Â 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">2,6,9-hetero trisubstituted purine analogs as Stat3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr6" xlink:type="simple" xlink:href="pii:S0223523416300897/gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig.Â 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Imidazopurine analogs as bruton's tyrosine kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr7" xlink:type="simple" xlink:href="pii:S0223523416300897/gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig.Â 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Purin-2-yl and purin-6-yl-aminoglucitol analogs as FGFR3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr8" xlink:type="simple" xlink:href="pii:S0223523416300897/gr8"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig.Â 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">6-oxygenated purine analogs as TAM inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr9" xlink:type="simple" xlink:href="pii:S0223523416300897/gr9"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig.Â 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Purine and pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine as PI3KÎ± inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr10" xlink:type="simple" xlink:href="pii:S0223523416300897/gr10"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig.Â 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Imidazolopyrimidines as PI3K inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr11" xlink:type="simple" xlink:href="pii:S0223523416300897/gr11"/></ce:link>
            </ce:figure>
            <ce:figure id="fig12">
               <ce:label>Fig.Â 12</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Xanthine analogs as fluorescent PI3KÎ± inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr12" xlink:type="simple" xlink:href="pii:S0223523416300897/gr12"/></ce:link>
            </ce:figure>
            <ce:figure id="fig13">
               <ce:label>Fig.Â 13</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="fspara0070" view="all">Benzimidazole analogs as PI3-kinase delta inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr13" xlink:type="simple" xlink:href="pii:S0223523416300897/gr13"/></ce:link>
            </ce:figure>
            <ce:figure id="fig14">
               <ce:label>Fig.Â 14</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="fspara0075" view="all">2,6,9-trisubstituted purine analogs as PI3-kinase delta inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr14" xlink:type="simple" xlink:href="pii:S0223523416300897/gr14"/></ce:link>
            </ce:figure>
            <ce:figure id="fig15">
               <ce:label>Fig.Â 15</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="fspara0080" view="all">1,2,4-triazole and purine acyclic cyclopropane nucleoside analogs as tyrosine kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr15" xlink:type="simple" xlink:href="pii:S0223523416300897/gr15"/></ce:link>
            </ce:figure>
            <ce:figure id="fig16">
               <ce:label>Fig.Â 16</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="fspara0085" view="all">Pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine as tyrosine kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr16" xlink:type="simple" xlink:href="pii:S0223523416300897/gr16"/></ce:link>
            </ce:figure>
            <ce:figure id="fig17">
               <ce:label>Fig.Â 17</ce:label>
               <ce:caption id="cap0090">
                  <ce:simple-para id="fspara0090" view="all">2,8-diamino purine analogs as reversible tyrosine kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr17" xlink:type="simple" xlink:href="pii:S0223523416300897/gr17"/></ce:link>
            </ce:figure>
            <ce:figure id="fig18">
               <ce:label>Fig.Â 18</ce:label>
               <ce:caption id="cap0095">
                  <ce:simple-para id="fspara0095" view="all">4-aminopurine derivatives as Stk1 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr18" xlink:type="simple" xlink:href="pii:S0223523416300897/gr18"/></ce:link>
            </ce:figure>
            <ce:figure id="fig19">
               <ce:label>Fig.Â 19</ce:label>
               <ce:caption id="cap0100">
                  <ce:simple-para id="fspara0100" view="all">8-arylated purine analogs as GSK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr19" xlink:type="simple" xlink:href="pii:S0223523416300897/gr19"/></ce:link>
            </ce:figure>
            <ce:figure id="fig20">
               <ce:label>Fig.Â 20</ce:label>
               <ce:caption id="cap0105">
                  <ce:simple-para id="fspara0105" view="all">2-aminopurine analogs as BRAF kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr20" xlink:type="simple" xlink:href="pii:S0223523416300897/gr20"/></ce:link>
            </ce:figure>
            <ce:figure id="fig21">
               <ce:label>Fig.Â 21</ce:label>
               <ce:caption id="cap0110">
                  <ce:simple-para id="fspara0110" view="all">Substituted purine derivatives as BRAF kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr21" xlink:type="simple" xlink:href="pii:S0223523416300897/gr21"/></ce:link>
            </ce:figure>
            <ce:figure id="fig22">
               <ce:label>Fig.Â 22</ce:label>
               <ce:caption id="cap0115">
                  <ce:simple-para id="fspara0115" view="all">2,8,9-substituted purine analogs as JNK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr22" xlink:type="simple" xlink:href="pii:S0223523416300897/gr22"/></ce:link>
            </ce:figure>
            <ce:figure id="fig23">
               <ce:label>Fig.Â 23</ce:label>
               <ce:caption id="cap0120">
                  <ce:simple-para id="fspara0120" view="all">Aminopurine analogs as JNK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr23" xlink:type="simple" xlink:href="pii:S0223523416300897/gr23"/></ce:link>
            </ce:figure>
            <ce:figure id="fig24">
               <ce:label>Fig.Â 24</ce:label>
               <ce:caption id="cap0125">
                  <ce:simple-para id="fspara0125" view="all">6-aminopurine analogs as casein kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr24" xlink:type="simple" xlink:href="pii:S0223523416300897/gr24"/></ce:link>
            </ce:figure>
            <ce:figure id="fig25">
               <ce:label>Fig.Â 25</ce:label>
               <ce:caption id="cap0130">
                  <ce:simple-para id="fspara0130" view="all">N-(3-((7<ce:italic>H</ce:italic>-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)sulfonamide analogs as Akt1 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr25" xlink:type="simple" xlink:href="pii:S0223523416300897/gr25"/></ce:link>
            </ce:figure>
            <ce:figure id="fig26">
               <ce:label>Fig.Â 26</ce:label>
               <ce:caption id="cap0135">
                  <ce:simple-para id="fspara0135" view="all">Diphenylmethylamine analogs as Akt1 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr26" xlink:type="simple" xlink:href="pii:S0223523416300897/gr26"/></ce:link>
            </ce:figure>
            <ce:figure id="fig27">
               <ce:label>Fig.Â 27</ce:label>
               <ce:caption id="cap0140">
                  <ce:simple-para id="fspara0140" view="all">Various substituted purine analogs as CDK1 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr27" xlink:type="simple" xlink:href="pii:S0223523416300897/gr27"/></ce:link>
            </ce:figure>
            <ce:figure id="fig28">
               <ce:label>Fig.Â 28</ce:label>
               <ce:caption id="cap0145">
                  <ce:simple-para id="fspara0145" view="all">Purine based platinum (II) oxalate complexes as CDK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr28" xlink:type="simple" xlink:href="pii:S0223523416300897/gr28"/></ce:link>
            </ce:figure>
            <ce:figure id="fig29">
               <ce:label>Fig.Â 29</ce:label>
               <ce:caption id="cap0150">
                  <ce:simple-para id="fspara0150" view="all">Purine and pyrimidine analogs as CDK2 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr29" xlink:type="simple" xlink:href="pii:S0223523416300897/gr29"/></ce:link>
            </ce:figure>
            <ce:figure id="fig30">
               <ce:label>Fig.Â 30</ce:label>
               <ce:caption id="cap0155">
                  <ce:simple-para id="fspara0155" view="all">Purine derived sulfonamide analogs as CDK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr30" xlink:type="simple" xlink:href="pii:S0223523416300897/gr30"/></ce:link>
            </ce:figure>
            <ce:figure id="fig31">
               <ce:label>Fig.Â 31</ce:label>
               <ce:caption id="cap0160">
                  <ce:simple-para id="fspara0160" view="all">6-pyridylmethylaminopurine analogs as CDK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr31" xlink:type="simple" xlink:href="pii:S0223523416300897/gr31"/></ce:link>
            </ce:figure>
            <ce:figure id="fig32">
               <ce:label>Fig.Â 32</ce:label>
               <ce:caption id="cap0165">
                  <ce:simple-para id="fspara0165" view="all">2,6,9-substituted purine analogs as CDK5 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr32" xlink:type="simple" xlink:href="pii:S0223523416300897/gr32"/></ce:link>
            </ce:figure>
            <ce:figure id="fig33">
               <ce:label>Fig.Â 33</ce:label>
               <ce:caption id="cap0170">
                  <ce:simple-para id="fspara0170" view="all">Various substituted 6-aminopurine analogs as fluorescent CDK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr33" xlink:type="simple" xlink:href="pii:S0223523416300897/gr33"/></ce:link>
            </ce:figure>
            <ce:figure id="fig34">
               <ce:label>Fig.Â 34</ce:label>
               <ce:caption id="cap0175">
                  <ce:simple-para id="fspara0175" view="all">2,6,9-trisubstituted purine analogs as CDK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr34" xlink:type="simple" xlink:href="pii:S0223523416300897/gr34"/></ce:link>
            </ce:figure>
            <ce:figure id="fig35">
               <ce:label>Fig.Â 35</ce:label>
               <ce:caption id="cap0180">
                  <ce:simple-para id="fspara0180" view="all">Macrocyclic 2-anilino-4-phenyl-purine analogs as PDK1 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr35" xlink:type="simple" xlink:href="pii:S0223523416300897/gr35"/></ce:link>
            </ce:figure>
            <ce:figure id="fig36">
               <ce:label>Fig.Â 36</ce:label>
               <ce:caption id="cap0185">
                  <ce:simple-para id="fspara0185" view="all">2,6,9-trisubstituted purine analogs as multiple CDK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr36" xlink:type="simple" xlink:href="pii:S0223523416300897/gr36"/></ce:link>
            </ce:figure>
            <ce:figure id="fig37">
               <ce:label>Fig.Â 37</ce:label>
               <ce:caption id="cap0190">
                  <ce:simple-para id="fspara0190" view="all">Guanidino analogs as CDK1/2 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr37" xlink:type="simple" xlink:href="pii:S0223523416300897/gr37"/></ce:link>
            </ce:figure>
            <ce:figure id="fig38">
               <ce:label>Fig.Â 38</ce:label>
               <ce:caption id="cap0195">
                  <ce:simple-para id="fspara0195" view="all">2,6,9-trisubstituted purine analog as CDK1 and CDK5 inhibitor.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr38" xlink:type="simple" xlink:href="pii:S0223523416300897/gr38"/></ce:link>
            </ce:figure>
            <ce:figure id="fig39">
               <ce:label>Fig.Â 39</ce:label>
               <ce:caption id="cap0200">
                  <ce:simple-para id="fspara0200" view="all">2-Anilino-4-aryl-8<ce:italic>H</ce:italic>-purine analogs as PDK1 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr39" xlink:type="simple" xlink:href="pii:S0223523416300897/gr39"/></ce:link>
            </ce:figure>
            <ce:figure id="fig40">
               <ce:label>Fig.Â 40</ce:label>
               <ce:caption id="cap0205">
                  <ce:simple-para id="fspara0205" view="all">Non-symmetrical monocationic purine analogs as ChoK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr40" xlink:type="simple" xlink:href="pii:S0223523416300897/gr40"/></ce:link>
            </ce:figure>
            <ce:figure id="fig41">
               <ce:label>Fig.Â 41</ce:label>
               <ce:caption id="cap0210">
                  <ce:simple-para id="fspara0210" view="all">Lead based purine analogs as Mps1 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr41" xlink:type="simple" xlink:href="pii:S0223523416300897/gr41"/></ce:link>
            </ce:figure>
            <ce:figure id="fig42">
               <ce:label>Fig.Â 42</ce:label>
               <ce:caption id="cap0215">
                  <ce:simple-para id="fspara0215" view="all">Purine-benzimidazole hybrids as Aurora-A kinaseÂ inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr42" xlink:type="simple" xlink:href="pii:S0223523416300897/gr42"/></ce:link>
            </ce:figure>
            <ce:figure id="fig43">
               <ce:label>Fig.Â 43</ce:label>
               <ce:caption id="cap0220">
                  <ce:simple-para id="fspara0220" view="all">(RS)-9-(2,3-dihydro-1,4-benzoxaheteroin-2-ylmethyl)-9<ce:italic>H</ce:italic>-purines as protein kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr43" xlink:type="simple" xlink:href="pii:S0223523416300897/gr43"/></ce:link>
            </ce:figure>
            <ce:figure id="fig44">
               <ce:label>Fig.Â 44</ce:label>
               <ce:caption id="cap0225">
                  <ce:simple-para id="fspara0225" view="all">Bozepinib as RNA-dependent protein kinase (PKR) inhibitor.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr44" xlink:type="simple" xlink:href="pii:S0223523416300897/gr44"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>TableÂ 1</ce:label>
               <ce:caption id="cap0230">
                  <ce:simple-para id="tspara0010" view="all">Purine based compounds patented during 2001â2015 as kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <tgroup cols="7">
                  <colspec colnum="1" colname="col1" colwidth="27*"/></colspec>
                  <colspec colnum="2" colname="col2" colwidth="14*"/></colspec>
                  <colspec colnum="3" colname="col3" colwidth="3*"/></colspec>
                  <colspec colnum="4" colname="col4" colwidth="21*"/></colspec>
                  <colspec colnum="5" colname="col5" colwidth="18*"/></colspec>
                  <colspec colnum="6" colname="col6" colwidth="7*"/></colspec>
                  <colspec colnum="7" colname="col7" colwidth="5*"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Title</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Patent no.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Year</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Inventors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Structure</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Type</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IC<inf loc="post">50</inf> (Target)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pyrimidine substituted purine compounds as kinase(s) inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0105382</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Apr-2015</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Dizhing Chen, Meredith Williams</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx2" xlink:type="simple" xlink:href="pii:S0223523416300897/fx2"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">39Â nM (mTOR) 11Â nM (PI3K)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âQuinazolinones as inhibitors of human phosphatidylinositol 3-kinase deltaâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0116266</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">May-2013</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kerry W. Fowwler, Danwen Huang, Edward A. Kesicki, Hua Chee OOI, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal D. Puri</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:type="simple" xlink:href="pii:S0223523416300897/fx3"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">12Â nM (PI3KÎ´)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âQuinazolinones as inhibitors of human phosphatidylinositol 3-kinase deltaâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0116266</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">May-2013</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kerry W. Fowwler, Danwen Huang, Edward A. Kesicki, Hua Chee OOI, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg,<br/></br>Kamal D. Puri</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:type="simple" xlink:href="pii:S0223523416300897/fx4"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">16Â nM (PI3KÎ´)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âQuinazolinones as inhibitors of human phosphatidylinositol 3-kinase deltaâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0116266</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">May-2013</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kerry W. Fowwler, Danwen Huang, Edward A. Kesicki, Hua Chee OOI, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal D. Puri</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:type="simple" xlink:href="pii:S0223523416300897/fx5"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">9Â nM (PI3KÎ´)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âQuinazolinones as inhibitors of human phosphatidylinositol 3-kinase deltaâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0116266</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">May-2013</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kerry W. Fowwler, Danwen Huang, Edward A. Kesicki, Hua Chee OOI, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal D. Puri</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:type="simple" xlink:href="pii:S0223523416300897/fx6"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">45Â nM (PI3KÎ´)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âQuinazolinones as inhibitors of human phosphatidylinositol 3-kinase deltaâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0116266</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">May-2013</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kerry W. Fowwler, Danwen Huang, Edward A. Kesicki, Hua Chee OOI, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal D. Puri</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:type="simple" xlink:href="pii:S0223523416300897/fx7"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">26Â nM (PI3KÎ´)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âSubstituted 6-(2-hydroxybenzyl,amino)purine derivatives, their use as medicaments and compositions containing these derivativeâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0070512</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Mar-2012</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Marek Zatloukal, Vladimir Krystof, labor Havlicek, Igor Popa, Karel Dolezal, Miroslav Strand, Radek Jorda</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:type="simple" xlink:href="pii:S0223523416300897/fx8"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">20Â nM (CDK2) 7Â nM (CDK9)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âSubstituted 6-(2-hydroxybenzyl,amino)purine derivatives, their use as medicaments and compositions containing these derivativeâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0070512</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Mar-2012</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Marek Zatloukal, Vladimir Krystof, labor Havlicek, Igor Popa, Karel Dolezal, Miroslav Strand, Radek Jorda</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:type="simple" xlink:href="pii:S0223523416300897/fx9"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">20Â nM (CDK2) 8Â nM (CDK9)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âSubstituted 6-(2-hydroxybenzyl,amino)purine derivatives, their use as medicaments and compositions containing these derivativeâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0070512</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Mar-2012</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Marek Zatloukal, Vladimir Krystof, labor Havlicek, Igor Popa, Karel Dolezal, Miroslav Strand, Radek Jorda</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:type="simple" xlink:href="pii:S0223523416300897/fx10"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">20Â nM (CDK2) 6Â nM (CDK9)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âSubstituted 6-(2-hydroxybenzyl,amino)purine derivatives, their use as medicaments and compositions containing these derivativeâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0070512</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Mar-2012</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Marek Zatloukal, Vladimir Krystof, labor Havlicek, Igor Popa, Karel Dolezal, Miroslav Strand, Radek Jorda</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:type="simple" xlink:href="pii:S0223523416300897/fx11"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">20Â nM (CDK2) 7Â nM (CDK9)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âSubstituted 6-(2-hydroxybenzyl,amino)purine derivatives, their use as medicaments and compositions containing these derivativeâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0070512</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Mar-2012</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Marek Zatloukal, Vladimir Krystof, labor Havlicek, Igor Popa, Karel Dolezal, Miroslav Strand, Radek Jorda</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx12" xlink:type="simple" xlink:href="pii:S0223523416300897/fx12"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">20Â nM (CDK2) 9Â nM (CDK9)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âPurine PI3K inhibitor compounds and methods of useâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0135988</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">May-2012</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Georgette Castanedo, Irina chuckowree, Adrian Folks, Daniel P. Sutherlin, Nan C. Wan</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx13" xlink:type="simple" xlink:href="pii:S0223523416300897/fx13"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><10Â nM (PI3K)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âPurine PI3K inhibitor compounds and methods of useâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0135988</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">May-2012</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Georgette Castanedo, Irina chuckowree, Adrian Folks, Daniel P. Sutherlin, Nan C. Wan</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx14" xlink:type="simple" xlink:href="pii:S0223523416300897/fx14"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><10Â nM (PI3K)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âPI3K Isoform selective inhibitorâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0130398</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2011</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Congxin Ling, Zhigang Li</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx15" xlink:type="simple" xlink:href="pii:S0223523416300897/fx15"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><30Â nM (PI3KÎ´)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âPI3K Isoform selective inhibitorâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0130398</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2011</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Congxin Ling, Zhigang Li</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx16" xlink:type="simple" xlink:href="pii:S0223523416300897/fx16"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><30Â nM (PI3KÎ´)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">â1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidine, purine, 7<italic>H</italic>-purin-8(9)-one, 3<italic>H</italic>-[1,2,3]triazolo[4,5-<italic>d</italic>]pyrimidine compounds, their use as MTOR kinase and PI3K kinase inhibitors and their synthesisâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0192176</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jul-2009</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Arie Zask, Christoph M. Dehnhardt, Joshua A. Kaplan, Efren Guillermo, Delos Santos, Aranapakam M. Venkatesan, Jeroen C. Verheijen</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx17" xlink:type="simple" xlink:href="pii:S0223523416300897/fx17"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.4Â nM (mTOR)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âKinase inhibitors and their usesâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0142402</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2007</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pingyu Ding, Ankush Argade, Dane Goff, Rajinder Singh, Esteban Masuda, Vanessa Taylor, Sacha Holland</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx18" xlink:type="simple" xlink:href="pii:S0223523416300897/fx18"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><1Â nM (JAK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âKinase inhibitors and their usesâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0142402</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2007</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pingyu Ding, Ankush Argade, Dane Goff, Rajinder Singh, Esteban Masuda, Vanessa Taylor, Sacha Holland</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx19" xlink:type="simple" xlink:href="pii:S0223523416300897/fx19"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><1Â nM (JAK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âKinase inhibitors and their usesâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0142402</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2007</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pingyu Ding, Ankush Argade, Dane Goff, Rajinder Singh, Esteban Masuda, Vanessa Taylor, Sacha Holland</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx20" xlink:type="simple" xlink:href="pii:S0223523416300897/fx20"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><1Â nM (JAK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âKinase inhibitors and their usesâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0142402</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2007</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pingyu Ding, Ankush Argade, Dane Goff, Rajinder Singh, Esteban Masuda, Vanessa Taylor, Sacha Holland</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx21" xlink:type="simple" xlink:href="pii:S0223523416300897/fx21"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><1Â nM (JAK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âKinase inhibitors and their usesâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US0142402</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2007</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pingyu Ding, Ankush Argade, Dane Goff, Rajinder Singh, Esteban Masuda, Vanessa Taylor, Sacha Holland</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx22" xlink:type="simple" xlink:href="pii:S0223523416300897/fx22"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><1Â nM (JAK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âPurine derivatives inhibitors of tyrosine protein kinase sykâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6589950</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">July-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Stephen P. Collingwood, Judy Hayler, Darren M. Le Grand, Henri Mattes, Keith A. Menear, Clive V.Walker, Xiao-Ling Cockcroft</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx23" xlink:type="simple" xlink:href="pii:S0223523416300897/fx23"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5Â nM (SYK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âPurine derivatives inhibitors of tyrosine protein kinase sykâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6589950</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">July-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Stephen P. Collingwood, Judy Hayler, Darren M. Le Grand, Henri Mattes, Keith A. Menear, Clive V.Walker, Xiao-Ling Cockcroft</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx24" xlink:type="simple" xlink:href="pii:S0223523416300897/fx24"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5Â nM (SYK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âPurine derivatives inhibitors of tyrosine protein kinase sykâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6589950</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">July-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Stephen P. Collingwood, Judy Hayler, Darren M. Le Grand, Henri Mattes, Keith A. Menear, Clive V.Walker, Xiao-Ling Cockcroft</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx25" xlink:type="simple" xlink:href="pii:S0223523416300897/fx25"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5Â nM (SYK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âPurine derivatives inhibitors of tyrosine protein kinase sykâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6589950</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">July-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Stephen P. Collingwood, Judy Hayler, Darren M. Le Grand, Henri Mattes, Keith A. Menear, Clive V.Walker, Xiao-Ling Cockcroft</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx26" xlink:type="simple" xlink:href="pii:S0223523416300897/fx26"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5Â nM (SYK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âPurine derivatives inhibitors of tyrosine protein kinase sykâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6589950</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">July-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Stephen P. Collingwood, Judy Hayler, Darren M. Le Grand, Henri Mattes, Keith A. Menear, Clive V.Walker, Xiao-Ling Cockcroft</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx27" xlink:type="simple" xlink:href="pii:S0223523416300897/fx27"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tyrosine kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5Â nM (SYK)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âMethods of using chemical libraries to search for new kinase inhibitorsâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6573044US0114672 US0176699 US6255485</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Nathanael S. Gray, Peter Schultz, Lisa Wodicka, Laurent Meijer, David J. Lockhart</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx28" xlink:type="simple" xlink:href="pii:S0223523416300897/fx28"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><50Â nM (CDK2)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âMethods of using chemical libraries to search for new kinase inhibitorsâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6573044US0114672 US0176699 US6255485</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Nathanael S. Gray, Peter Schultz, Lisa Wodicka, Laurent Meijer, David J. Lockhart</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx29" xlink:type="simple" xlink:href="pii:S0223523416300897/fx29"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><50Â nM (CDK2)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âMethods of using chemical libraries to search for new kinase inhibitorsâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6573044US0114672 US0176699 US6255485</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Nathanael S. Gray, Peter Schultz, Lisa Wodicka, Laurent Meijer, David J. Lockhart</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx30" xlink:type="simple" xlink:href="pii:S0223523416300897/fx30"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><50Â nM (CDK2)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âMethods of using chemical libraries to search for new kinase inhibitorsâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6573044US0114672 US0176699 US6255485</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Nathanael S. Gray, Peter Schultz, Lisa Wodicka, Laurent Meijer, David J. Lockhart</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx31" xlink:type="simple" xlink:href="pii:S0223523416300897/fx31"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><50Â nM (CDK2)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âMethods of using chemical libraries to search for new kinase inhibitorsâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6573044US0114672 US0176699 US6255485</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Nathanael S. Gray, Peter Schultz, Lisa Wodicka, Laurent Meijer, David J. Lockhart</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx32" xlink:type="simple" xlink:href="pii:S0223523416300897/fx32"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><50Â nM (CDK2)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">âMethods of using chemical libraries to search for new kinase inhibitorsâ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">US6573044US0114672 US0176699 US6255485</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Jun-2003</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Nathanael S. Gray, Peter Schultz, Lisa Wodicka, Laurent Meijer, David J. Lockhart</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx33" xlink:type="simple" xlink:href="pii:S0223523416300897/fx33"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cyclin dependent protein kinase inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"><50Â nM (CDK2)</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Review article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523416300897-d4abd92e2cf773ac73a411f61a55fa5a">
                  <ce:given-name>Sahil</ce:given-name>
                  <ce:surname>Sharma</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0010">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523416300897-1d171fa4112f26665d11f64fa9ecdd0d">
                  <ce:given-name>Jagjeet</ce:given-name>
                  <ce:surname>Singh</ce:surname>
                  <ce:cross-ref id="crosref0795" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523416300897-ec3b878aee413791b22250bc3f6c4202">
                  <ce:given-name>Ritu</ce:given-name>
                  <ce:surname>Ojha</ce:surname>
                  <ce:cross-ref id="crosref0800" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523416300897-21529ccfb8c833653bdd7852d90e3114">
                  <ce:given-name>Harbinder</ce:given-name>
                  <ce:surname>Singh</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0025">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523416300897-c5f8764d2d1bd0d7e6fe38c83b9c6b7c">
                  <ce:given-name>Manpreet</ce:given-name>
                  <ce:surname>Kaur</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0030">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523416300897-51bb0e3d62081f54a25e8e7a810c36a1">
                  <ce:given-name>P.M.S.</ce:given-name>
                  <ce:surname>Bedi</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0035">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523416300897-315e3905c75ed8e28645aa7473591e4e">
                  <ce:given-name>Kunal</ce:given-name>
                  <ce:surname>Nepali</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0040">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0045">
                     <ce:sup loc="post">â</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1">
                  <ce:label>a</ce:label>
                  <ce:textfn>Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Pharmaceutical Sciences</sa:organization>
                     <sa:organization>Guru Nanak Dev University</sa:organization>
                     <sa:city>Amritsar</sa:city>
                     <sa:state>Punjab</sa:state>
                     <sa:postal-code>143005</sa:postal-code>
                     <sa:country>India</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff2">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Pharmacy, Rayat-Bahara Group of Institutes, Hoshiarpur, 146001, Punjab, India</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Pharmacy</sa:organization>
                     <sa:organization>Rayat-Bahara Group of Institutes</sa:organization>
                     <sa:city>Hoshiarpur</sa:city>
                     <sa:state>Punjab</sa:state>
                     <sa:postal-code>146001</sa:postal-code>
                     <sa:country>India</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>â</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="19" month="9" year="2015"/></ce:date-received>
            <ce:date-revised day="4" month="2" year="2016"/></ce:date-revised>
            <ce:date-accepted day="5" month="2" year="2016"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Kinases control a diverse set of cellular processes comprising of reversible phosphorylation of proteins. Protein kinases play a pivotal role in human tumor cell proliferation, migration and survival of neoplasia. In the recent past, purine based molecules have emerged as significantly potent kinase inhibitors. In view of their promising potential for the inhibition of kinases, this review article focuses on purines which have progressed as kinase inhibitors during the last five years. A detailed account of the design strategies employed for the synthesis of purine analogs exerting inhibitory effects on diverse kinases has been presented. Apart from presenting the design strategies, the article also highlights the structure activity relationship along with mechanistic insights revealed during the biological evaluation of the purine analogs for kinase inhibition. The interactions with the amino acid residues responsible for kinase inhibitory potential of purine based molecules have also been discussed. In this assemblage, purine based protein kinase inhibitors patented in the past have also been summarized in the tabular form. This compilation will be of great interest for the researchers working in the area of protein kinase inhibitors.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:link locator="fx1" xlink:type="simple" xlink:href="pii:S0223523416300897/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Purine</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Cancer</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Kinases</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Cell lines</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Structure activity relationship</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0035">
                  <ce:text>Design strategies</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0035" view="all">Protein kinases constitute one of the largest and most functionally diverse gene families that control a diverse set of cellular processes comprising of reversible phosphorylation of proteins <ce:cross-ref refid="bib1" id="crosref0050">[1]</ce:cross-ref>. It has become very clear that phosphorylation of amino acids viz. serine, threonine, tyrosine and histidine residues by protein kinases plays an essential role in almost all the molecular aspects of cell life <ce:cross-ref refid="bib2" id="crosref0055">[2]</ce:cross-ref>. It is a well known fact that all species are equipped with a wide variety of superfamily of kinase genes (e.g. humans: >850 kinases among 30,000 genes; <ce:italic>Caenorhab ditiselegans</ce:italic>: 493 kinases among 19,099 genes; <ce:italic>Drosophila melanogaster</ce:italic>: 251 kinases among 13,601 genes; and <ce:italic>Saccharomyces cerevisiae</ce:italic>: 124 kinases among 6000 genes) <ce:cross-ref refid="bib3" id="crosref0060">[3]</ce:cross-ref>. Studies suggest that, the members of this enzyme family i.e. protein kinase play a critical role in the proliferation of human tumor cell and also in the survival and migration of neoplasia. Thus, in the past several years, kinase inhibition has been considered to be an emerging strategy in the cancer treatment. These kinase inhibitors specifically block the action of one or more protein kinases by targeting their ATP binding pocket and are characterized by the amino acid whose phosphorylation is inhibited. Together with the less conserved surrounding pockets, this ATP binding pocket has become the spotlight of design and discovery of various inhibitors <ce:cross-ref refid="bib4" id="crosref0065">[4]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0040" view="all">In the last two decades, lots of efforts to discover selective inhibitors of kinases that are deregulated in cancer have been made. There are many examples of natural as well as synthetic molecules that are found to act as competitive kinase inhibitors. Such inhibitors provide impending knowledge as to how the enzyme (kinase) functions can be regulated by the regions lying outside the catalytic domain <ce:cross-ref refid="bib5" id="crosref0070">[5]</ce:cross-ref>. There are drugs in clinical trials that can compete with adenosine triphosphate (ATP), the phosphorylating entity, the substrate or both or can act in an allosteric fashion, namely bind to a site outside the active site, affecting its activity by a conformational change <ce:cross-refs id="crosrefs0155" refid="bib6 bib7 bib8">[6â8]</ce:cross-refs>.</ce:para>
                  <ce:para id="p0045" view="all">Imatinib (Gleevac), a tyrosine kinase inhibitor was the first most successful candidate approved by FDA in May 2001, around 15 years ago for the treatment of BCR-Abl driven chronic myelogenous leukemia cancers. The huge clinical success of this drug has triggered the discovery of various new kinase inhibitors. Reports indicates that in the pharmaceutical industry, kinase inhibitors currently comprise up to 30% of drug-discovery programs, and large number of compounds having kinase inhibitory potential are now in clinical trials. Till date, 32 protein kinase inhibitors are approved by FDA (<ce:cross-ref refid="fig1" id="crosref0075">Fig.Â 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0050" view="all">Purine is a privileged heterocyclic nucleus which exists in the chemical architecture of various bioactive compounds. Numerous reports on the use of purine analogs in the treatment of acute leukemias (thiopurines, pentostatin), as antiviral (acyclovir, penciclovir, ganciclovir), as immunosuppressive (azathioprine), as antitumor (vidarabine), as bronchodilator (theophylline) have been revealed. Over the years, purine nucleus has appeared as an important pharmacophore interacting with the synthesis, functions of nucleic acids and enzymes and are one of the most widely used heterocycles in the development of protein kinase inhibitors. A fair amount of research has been done and several patents have also been published highlighting the kinase inhibitory action of purines. Caffeine, 2-aminopurine, purvalanol-A, seleciclib, FSBA, adenosine-thiol analog possessing purine as the basic moiety, fall under this category. The introduction of substituents on the 2, 6 and 9 positions of the purine ring is anticipated to yield compounds with enhanced binding affinity and selectivity toward kinases <ce:cross-ref refid="bib9" id="crosref0080">[9]</ce:cross-ref>. Purine based protein kinase inhibitors in pre-clinical/clinical trials are shown in <ce:cross-ref refid="fig2" id="crosref0085">Fig.Â 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>. In view of the prominent role of purines in the inhibition of kinases, there is need for compilation of data specifying design strategies employed for the synthesis of purine analogs exerting inhibitory effects on diverse kinases, their structure activity relationship, mechanistic insights and various interactions with the amino acid residues of kinase binding domain.</ce:para>
                  <ce:para id="p0055" view="all">Therefore, this review article basically highlights the discovery of purine derivatives as kinase inhibitors during the last five years. A detailed account of the design strategies employed for the synthesis of purine analogs exerting inhibitory effects on diverse kinases has been presented in this compilation. In addition to the design strategies, the article also highlights the structure activity relationship along with mechanistic insights revealed during the biological evaluation of the purine analogs for kinase inhibition. The interactions with the amino acid residues responsible for kinase inhibitory potential of purine based molecules have also been discussed. In this assemblage, purine based protein kinase inhibitors patented in the past have also been summarized in the tabular form. This compilation will be of great interest for the researchers working in the area of protein kinase inhibitors.</ce:para>
                  <ce:para id="p0060" view="all">In the present review, purine based kinase inhibitors have been classified into various categories. The classification is mentioned below:<ce:list id="olist0010">
                        <ce:list-item id="o0010">
                           <ce:label>1)</ce:label>
                           <ce:para id="p0065" view="all">Tyrosine specific protein kinase inhibitors<ce:list id="olist0015">
                                 <ce:list-item id="o0015">
                                    <ce:label>a)</ce:label>
                                    <ce:para id="p0070" view="all">Non-receptor tyrosine kinase inhibitors</ce:para>
                                 </ce:list-item>
                                 <ce:list-item id="o0020">
                                    <ce:label>b)</ce:label>
                                    <ce:para id="p0075" view="all">Receptor associated tyrosine kinase inhibitors</ce:para>
                                 </ce:list-item>
                                 <ce:list-item id="o0025">
                                    <ce:label>c)</ce:label>
                                    <ce:para id="p0080" view="all">Lipid associated tyrosine specific protein kinase inhibitors</ce:para>
                                 </ce:list-item>
                                 <ce:list-item id="o0030">
                                    <ce:label>d)</ce:label>
                                    <ce:para id="p0085" view="all">Other tyrosine specific protein kinase inhibitors</ce:para>
                                 </ce:list-item>
                              </ce:list>
                           </ce:para>
                        </ce:list-item>
                        <ce:list-item id="o0035">
                           <ce:label>2)</ce:label>
                           <ce:para id="p0090" view="all">Specific protein kinase inhibitors<ce:list id="olist0020">
                                 <ce:list-item id="o0040">
                                    <ce:label>a)</ce:label>
                                    <ce:para id="p0095" view="all">Serine/threonine specific protein kinase inhibitors</ce:para>
                                 </ce:list-item>
                                 <ce:list-item id="o0045">
                                    <ce:label>b)</ce:label>
                                    <ce:para id="p0100" view="all">Cyclin-dependent specific protein kinase inhibitors</ce:para>
                                 </ce:list-item>
                                 <ce:list-item id="o0050">
                                    <ce:label>c)</ce:label>
                                    <ce:para id="p0105" view="all">Other specific protein kinase inhibitors</ce:para>
                                 </ce:list-item>
                              </ce:list>
                           </ce:para>
                        </ce:list-item>
                        <ce:list-item id="o0055">
                           <ce:label>3)</ce:label>
                           <ce:para id="p0110" view="all">Dual specificity (tyrosine/specific protein) protein kinase inhibitors</ce:para>
                        </ce:list-item>
                        <ce:list-item id="o0060">
                           <ce:label>4)</ce:label>
                           <ce:para id="p0115" view="all">Miscellaneous kinase inhibitors</ce:para>
                        </ce:list-item>
                     </ce:list>
                  </ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Tyrosine specific protein kinase inhibitors</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Non-receptor tyrosine kinase inhibitors</ce:section-title>
                     <ce:para id="p0120" view="all">Janus kinases (jak) are the family of intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. There are four known mammalian kinases in the JAK family: JAK1, JAK2, JAK3 and TYK3 <ce:cross-ref refid="bib10" id="crosref0090">[10]</ce:cross-ref>. Wang etÂ al. discovered the 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors. All the synthesized compounds were assayed against GM-CSF stimulated TF-1Â cell line (an erythroleukemic cell line). In this assay, TF-1Â cells were stimulated with GM-CSF and FACS was used to measure the intracellular concentration of pSTAT5. The assay revealed that compounds 1, 2, 3, 4 and 5 were the potent JAK2 inhibitors in sub-micromolar range and the compounds, with 3- and 4-substitution on deazapurine nucleus possessed moderate to potent JAK2 inhibitory activities. Docking of compound 5Â at the active site of JAK2 kinase, suggested that a hybrid structure, with a bridge between positions 3 and 4 on the azaindole/deazapurine core, provided a novel series of JAK2 inhibitors <ce:cross-ref refid="bib11" id="crosref0095">[11]</ce:cross-ref> (<ce:cross-ref refid="fig3" id="crosref0100">Fig.Â 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0125" view="all">The Src (acronym of sarcoma) family is the oldest and most studied class of non-receptor tyrosine kinases. In humans, it consists of 11 members (Blk, Brk, Fgr, Frk, Fyn, Hck, Lck, Lyn, c-Src, Srm, c-Yes). Overexpression, deregulation or mutation of these enzymes has been observed and studied in many human malignancies, including colon, breast and pancreatic cancers <ce:cross-refs refid="bib12 bib13 bib14" id="crosrefs0010">[12â14]</ce:cross-refs>. Therefore, the Src-family constitutes an attractive target for the design of new therapeutic agents against different pathologies, mainly against cancer and bone diseases <ce:cross-refs refid="bib15 bib16 bib17" id="crosrefs0015">[15â17]</ce:cross-refs>. Prompted by this, Verones etÂ al. synthesized and evaluated 4-aminotetrahydroquinazolino[3,2-<ce:italic>e</ce:italic>]purine derivatives as Src kinase inhibitors. All the synthesized compounds were evaluated for Src kinase inhibition and cytotoxicity in murine leukemia L1210Â cell line. Results of biological evaluation showed that compounds 7, 8 and 9 possessed an interesting activity profile. Docking studies were also performed to analyze the binding mode of compounds in the ATP binding site of Src kinase and to identify the structural determinants of their interaction with the amino acid residues <ce:cross-ref refid="bib18" id="crosref0105">[18]</ce:cross-ref> (<ce:cross-ref refid="fig4" id="crosref0110">Fig.Â 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0130" view="all">c-Src kinase, a Src kinase of non-receptor tyrosine kinase family <ce:cross-refs id="crosrefs0150" refid="bib19 bib20">[19,20]</ce:cross-refs>, overexpression of which also causes variety of human tumors <ce:cross-refs refid="bib21 bib22 bib23 bib24 bib25 bib26 bib27" id="crosrefs0020">[21â27]</ce:cross-refs>. Therefore, the discovery of c-Src kinase inhibitors shows immense potential to treat tumors <ce:cross-refs refid="bib28 bib29 bib30 bib31 bib32 bib33 bib34 bib35" id="crosrefs0025">[28â35]</ce:cross-refs>. By this inspiration, Huang etÂ al. synthesized a series of 32 novel purine derivatives and evaluated them against c-Src tyrosine kinase. Study showed that all the compounds exhibited potent inhibitory activity against c-Src kinase with IC<ce:inf loc="post">50</ce:inf> values ranging from 0.02Â Î¼M to 3.14Â Î¼M. Compound 10 was identified as one of the most potent agent with highest hit rate and IC<ce:inf loc="post">50</ce:inf> value 120 times lower than those of the other hits. To explore the various interactions between the most active compound and Src kinase, molecular docking simulation was also carried out <ce:cross-ref refid="bib36" id="crosref0115">[36]</ce:cross-ref> (<ce:cross-ref refid="fig5" id="crosref0120">Fig.Â 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0135" view="all">Purine scaffolds could be functionalized as part of a pharmacophore model to bind and inhibit the Src Homology 2 (SH2) domain of the signal transducer and activator of transcription 3 (Stat3) proteins <ce:cross-refs refid="bib37 bib38 bib39 bib40 bib41 bib42 bib43" id="crosrefs0030">[37â43]</ce:cross-refs>. Stat3 plays a key role in regulating cancer cell growth and differentiation. Hyperactivation of Stat3 protein levels has been shown to be transformative, leading to uncontrolled cell proliferation and apoptotic resistance in a multitude of human cancer cells. Thus, potent Stat3 inhibitors have tremendous potential as novel therapeutics <ce:cross-refs refid="bib44 bib45" id="crosrefs0035">[44,45]</ce:cross-refs>. To design Stat3 inhibitors with improved cell permeability and enhanced cytotoxicity towards cancer cells, Shahani etÂ al. rationally synthesized purine based Stat3 inhibitors by masking the N9 carboxylic acid substituent using prodrug strategies and by introducing bioisosters of carboxylic acid to improve the inhibitor's characteristics. For cytotoxic evaluation, the synthesized purine analogs were subjected to breast cancer (MDA-MB-468), human prostate carcinoma (DU 145), and acute myeloid leukemia 2 (OCI-AML2) cell lines and assessed for inhibitor-induced cytotoxicity using an MTS colorimetric assay. In MDA-MB-468Â cells, compound 11 showed promising cell cytotoxicity (EC<ce:inf loc="post">50</ce:inf>Â =Â 19.9Â Â±Â 0.9Â Î¼M). Further testing on a panel of eleven multiple myeloma (MM) primary cancer cell lines was also performed, where compound 11 demonstrated potent, dose-dependent cytotoxic effects in a number of cell lines with XG6 cell lines as the most sensitive one, possessing high levels of activated Stat3, completely inhibited at 10Â Î¼M concentration of compound 11. To assess for Stat3 SH2 domain binding affinities and inhibitory activity, compound 11 was subjected to fluorescence polarization (FP) Stat3 binding assay and Stat3 phosphorylation measured through flow cytometry. Compound 11 failed to displace the fluorescent peptide even at 100Â Î¼M and failed to inhibit Stat3 phosphorylation at concentrations above cytotoxic IC<ce:inf loc="post">50</ce:inf> values, but, targets JAK family kinases, ABL1 (non-phosphorylated F317L), AAK1 (adapter-associated protein kinase 1) evidenced by kinase filtration binding assay, suggested that the Stat3 SH2 domain was not the cellular target in MM cells <ce:cross-ref refid="bib46" id="crosref0125">[46]</ce:cross-ref> (<ce:cross-ref refid="fig6" id="crosref0130">Fig.Â 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0140" view="all">Non receptor Bruton's tyrosine kinase (BTK) is a member of the Tec family of non-receptor tyrosine kinases. BTK is expressed in most hematopoietic cells such as B cells, mast cells, and macrophages but not in T cells and mutations in the BTK gene lead to defects in B cell development at the pre-B cell stage causing X-linked a gamma globulinemia in humans <ce:cross-ref refid="bib47" id="crosref0135">[47]</ce:cross-ref>. Interesting inhibition profile of imidazo[1,2-<ce:italic>a</ce:italic>]pyrazines (12 & 13) against BTK, prompted Shi etÂ al. to synthesize various derivatives by isosterically replacing imidazopyrazine moiety with different heterocyclic cores, in search of potent BTK inhibitors. BTK homology model of these heterocyclic isosters derivatives yielded purine analogs as potent and selective BTK inhibitors (14 & 15). Subsequent SAR studies of the purine series led to the discovery of 16 as a lead compound and found to be selective when screened against a panel of 400 kinases. The compound also act as a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited <ce:italic>inÂ vivo</ce:italic> efficacy in a mouse PCA (Passive Cutaneous Anaphylaxis) model. Its X-ray co-crystal structure with BTK showed that the high selectivity is gained from filling a BTK specific lipophilic pocket <ce:cross-ref refid="bib48" id="crosref0140">[48]</ce:cross-ref> (<ce:cross-ref refid="fig7" id="crosref0145">Fig.Â 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Receptor associated tyrosine kinase inhibitors</ce:section-title>
                     <ce:para id="p0145" view="all">FGFRs are receptor tyrosine kinases (RTKs) which bind to fibroblast growth factors (FGF). The somatic mutations of one of its homologous member, FGFR3 are frequently associated with bladder and cervical cancers <ce:cross-ref refid="bib49" id="crosref0150">[49]</ce:cross-ref> as well as multiple myeloma <ce:cross-ref refid="bib50" id="crosref0155">[50]</ce:cross-ref> and occasionally with prostate and colorectal tumors <ce:cross-refs refid="bib51 bib52" id="crosrefs0040">[51,52]</ce:cross-refs>. RTK inhibitors usually target the ATP binding site, in which they occupy the adenine region (hydrogen bonded to the hinge) and one of the hydrophobic pockets <ce:cross-ref refid="bib53" id="crosref0160">[53]</ce:cross-ref>. As ATP mimics, purine derivatives are known to be potent and versatile inhibitors of kinases and an attractive scaffold to develop kinase inhibitors <ce:cross-ref refid="bib54" id="crosref0165">[54]</ce:cross-ref>. Tak-tak etÂ al. designed and synthesized purin-2-yl and purin-6-yl-aminoglucitols as C-nucleosidic ATP mimics by keeping the purine ring as scaffold and exploring the possibility of other binding modes by varying the orientation of ribose mimic and the lipophilic chain. Evaluation of the synthesized compounds for FGFR3 inhibition by kinase assays revealed that compounds were all able to inhibit FGFR3 kinase activity at a concentration of 50Â Î¼M. Compound 17, bearing an iodine atom at position 2 was found to be the best inhibitor. Further computational studies revealed that besides being located in the ATP binding site, compound 17 exhibits a typical binding pattern made of hydrogen bonds and hydrophobic interactions but also uncommon halogen bonds <ce:cross-ref refid="bib55" id="crosref0170">[55]</ce:cross-ref> (<ce:cross-ref refid="fig8" id="crosref0175">Fig.Â 8</ce:cross-ref>
                        <ce:float-anchor refid="fig8"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0150" view="all">The receptor tyrosine kinases (RTKs) are transmembrane proteins which transduce signals from extracellular medium to the cytoplasm. They regulate cellular functions such as growth, differentiation or motility. There are 58 RTKs in the human genome, which have been classified into 20 subfamilies <ce:cross-ref refid="bib56" id="crosref0180">[56]</ce:cross-ref>. Mer, Axl and Tyro3 are the three human RTKs that belong to the TAM subfamily <ce:cross-ref refid="bib57" id="crosref0185">[57]</ce:cross-ref>. The common approach to design kinase inhibitors is to synthesize ATP competitive compounds, i.e. compounds that bind to the active site when the kinase is in the DFG-in conformation. These inhibitors are called type I inhibitors having poor kinase selectivity due to highly conserved nature of the ATP-binding region <ce:cross-ref refid="bib58" id="crosref0190">[58]</ce:cross-ref>. The second broad class of kinase inhibitors, named type II inhibitors, targets an inactive form of the kinase, in which the protein adopts the DFG-out conformation. In this conformation, a large conformational change of the conserved DFG motif and of the activation loop creates a large hydrophobic pocket adjacent to the active site, the allosteric site, into which type II inhibitors can bind <ce:cross-refs refid="bib59 bib60" id="crosrefs0045">[59,60]</ce:cross-refs>. SuÃ¡rez etÂ al. designed a type II inhibitor specific for this family, i.e. able to interact with the allosteric pocket and with the hinge region of the kinase and report the synthesis of several series of purine analogs of BMS-777607 (18) (type II inhibitor active against Tyro3, Mer and Axl and also inhibits Met, a protein whose sequence does not contain the TAM signature but has 40% sequence similarity with proteins of the TAM subfamily). All the synthesized molecules were evaluated at a concentration of 1 and 75Â Î¼M against five tyrosine kinases, namely Tyro3, Axl, Mer, Met, and Abl1. Abl1 was included in these tests because it belongs to the RTK family, but is not a member of the TAM subfamily to test specificity for the TAM subfamily. <ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf>s were determined for the most active inhibitors against proteins of the TAM family. The most potent inhibitor 19 exhibited <ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf>s of 39, 42, 65 and 200Â nM against Axl, Mer, Met and Tyro3 respectively. The antiproliferative activities of the compounds were evaluated at 10<ce:sup loc="post">â5</ce:sup>Â M against four human tumor cell lines, including KB (oral carcinoma), HT29 (colorectal carcinoma), MCF7 (breast carcinoma) and PC3 (prostate adenocarcinoma) and one non tumoral cell line, Vero cells (Kidney Vero cells). For all compounds, no cytotoxicity was detected and growth inhibition of the cell lines was smaller than 10%, at the concentration tested <ce:cross-ref refid="bib61" id="crosref0195">[61]</ce:cross-ref> (<ce:cross-ref refid="fig9" id="crosref0200">Fig.Â 9</ce:cross-ref>
                        <ce:float-anchor refid="fig9"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Lipid associated tyrosine specific protein kinase inhibitors</ce:section-title>
                     <ce:para id="p0155" view="all">Lipid Phosphatidylinositol-3-kinases (PI3K) are the lipid kinases associated with Receptor Tyrosine Kinases (RTKs) and Ras <ce:cross-refs refid="bib62 bib63" id="crosrefs0050">[62,63]</ce:cross-refs>. Of the 4 subtypes of class PI3Ks, p110Î± (PI3K-Î±) deregulation has been shown to stimulate cell growth and inhibit apoptosis in epithelial tumor cells <ce:cross-refs refid="bib64 bib65 bib66" id="crosrefs0055">[64â66]</ce:cross-refs>. Gilbert etÂ al. synthesized a series of novel purine and pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine as PI3 kinase-Î± inhibitors. Compounds were assayed for cellular proliferation activity by monitoring cell growth densities in Caco2, LoVo, and PC3MM2 cell cultures, PI3K-Î± and PI3K-Î³ inhibition by monitoring PIP3 production in fluorescence polarization assays, mTOR potency using the DELFIA format assaying for phosphorylated His6-SK6 and inhibition of PI3K signaling in MDA-361Â cells, detected by immunoblotting protein lysates for phosphorylated-Akt (p-Akt). Purine inhibitors showed potent PI3K-Î± activity, and good selectivity (>10-fold) versus PI3K-Î³ and mTOR. While, the related pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidines maintained good PI3K-Î± potency as well as showed excellent potency against mTOR. Superior potency and selectivity of the purine series of inhibitors against PI3K-Î± was further rationalized by using PI3K-Î± homology model, derived from an X-ray structure of PI3K-Î³, and compound 20. The critical H-bond between Val851 and the oxygen of the morpholine explains the reduction in potency seen for compound with piperidine instead of morpholine. (3-HOCH<ce:inf loc="post">2</ce:inf>)Ph moiety enhanced the potency due to its additional hydrogen bonding with Asp810. The reduced selectivity versus PI3K-Î³ seen in 20 versus 21 was rationalized by the protonatable piperidine nitrogen being better tolerated by Asp950 in PI3K-Î³ versus Ser919 and Ser2342 residues in PI3K-Î± and mTOR. Large hydrophobic groups on the piperidine were better tolerated by hydrophobic residues in PI3K-Î± (Met858) and mTOR (Leu2264) versus the more hydrophilic Lys890 in PI3K-Î³ <ce:cross-ref refid="bib67" id="crosref0205">[67]</ce:cross-ref> (<ce:cross-ref refid="fig10" id="crosref0210">Fig.Â 10</ce:cross-ref>
                        <ce:float-anchor refid="fig10"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0160" view="all">The phosphatidylinositide-3-kinase (PI3K/Akt) signaling pathway has been recognized as a key pathway in cell proliferation, growth, survival, protein synthesis and glucose metabolism <ce:cross-refs refid="bib68 bib69 bib70 bib71 bib72 bib73" id="crosrefs0060">[68â73]</ce:cross-refs>. Phosphatidylinositol-3-kinases (PI3Ks) phosphorylate the phosphatidylinositol-diphosphate (PIP-2) to its corresponding phosphatidylinositol-triphosphate (PIP-3) and belong to the super family of PI3K related Kinases (PIKKs) which includes mTOR, ATM, ATR and DNA-PK. The product of PI3K activity, PIP-3, acts as a second messenger that is responsible for the activation of the downstream kinase Akt <ce:cross-ref refid="bib68" id="crosref0215">[68]</ce:cross-ref>. This prompted Venkatesan etÂ al. to synthesize novel 4-morpholino-2-aryl-purine derivatives as potent PI3KÎ±/mTOR inhibitors, using PI3K-Î± homology model, derived from an X-ray structure of PI3K-Î³, and compound 22. Among all the synthesized compounds, 23â26 possessed moderate to excellent activity against dual PI3Ks/mTOR. The most potent and PI3Ks selective compound in this series (23), showed IC<ce:inf loc="post">50</ce:inf> values of 0.685Â Î¼M versus MDA-361 (breast) and 0.512Â Î¼M versus PC3MM3 (prostate) human tumor cell lines and also had good microsomal stabilities. Compound 23 was further assayed <ce:italic>inÂ vitro</ce:italic> for its ability to suppress appropriate cellular biomarkers. PI3 Ka inhibition should result in suppression of the phosphorylation of Akt particularly at the threonine 308 site. Compound 23 was found to inhibit Akt T308 phosphorylation in MDA361 breast tumor cells, with an IC<ce:inf loc="post">50</ce:inf> value of about 300Â nM, after a 4Â h exposure time and also induced cleaved PARP (a marker for cell apoptosis) at 10 and 30Â Î¼M, thus, showed a good correlation between cell growth inhibition and biomarker (pAkt at T308) suppression <ce:cross-ref refid="bib74" id="crosref0220">[74]</ce:cross-ref> (<ce:cross-ref refid="fig11" id="crosref0225">Fig.Â 11</ce:cross-ref>
                        <ce:float-anchor refid="fig11"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0165" view="all">Phosphoinositide 3 kinases (PI3Ks) catalyze phosphorylation of the 3-hydroxyl position of PIP2 (phosphatidylinositol-4,5-diphosphate) to PIP3 (phosphatidylinositol 3,4,5-triphosphate) which can regulate multiple physiological processes, including cell growth, differentiation, survival, and motility <ce:cross-ref refid="bib75" id="crosref0230">[75]</ce:cross-ref>. PI3KÎ± has emerged as an attractive target for cancer treatment because the amplification of PI3KÎ± is one of the most common molecular findings in human malignancies <ce:cross-ref refid="bib76" id="crosref0235">[76]</ce:cross-ref> and several PI3KÎ± inhibitors are currently under evaluation in human clinical trials <ce:cross-ref refid="bib77" id="crosref0240">[77]</ce:cross-ref>. Cell-permeable fluorescent PI3KÎ± inhibitors could allow their subcellular localization to be monitored in live cells by fluorescence microscopy. Keeping this in view, Kim etÂ al. designed family of potent fluorescent PI3KÎ± inhibitors, based on considerations regarding space and environmental polarity in p110Î± homology model, in which part of the fluorophore was engineered to be a pharmacophore capable of inhibiting PI3KÎ±. A variety of xanthine derivatives exhibiting fluorescence were synthesized and screened for both <ce:italic>inÂ vitro</ce:italic> PI3K inhibition and cell viability, by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in T47D, SK-BR3, and MCF-7 human breast cancer cell cultures. Compound 27 (PI3KÎ±/IC<ce:inf loc="post">50</ce:inf>Â =Â 0.068Â Î¼M, T47D cell viability: IC<ce:inf loc="post">50</ce:inf>Â =Â 0.9Â Î¼M) was found to block cancer cell proliferation <ce:cross-ref refid="bib78" id="crosref0245">[78]</ce:cross-ref> (<ce:cross-ref refid="fig12" id="crosref0250">Fig.Â 12</ce:cross-ref>
                        <ce:float-anchor refid="fig12"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0170" view="all">Phosphoinositide 3-kinase delta (PI3KÎ´) participates in the activation of leukocytes by catalyzing the production of the cellular second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) <ce:cross-refs refid="bib79 bib80" id="crosrefs0065">[79,80]</ce:cross-refs>. Inhibition of PI3KÎ´ is therefore considered to be an attractive mechanism for the treatment of inflammatory diseases and leukocyte malignancies <ce:cross-ref refid="bib81" id="crosref0255">[81]</ce:cross-ref>. It is well reported that highly selective PI3KÎ´ inhibitors (28, 29) can be obtained by appropriate modification of heterocycles that occupy the affinity pocket of the PI3K enzymes. Murray etÂ al. carried out the structural optimization of 29 to identify benzimidazole-based inhibitors of PI3KÎ´ with improved selectivity against other PI3K isoforms, promising physical properties, improved <ce:italic>inÂ vitro</ce:italic> and <ce:italic>inÂ vivo</ce:italic> pharmacokinetic properties as well as anti-inflammatory properties <ce:italic>inÂ vivo</ce:italic>. Using a structure-based design approach, a series of potent and selective benzimidazole-based inhibitors of PI3KÎ´ (30, 31) were identified. The structural information gathered indicates that the PI3K-isoform selectivity can be achieved with inhibitors that do not occupy the selectivity pocket between Trp760 and Met752 that is induced by other families of PI3KÎ´ inhibitors. Instead, the selectivity of the compounds for inhibition of PI3KÎ´ relative to other PI3K isoforms appears to be due primarily to the strong interactions these inhibitors are able to make with Trp760 in the PI3KÎ´ binding pocket. The pharmacokinetic properties and the ability to inhibit the function of B-cells (as B-cell activation plays a critical role in many inflammatory diseases) <ce:italic>inÂ vivo</ce:italic> of representative compounds were also described. Compound 30 inhibited the activation of B-cells, as measured by CD86 expression, following anti-IgD stimulation <ce:cross-ref refid="bib82" id="crosref0260">[82]</ce:cross-ref> (<ce:cross-ref refid="fig13" id="crosref0265">Fig.Â 13</ce:cross-ref>
                        <ce:float-anchor refid="fig13"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0175" view="all">Lipid Phosphoinosotide-3-kinase delta (PI3KÎ´) is a heterodimeric lipid kinase, highly expressed in lymphocytes and mast cells <ce:cross-refs refid="bib83 bib84 bib85 bib86 bib87" id="crosrefs0070">[83â87]</ce:cross-refs>. In an effort to identify potent and isoform selective inhibitors of PI3KÎ´, Safina etÂ al. explored structurally distinct selective PI3KÎ´ inhibitor 32 as the starting compound, which selectively inhibited PI3KÎ´ relative to closely related lipid kinases, possessed moderate selectivity tested positive for genotoxicity in both human chromosomal aberration test (HCA) and <ce:italic>inÂ vitro</ce:italic> micronucleus test (MNT) assays. With the aim to disrupt the structural features responsible for <ce:italic>inÂ vitro</ce:italic> genotoxicity by restricting conformational preferences and decreasing structural planarity, the two specific structural regions of compound 32 (a) methylene region and (b) 2-benzimidazole region were explored and lead to compounds testing negative in the HC-MNT assay but positive in the HCA assay. Focusing on the methylene linker region, a variety of conformationally restrictive linker replacements were explored. Groups that restricted torsional angles (<30Â°) to favor ligand interactions with PI3KÎ´âs Trp760 provided a variety of analogs with increased PI3KÎ´ potency and selectivity. Lead compound GNE-293 (33) tested negative in the HCA assay and possessed favorable pharmacokinetic properties and excellent potency (Ki<ce:inf loc="post">app</ce:inf>Â =Â 0.47Â nM) <ce:cross-ref refid="bib88" id="crosref0270">[88]</ce:cross-ref> (<ce:cross-ref refid="fig14" id="crosref0275">Fig.Â 14</ce:cross-ref>
                        <ce:float-anchor refid="fig14"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">Other tyrosine specific protein kinase inhibitors</ce:section-title>
                     <ce:para id="p0180" view="all">Acyclovir (ACV) is acyclic guanosine analog which is a selective anti-herpes simplex virus agent initiated investigation of new acyclic nucleoside analogs with better antiviral activity properties than ACV <ce:cross-ref refid="bib89" id="crosref0280">[89]</ce:cross-ref>. These efforts resulted in Gancyclovir (GCV) and Pancyclovir (PCV), the broad spectrum antiviral agents. The two hydroxyl groups of GCV help to substrate recognition as of 2Ê¹-deoxyribose moiety in natural nucleosides <ce:cross-ref refid="bib90" id="crosref0285">[90]</ce:cross-ref>. Furthermore based on these findings, a compound (A-5021) was developed as a nucleoside analog which potentially inhibited the HSV-1, HSV-2, varicella-zoster virus (VZV), Epstein-Barr virus (EBV) and human herpes virus type 6 (HHV-6). The inhibition potency of this compound is superior over ACV, GCV, PCV and was found to be inactive against HIV but its cytosine derivative was moderately active and some thymine, hypoxanthine, 2,6-diaminopurine derivatives showed weak activity. These important findings led Benci etÂ al. to synthesize new series of 1,2,4-triazole and purine acyclic cyclopropane nucleoside analogs. To evaluate their potential as antiviral and cytostatic potency microtitre plate method was employed. The cell growth rate was also determined by using MTT assay. Antiviral study showed that none of the compounds were able to significantly inhibit the 1Â Î¼M dThd phosphorylation by HSV-1 and VZV thymine kinase at 500Â Î¼M concentrations. The <ce:italic>inÂ vitro</ce:italic> cytostatic studies revealed that 6-pyrrolylpurine derivative containing substituted carboxylic group at position 1 of cyclopropane ring (compound 42) showed moderate activity against the growth of MCF-7Â cells (IC<ce:inf loc="post">50</ce:inf>Â =Â 65.54Â Î¼M) and no cytotoxic effect on normal human fibroblasts (WI 38) <ce:cross-ref refid="bib91" id="crosref0290">[91]</ce:cross-ref> (<ce:cross-ref refid="fig15" id="crosref0295">Fig.Â 15</ce:cross-ref>
                        <ce:float-anchor refid="fig15"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0185" view="all">EGFR (endothelium growth factor receptors) dependent aberrant signaling is associated with cancer cell proliferation, apoptosis, angiogenesis and metastasis <ce:cross-ref id="crosref0790" refid="bib92">[92]</ce:cross-ref>. Anilinoquinazoline-containing compounds, erlotinib (43) and gefitinib (44) have been approved for the chemotherapeutic treatment of patients with advanced non small lung cancer <ce:cross-refs refid="bib93 bib94 bib95" id="crosrefs0075">[93â95]</ce:cross-refs>. They are considered as 4-substituted amino pyrimidine pharmacophoric core derivatives that bind to the hinge region of the kinase enzyme. On the basis of the bioisosterism between benzene and pyrazole which is well known <ce:cross-ref id="crosref0780" refid="bib92">[92]</ce:cross-ref> and widely documented in the biologically active drugs, pyrazolopyrimidine cores were evaluated as isosters for quinazoline cores. Among the synthesized analogs containing 4-substituted phenylaminopyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine, compounds 45a and 45b showed good affinity for enzyme binding site <ce:cross-refs refid="bib96 bib97 bib98 bib99 bib100 bib101 bib102" id="crosrefs0080">[96â102]</ce:cross-refs>. Several pyrazolopyrimidine derivatives were designed and synthesized as from the pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine intermediates and were tested for their anticancer activity using human breast carcinoma cell line (MCF-7) by Sulphordhodamine-B (SRB) assay and IC<ce:inf loc="post">50</ce:inf> values were calculated using sigmoidal dose response curve fitting models. The study showed that three compounds 46â48 appeared to be sensitive against MCF-7 cells and exhibited more than 50% inhibition. The other tested compounds were devoid of activity. The molecular docking study also supports the biological results <ce:cross-ref refid="bib103" id="crosref0300">[103]</ce:cross-ref> (<ce:cross-ref refid="fig16" id="crosref0305">Fig.Â 16</ce:cross-ref>
                        <ce:float-anchor refid="fig16"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0190" view="all">Lung cancer has become the leading cause of cancer-related deaths worldwide <ce:cross-ref refid="bib104" id="crosref0310">[104]</ce:cross-ref>. More than 80% of all lung cancers are identified as non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) has been established as one of the most important therapeutic targets for NSCLC. NSCLCs with EGFR-activating mutations (caused by Thr-to-Met substitution at residue 790 (T790M) in the EGFR exon) eventually develop resistance to the drugs. T790M mutation greatly increases the ATP binding affinity of the oncogenic activating mutant <ce:cross-refs refid="bib105 bib106 bib107 bib108" id="crosrefs0085">[105â108]</ce:cross-refs>. In order to develop next-generation reversible EGFR inhibitors that can inhibit the drug-resistant T790M bearing mutants by binding to the T790M mutant with higher affinity, Yang etÂ al. performed a virtual screening followed by kinase inhibitory assays against a library of known kinase inhibitors. Among the tested compounds, N-(4-(4-methylpiperazin-1-yl)phenyl)-N-phenyl-9<ce:italic>H</ce:italic>-purine-2,8-diamine (49) exhibited some ability to inhibit both EGFR-activating and resistance mutations. To optimize the structure of compound 49, a series of novel 2,8-dianilinopurine derivatives were synthesized. Synthetics were subjected to cell-based assays two human NSCLC cell lines, HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively and a human hepatocellular carcinoma cell line, HepG2 (not dependent on EGFR signaling for cell growth) to rule out activity due to non-EGFR-mediated effects. The results indicated that 50 exhibited significantly increased anti-viability potency against HCC827 and H1975 cell lines and weak inhibition against HepG2. SAR demonstrates that a substituent of suitable size at the N-9 position of the purine scaffold can increase the binding affinity. Substitutions of the 2-anilino and 8-anilino groups onto the phenyl ring did not increase the bioactivity. Further, to rationalize the observed SAR, molecular docking studies were performed. Compound 50 (most active in cell based assays) was further examined for binding affinities to various EGFR mutations, kinase inhibition profile against human EGFR and a panel of other selected protein kinases, <ce:italic>inÂ vitro</ce:italic> anti-viability activity against various cancer cell lines, inhibition of EGFR auto phosphorylation and the inactivation of downstream signaling proteins in cell cultures, <ce:italic>inÂ vivo</ce:italic> anti-NSCLC effects and pharmacokinetic parameters in plasma after the oral administration of a 20Â mg/kg dose to SpragueâDawley rats. <ce:italic>InÂ vitro</ce:italic> assays indicated that compound 50 has a high potency against both EGFR-activating and drug-resistant EGFR mutants and good kinase spectrum selectivity, while also inhibiting several other oncokinases. Compound 50 significantly inhibited EGFR phosphorylation and the activation of downstream signaling proteins. <ce:italic>InÂ vivo</ce:italic> antitumor activity assays showed that an oral, once-daily dose of compound 50 at 5Â mg/kg for 15 days led to complete tumor regression in the HCC827 xenograft model and that a once-daily dose of compound 50 at 50Â mg/kg exhibited considerable tumor inhibition in the H1975 xenograft model. Preliminary pharmacokinetic studies indicated that compound 50 possesses good pharmacokinetic properties <ce:cross-ref refid="bib109" id="crosref0315">[109]</ce:cross-ref> (<ce:cross-ref refid="fig17" id="crosref0320">Fig.Â 17</ce:cross-ref>
                        <ce:float-anchor refid="fig17"/></ce:float-anchor>).</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0060">Specific protein kinase inhibitors</ce:section-title>
                  <ce:section id="sec3.1" view="all">
                     <ce:label>3.1</ce:label>
                     <ce:section-title id="sectitle0065">Serine/threonine specific protein kinase inhibitors</ce:section-title>
                     <ce:para id="p0195" view="all">Kinase-mediated phosphorylation of intracellular proteins is a crucial pathway by which signals are transmitted within the cell. In bacteria, communication is achieved by two-component systems (TCS) as well as by eukaryotic-type serine/threonine kinases (STK) <ce:cross-refs refid="bib110 bib111 bib112" id="crosrefs0090">[110â112]</ce:cross-refs>. These kinases are proposed to be regulators of metabolic processes, including transcription, growth, differentiation, cell development, sporulation, biofilm formation and interaction with host cells. So this conserved family of bacterial STK (in Streptococcus agalactiae) unique to Gram-positive species, has emerged as an attractive potential antibacterial target <ce:cross-refs refid="bib113 bib114 bib115 bib116 bib117 bib118 bib119 bib120" id="crosrefs0095">[113â120]</ce:cross-refs>. This prompted Oxoby etÂ al. to investigate structureâactivity relationship study from a screening hit and structure-based design strategy which led to the identification of bisarylureas as potent inhibitors of Streptococcus agalactiae Stk1. High-throughput screening library of molecules allowed identification of the 6-(3-aminopropanol)-substituted purine compound 51 as an inhibitor of <ce:italic>Streptococcus agalactiae</ce:italic> Stk1 with an IC<ce:inf loc="post">50</ce:inf> of 66Â Î¼M. By using homology modeling of this compound, various binding sites were determined to synthesize various analogs and to investigate the SAR of these series. Various modifications were made on the purine moiety, phenyl ring (at 2nd position on purine) and aminopropanol by using docking studies to support the hypothesis which resulted into four series of analogs. These small molecules represented encouraging lead for the development of novel anti-infective drugs based on the concept of anti-virulence <ce:cross-ref refid="bib121" id="crosref0325">[121]</ce:cross-ref> (<ce:cross-ref refid="fig18" id="crosref0330">Fig.Â 18</ce:cross-ref>
                        <ce:float-anchor refid="fig18"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0200" view="all">Glycogen synthase kinase-3(GSK-3) is a family of serine/thre-onine protein kinases which are involved in a great number of physiological events and human diseases, including neurodegenerative diseases, diabetes, inflammation and cancers <ce:cross-ref refid="bib122" id="crosref0335">[122]</ce:cross-ref>. Ibrahim etÂ al. assayed the novel 8-arylated purines as inhibitors of glycogen synthase kinase. Compounds have been tested at 10Â mM concentration against a panel often kinases. Various enzymes were involved in the enzyme assay such as GSK-3b, casein kinase 2, and Tyro3 receptor kinase, CDK5/p25, EGFR, CK2a, and MAPKAPK2. Among all the compounds 53, 54 and 55 exhibited the significant inhibition against glycogen synthase kinase with IC<ce:inf loc="post">50</ce:inf> 0.016, 0.365 and 0.0169Â Î¼M, respectively <ce:cross-ref refid="bib123" id="crosref0340">[123]</ce:cross-ref> (<ce:cross-ref refid="fig19" id="crosref0345">Fig.Â 19</ce:cross-ref>
                        <ce:float-anchor refid="fig19"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0205" view="all">VRAF murine sarcoma viral oncogene homologue B1 (BRAF) is a serine-threonine kinase and a component of Ras/Raf/MEK/ERK signaling pathway that regulates cell growth, division and differentiation and due to the frequent occurrence of oncogenic mutations in rapidly growing fibrosarcoma (RAF) family members, this pathway has long been associated with human cancers <ce:cross-ref refid="bib124" id="crosref0350">[124]</ce:cross-ref>. The V600E mutation (substitution of glutamate for valine at amino acid residue 600) induced over activation of BRAF has been identified in a variety of human cancers such as ovarian, colorectal and thyroid carcinomas, thus inhibition of BRAF kinase activity as a promising therapeutic strategy for the treatment of cancer <ce:cross-refs refid="bib125 bib126 bib127" id="crosrefs0100">[125â127]</ce:cross-refs>. Park etÂ al. identified novel classes of BRAF inhibitors. Six compounds with percent of control (POC) values less than 60 were selected and their <ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf> values were determined. The compounds 56 and 57 with 9<ce:italic>H</ce:italic>-purine and phthalazine groups, respectively, exhibited good potency with <ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf> values of 0.7 and 2.1Â Î¼M respectively. Detailed binding mode analyses with docking simulations revealed that these inhibitors could be stabilized in ATP-binding site by simultaneous establishment of multiple hydrogen bonds and van der Waals contacts <ce:cross-ref refid="bib128" id="crosref0355">[128]</ce:cross-ref> (<ce:cross-ref refid="fig20" id="crosref0360">Fig.Â 20</ce:cross-ref>
                        <ce:float-anchor refid="fig20"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0210" view="all">Keeping in view that VRAF murine sarcoma viral oncogene homologue B1 (BRAF) kinase has been considered to be a promising therapeutic target for various human cancers <ce:cross-ref refid="bib129" id="crosref0365">[129]</ce:cross-ref>, Park etÂ al. working on similar lines identified novel classes of BRAF kinase inhibitors with micromolar activity utilizing the structure-based virtual screening with docking simulations between BRAF kinase and its candidate inhibitors. These potent inhibitors were categorized into two scaffolds: 58 (phenyl-(9H-purin-6-yl) amine) and 59 (phenyl-(5-phenyl-phthalazin-1-yl) amine). Five substituent variants of scaffold 58 and three variants of scaffold 59 were explored to identify the substituents that can enhance the binding affinities against BRAF kinase. For each of the two inhibitor scaffolds, approximately 100,000 derivatives were generated and scored according to the calculated binding affinities. The 1000 top-scored molecules for each scaffold were then checked for commercial availability. Finally, 91 and 52 derivatives of 58 and 59 were, respectively purchased from compound suppliers and tested for binding affinity over BRAF kinase at 50Â Î¼M concentration in a high-throughput binding assay. Twenty-four compounds exhibited high affinity and were selected for the further determination of <ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf> values. Out of 91 derivatives of 4 tested, 16 were found to have POC values less than 30 and <ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf> values less than 10Â Î¼M for BRAF kinase. Compound 60 (<ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf>Â =Â 0.43Â Î¼M) appeared to be the most active compound among this series. Eight derivatives of 59 were found with POC values less than 30 and the <ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf> values ranging from 2 to 10Â Î¼M. Compound 61 (<ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf>Â =Â 2.5Â Î¼M) appeared to be the most active compound among this series. Detailed binding mode analyses with docking simulations show that the compounds can be stabilized in ATP-binding site by the simultaneous establishment of multiple hydrogen bonds and van der Waals contacts <ce:cross-ref refid="bib130" id="crosref0370">[130]</ce:cross-ref> (<ce:cross-ref refid="fig21" id="crosref0375">Fig.Â 21</ce:cross-ref>
                        <ce:float-anchor refid="fig21"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0215" view="all">Idiopathic pulmonary fibrosis (IPF) is a fatal disease manifested by a progressive loss of lung function through fibrotic changes in the lung tissue <ce:cross-ref refid="bib131" id="crosref0380">[131]</ce:cross-ref>. Aminopurine based Jun N-terminal kinase (JNK) inhibitors demonstrated pharmacological efficacy in animal models of inflammation and fibrosis <ce:cross-ref refid="bib132" id="crosref0385">[132]</ce:cross-ref>. Thus, Krenitsky etÂ al. designed a purine sub-series with lower molecular weight and lipophilicity by placing various substituents at C2, C8 and N9 position and collected their rat PK data to understand the parameters and issues affecting plasma exposure which led to the identification of four structurally diverse inhibitors (62â65). Differentiation based on PK profiles in multiple species as well as activity in a chronic efficacy model led to the identification of 64. Its improved potency (10-fold in the JNK1 assay) compared to its R-isomer, was rationalized by the crystal structure of 64 in the JNK3 active site. Compound 64 was recommended as a clinical candidate for the treatment of Idiopathic pulmonary fibrosis <ce:cross-ref refid="bib133" id="crosref0390">[133]</ce:cross-ref> (<ce:cross-ref refid="fig22" id="crosref0395">Fig.Â 22</ce:cross-ref>
                        <ce:float-anchor refid="fig22"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0220" view="all">JNKs (Jun N-terminal kinases) are serineâthreonine kinases that belong to the MAP kinase family of enzymes, and perform essential roles in cellular activation resulting in inflammatory and apoptotic responses <ce:cross-ref refid="bib134" id="crosref0400">[134]</ce:cross-ref>. Compound 66, an ATP-competitive inhibitor of JNK demonstrated moderate selectivity and metabolic stability in rat and human <ce:cross-ref refid="bib135" id="crosref0405">[135]</ce:cross-ref>. Krenitsky etÂ al. optimized an aminopurine lead (66) with modest potency and poor overall kinase selectivity to identify potent selective JNK or JNK/p38a dual inhibitors with favorable physico-chemical properties for intravenous administration. Kinase selectivity was improved by introduction of an aliphatic side chain at the C-2 position. The co-crystal structure of compound 66 in the JNK3 ATP-binding site summarizes selected residues of the JNK3 ATP binding site, which appears important for binding of the aminopurine scaffold: hinge, lipophilic back pocket, ribose-binding pocket and solvent-exposed region. Hydrophobic back pocket is frequently referred to as a selectivity pocket owing to structural differences between JNK1 and JNK2/JNK3 isoforms. Owing to this critical structural information, systematic modification of the C2, C8 and N9 substituents was carried out to explore the structure activity relationship. Attempts were made to improve the aqueous solubility and rat intravenous clearance of the most potent compound 67. Due to unsuccessful attempts, efforts were focused on small, intrinsically soluble inhibitors with low rat intravenous clearance which led to the synthesis of C8 fluorinated analogs of 68. Based on rat intravenous PK parameters and the improved aqueous solubility as the HCl salt analog 69 was selected for further profiling. On the basis of <ce:italic>inÂ vivo</ce:italic> efficacy in a mouse concanavalin A (ConA)-induced liver injury model, efficacy in a rat ischemia reperfusion model with hepatectomy, intravenous PK profiling and <ce:italic>inÂ vitro</ce:italic> safety profiling studies, compound 69 was selected as a potential clinical candidate for diseases manifested by ischemia reperfusion injury <ce:cross-ref refid="bib136" id="crosref0410">[136]</ce:cross-ref> (<ce:cross-ref refid="fig23" id="crosref0415">Fig.Â 23</ce:cross-ref>
                        <ce:float-anchor refid="fig23"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0225" view="all">The casein kinase 1 (CK1) family of serine/threonine-specific kinases comprises of seven members (Î±, Î²1, Î´, É, Î³1, Î³2 and Î³3); each isoform possesses preference for pre-phosphorylated substrates <ce:cross-ref refid="bib137" id="crosref0420">[137]</ce:cross-ref>. CK1 kinases regulate diverse processes including Wnt signaling, membrane trafficking, the actin cytoskeleton, the DNA damage response, and circadian rhythms <ce:cross-ref refid="bib138" id="crosref0425">[138]</ce:cross-ref>. Human pathologies, such as, neurodegenerative diseases, sleep disorders and cancer are linked to abnormal CK1Î´ and CK1É activity. CK1 kinases are expressed in the central nervous system and CK1Î´ is thought to play roles in dopamine signaling, neurotransmitter release and the phosphorylation of neurotransmitter receptors <ce:cross-ref refid="bib139" id="crosref0430">[139]</ce:cross-ref>. Casein kinases 1Î´ and 1É are highly expressed in some cancers and appear to control tumor cell growth, apoptosis, metabolism and differentiation <ce:cross-refs refid="bib140 bib141 bib142" id="crosrefs0105">[140â142]</ce:cross-refs>. These important biological roles encouraged Bibian and his co-workers to develop CK1Î´/É inhibitors. By means of high-throughput screening, SR-653234 (70) was identified as a promising hit. Extensive mechanistic and biochemical profiling studies revealed SR-653234 (70) and its analog SR-1277 (71) as highly selective CK1Î´/É inhibitors. A series of analogs of SR-653234 with a range of substituents in the benzimidazole ring were synthesized. To address the problem of low solubility (1Â Î¼M in PBS buffer) of lead compound SR-1277 (71), additional analogs with piperazine and piperidine substituents were synthesized. Kinetic analysis demonstrated that the purine scaffold CK1Î´/É inhibitors SR-2890 (72) and SR-3029 (73) with measured K<ce:inf loc="post">i</ce:inf>'s 14Â nM and 97Â nM, respectively are ATP competitive. The inhibitors were subjected to MTT assay against the human melanoma A375Â cell line and further the potent (EC<ce:inf loc="post">50</ce:inf>Â <Â 200Â nM) inhibitors were assessed for <ce:italic>inÂ vitro</ce:italic> DMPK assays (microsome stability, inhibition of cytochrome P450 1A2, 2C9, 2D6, and 3A4). The studies established the high selectivity of SR-2890 (72) and SR-3029 (73) as CK1Î´/É inhibitors, with only 6 off-target kinases inhibited â¥90% at 10Â Î¼M by SR-3029 (73) and that SR-2890 (72) is less kinase selective than either SR-1277 (71) or SR-3029(73). These efforts led to the identification of SR-2890 (72) and SR-3029 (73) that have <ce:italic>inÂ vitro</ce:italic> and <ce:italic>inÂ vivo</ce:italic> PK properties suitable for use in xenograft studies of human cancers, including brain cancers in the case of SR-3029 <ce:cross-ref refid="bib143" id="crosref0435">[143]</ce:cross-ref> (<ce:cross-ref refid="fig24" id="crosref0440">Fig.Â 24</ce:cross-ref>
                        <ce:float-anchor refid="fig24"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0230" view="all">Xu etÂ al. designed and synthesized a series of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer. In an effort to search for small molecular entities with both anti-protein kinase and anti-angiogenesis activities and conventional anticancer property for cancer treatment compound 74 (N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amide derivative) was used as a leading anti-angiogenic and anticancer agent for further structure optimization. Biological characterization revealed that several compounds of the series exerted enhanced anti-proliferative activity against human umbilical vein endothelial cells (HUVECs) and several cancer cell lines (MDA-MB-231 (breast cancer), HCT116 (colon cancer) and PC-3 (prostate cancer) and high specific protein kinase and angiogenesis inhibition. The SAR indicated that the substitution of sulfonamide structure for amide fragment played an essential role for the advance of inhibitory activities. In addition, the replacement of 1H-1,2,4-triazole ring by 7H-purine did not result in obvious decrease of inhibition efficacy, indicating that the sulfonamide structure contributes even more to the inhibition efficacy than the 1H-1,2,4-triazole ring and sulfuryl structure and plane geometrical conformation of R group are critical to the anti-proliferative activities. Among these compounds, compound 75 demonstrated comparable <ce:italic>inÂ vitro</ce:italic> anti-angiogenic activities to pazopanib in both HUVEC tube formation assay and the rat thoracic aorta rings (TARs) test. The results of kinase assay and molecular docking study exhibited that 7H-purine structure of compound 75 can form special interaction with Akt1 and Abl kinases and was identified to inhibit Akt1 (IC<ce:inf loc="post">50</ce:inf>Â =Â 1.73Â Î¼M) and Abl tyrosine kinase (IC<ce:inf loc="post">50</ce:inf>Â =Â 1.53Â Î¼M) effectively <ce:cross-ref refid="bib144" id="crosref0445">[144]</ce:cross-ref> (<ce:cross-ref refid="fig25" id="crosref0450">Fig.Â 25</ce:cross-ref>
                        <ce:float-anchor refid="fig25"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0235" view="all">PKB/Akt, a serine/threonine kinase, functions as a key signaling node in the PI3K/Akt/mTOR pathway that plays a critical role in cell growth, proliferation, motility and survival <ce:cross-refs refid="bib145 bib146 bib147 bib148 bib149 bib150" id="crosrefs0110">[145â150]</ce:cross-refs>. Keeping this in view, a series of diphenylmethylamine derivatives were rationally designed, synthesized and biologically evaluated for Akt1 inhibitory activities by Liu etÂ al. Analogs of 76 were generated â<ce:italic>in silico</ce:italic>â and virtually evaluated. The preliminary results revealed that both of 77 and 78 showed good scores in pharmacophore and molecular docking models, when bulky alkyl group was introduce onto primary amine of 76 (e.g. isopropyl for 77 and cyclopropyl for 78). These two compounds were synthesized and biologically evaluated. They exhibited significant Akt1 inhibitory activities (IC<ce:inf loc="post">50</ce:inf>, 77: 0.16Â Î¼M; 78: 0.47Â Î¼M). In attempt to improve their potency and/or selectivity, more extensive modifications of diphenylmethylamine derivatives were performed. Different substituents, including hydrophobic, hydrophilic, aliphatic and aromatic groups were introduced to primary amine of diphenylmethylamine skeleton, while replacing the purine moiety of the parent compound with pyridine and pyrazole, which are privileged fragments of numerous kinase inhibitors. Among all the designed compounds, compound 79 exhibited the most potent Akt1 inhibitory activity and cytotoxity. Further kinase selectivity studies of compound 79 were performed, indicating its excellent selectivity against Aurora A, Drak, IKKb, GSK3b, SYK and JAK2, and moderate selectivity against PKC and BRAF. Insight into the structure activity relationship (SAR), molecular docking studies were further performed and a refined pharmacophore model was obtained using the most active compounds 77, 79 and 80 via application of HipHop program <ce:cross-ref refid="bib151" id="crosref0455">[151]</ce:cross-ref> (<ce:cross-ref refid="fig26" id="crosref0460">Fig.Â 26</ce:cross-ref>
                        <ce:float-anchor refid="fig26"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec3.2" view="all">
                     <ce:label>3.2</ce:label>
                     <ce:section-title id="sectitle0070">Cyclin-dependent specific protein kinase inhibitors</ce:section-title>
                     <ce:para id="p0240" view="all">Cyclin-dependent kinases (CDK) are key regulators in mammalian cell cycle. Regulation of CDKs occurs through cyclin production, destruction, relocation, inhibitory and activating phoshorylation events. Each cyclin associates with one or two CDKs, and most CDKs associate with one or two cyclins <ce:cross-ref refid="bib152" id="crosref0465">[152]</ce:cross-ref> Although genetic and RNA studies suggest CDK2 and CDK4 may not be essential for cell cycle progression <ce:cross-refs refid="bib153 bib154" id="crosrefs0115">[153,154]</ce:cross-refs>, some experiments have shown that CDK1 kinase activity is critical for cell cycle progression through mitosis <ce:cross-ref refid="bib154" id="crosref0470">[154]</ce:cross-ref>. Al-Sha'er etÂ al. discovered the novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and <ce:italic>in silico</ce:italic> screening followed by <ce:italic>inÂ vitro</ce:italic> bioassay. <ce:italic>InÂ vitro</ce:italic> assay was conducted employing recombinant human CDK1/CycB kinase. The HYPOGEN module was employed from the CATALYST software package to construct numerous plausible binding hypotheses for CDK1 inhibitors. Subsequently, genetic function algorithm (GFA) and multiple linear regression (MLR) analysis were employed to search for an optimal QSAR that combines high-quality binding pharmacophores with other molecular descriptors and capable of explaining bioactivity variation across a collection of diverse CDK1 inhibitors. CATALYST models drug-receptor interactions using information derived from the ligand structures HYPOGEN identifies a 3D array of a maximum of five chemical features common to active training ligands that provides relative alignment for each input molecule consistent with binding to a proposed common receptor site. The 2D structures of the inhibitors were imported into CATALYST and converted automatically into plausible 3D single conformer representations. The resulting 3D structures were used as starting points for conformational analysis and in the determination of various molecular descriptors for QSAR modeling. Eventually, 180 pharmacophore models emerged from 18 automatic HYPOGEN runs, out of which only 91 models illustrated confidence levels 85%. Successful models were clustered and their best representatives were used in subsequent QSAR modeling. QSAR analysis was searched for the best combination of orthogonal pharmacophores and other structural descriptors (connectivity, topological, 2D, etc.) capable of explaining bioactivity variation across the collected list electrophilicity was found to favor anti-CDK1 bioactivity. Emergence of two hydrophobic descriptors in the QSAR equations, namely, AtypeC8 and AtypeH52, suggest that molecular hydrophobicity enhances anti-CDK1 properties. QSAR-selected pharmacophores with exclusion spheres employing HipHop-Refine module within CATALYST was used to define the size of the binding pocket so that to overcome the lack steric constrains. To further validate the resulting models (both QSAR and pharmacophores), then QSAR-selected pharmacophores was subjected to receiver-operating characteristic (ROC) analysis. In ROC analysis, the ability of a particular pharmacophore model to correctly classify a list of compounds as actives or inactives is indicated by the area under the curve (AUC) of the corresponding ROC as well as other parameters. Out of the 88 highest-ranking hits acquired for experimental validation, 11 compounds (81â91) were found to possess significant inhibitory activities against CDK1. The most potent NCI hit illustrated was compound 82 (IC<ce:inf loc="post">50</ce:inf>Â =Â 0.83Â Î¼M) which can act as a lead for subsequent development into potential anticancer agents <ce:cross-ref refid="bib155" id="crosref0475">[155]</ce:cross-ref> (<ce:cross-ref refid="fig27" id="crosref0480">Fig.Â 27</ce:cross-ref>
                        <ce:float-anchor refid="fig27"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0245" view="all">2-(1-Ethyl-2-hydroxyethylamino)-N6-(benzyl)-9-isopropyladenine (Roscovitine; Ros) is a substance derived from a plant hormone N6-(benzyl)adenine-(6-benzylaminopurine) <ce:cross-ref refid="bib156" id="crosref0485">[156]</ce:cross-ref>. Roscovitine belongs to the group of adenine-based cyclin-dependent kinase inhibitors (CDKI), specifically and was recently successfully tested <ce:italic>inÂ vivo</ce:italic> on patients with non-small cell lung cancer <ce:cross-refs refid="bib157 bib158" id="crosrefs0120">[157,158]</ce:cross-refs>. TrÃ¡vnÃ­cek etÂ al. synthesized, characterized and evaluated the <ce:italic>inÂ vitro</ce:italic> cytotoxicity of Roscovitine-based CDK inhibitors acting as N-donor ligands in the platinum (II) oxalato complexes. Four mononuclear platinum (II) oxalato complexes (92â95) of the general composition [Pt(ox)(nRos)<ce:inf loc="post">2</ce:inf>]âxH<ce:inf loc="post">2</ce:inf>O (xÂ =Â 1/4 for 92, 1 for 93, 1/2 for 94 and 3/4 for 95) were fully characterized by various physical methods. From the single crystal X-ray was concluded that these compounds have a distorted square-planar arrangement around the central Pt(II) atom, which is tetra-coordinated by two nRos molecules (bound through their N7 atoms) and by one bidentate coordinated oxalate dianion, thus giving a PtN2O2 donor set. <ce:italic>InÂ vitro</ce:italic> cytotoxic activity of the complexes against ovarian carcinoma (A2780), cisplatin resistant ovarian carcinoma (A2780cis), malignant melanoma (G-361), lung carcinoma (A549), cervix epitheloid carcinoma (HeLa), breast adenocarcinoma (MCF7) and osteosarcoma (HOS) human cancer cell lines was evaluated. The complexes showed higher <ce:italic>inÂ vitro</ce:italic> anticancer activity against cervix epitheloid carcinoma and cisplatin resistant ovarian carcinoma human cancer cell lines as compared with the commercially used platinum-based drugs cisplatin and oxaliplatin. Moreover, the complex 93 was also tested, as a representative sample, for its cytotoxicity in primary cultures of human hepatocytes and it was found to be non-hepatotoxic up to the concentration of 50.0Â mM. The prepared complexes 92â95 represents the first examples of platinum (II) oxalato complexes with adenine-based potent CDK inhibitors acting as carrier N-donor ligands <ce:cross-ref refid="bib159" id="crosref0490">[159]</ce:cross-ref> (<ce:cross-ref refid="fig28" id="crosref0495">Fig.Â 28</ce:cross-ref>
                        <ce:float-anchor refid="fig28"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0250" view="all">Keeping in view, the crucial role of CDK2 in the G<ce:inf loc="post">2</ce:inf> phase of the cell cycle <ce:cross-refs refid="bib160 bib161 bib162 bib163 bib164 bib165 bib166 bib167 bib168 bib169 bib170" id="crosrefs0125">[160â170]</ce:cross-refs> and binding mode suggested by the molecular modeling work on the cyclin-dependent kinase2 (CDK2) in complex with ligand (98), where the essential hetero-bicyclic ring system was located in the ATP binding site, making polar interactions to gain access to the phosphate binding region of the ATP-kinases pocket, Elgazwy etÂ al. synthesized a series of novel purine derivatives and biologically evaluated for their <ce:italic>inÂ vitro</ce:italic> anti-CDK2/cyclin A3 using enzyme prepared from starfish oocytes and antitumor activity in Ehrlich ascites carcinoma (EAC) cell based assay. Among all the synthesized novel purine derivatives, compounds 97 and 98 demonstrated most potent CDK2/cyclin A3 and EAC cell growth inhibition. Molecular modeling study of the most potent novel purine derivatives into cyclin dependant kinase2 (CDK2) active site were found to show the highest docking scores and fit values, which appeared coherent with the obtained biological data <ce:cross-ref refid="bib163" id="crosref0500">[163]</ce:cross-ref> (<ce:cross-ref refid="fig29" id="crosref0505">Fig.Â 29</ce:cross-ref>
                        <ce:float-anchor refid="fig29"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0255" view="all">In view of CDK2 inhibition by <ce:italic>O</ce:italic>
                        <ce:sup loc="post">6</ce:sup>-cyclohexylmethoxy-2-(4Ê¹-sulfamoylanilino)purine (99, IC<ce:inf loc="post">50</ce:inf>Â =Â 0.005Â Î¼M), Wong etÂ al. synthesized a sulfonamide-based kinase inhibitors derived from 99 to explore the effect of moving sulfonamide group to the <ce:italic>meta</ce:italic> position of the benzenoid ring, inserting a methylene group between the sulfonamide and benzenoid moiety and substitution on N of sulfonamide. All the synthesized derivatives were evaluated for CDK2 Inhibition, but unfortunately, none of the compound better CDK2 inhibition profile than 99 <ce:cross-ref refid="bib171" id="crosref0510">[171]</ce:cross-ref> (<ce:cross-ref refid="fig30" id="crosref0515">Fig.Â 30</ce:cross-ref>
                        <ce:float-anchor refid="fig30"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0260" view="all">The cyclin dependent kinases (CDKs) form heterodimeric complexes with their cyclin partners, the levels of which depend upon the balance between protein synthesis and proteasomal degradation, and these complexes play important roles in regulating cellular processes, especially in the progression of the cell cycle <ce:cross-refs refid="bib172 bib173" id="crosrefs0130">[172,173]</ce:cross-refs>. The deregulation of CDK-cyclin activity in cancer cells resulted in extensive investigation for CDK inhibitors as therapeutic agents for treatment of various cancers. The low potency of selicilib (100) and its carboxylic acid metabolite as a CDK inhibitor urged Wilson etÂ al. to design and synthesize novel pyridylmethylaminopurines (101) designed to have increased aqueous solubility (by introduction of a pyridine substituent), and to prevent side-chain oxidation to the level of carboxylic acid (by modification of the primary alcohol present in seliciclib) thereby resulting in analogs with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. By the evaluation of kinase inhibition and kinase selectivity profile, anti-proliferative activity and metabolic stability, the secondary alcohols (102) and (104) (Î±R and Î±S respectively) and the tertiary dimethylcarbinols (103) and (105) (Î±R and Î±S respectively) were found to be the most potent analogs, further selected for additional biochemical assays, PK profiling and efficacy studies <ce:italic>inÂ vivo</ce:italic>. The major diastereomers Î±SÎ²R-5 (106) and Î±RÎ²S-3 (107) were confirmed to be primarily responsible for the observed biological activity. The water soluble purine CDK inhibitor (106) (CCT68127) with improved potency versus CDK2/cyclin E (IC<ce:inf loc="post">50</ce:inf>Â =Â 30Â nM), good potency versus CDK9 (IC<ce:inf loc="post">50</ce:inf>Â =Â 107Â nM), enhanced anti-proliferative activity against cancer cells (mean GI<ce:inf loc="post">50</ce:inf>Â =Â 700Â nM), increased stability towards mouse microsomes (67% remaining at 30Â min), promising <ce:italic>inÂ vivo</ce:italic> PK properties and efficacy <ce:italic>inÂ vivo</ce:italic> following oral administration appeared to be the most potent CDK inhibitor <ce:cross-ref refid="bib174" id="crosref0520">[174]</ce:cross-ref> (<ce:cross-ref refid="fig31" id="crosref0525">Fig.Â 31</ce:cross-ref>
                        <ce:float-anchor refid="fig31"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0265" view="all">(R)-roscovitine (selicilib, CYC202), a potent and Cdk-selective inhibitor is found to possess anticancer activity in various <ce:italic>inÂ vitro</ce:italic> and <ce:italic>inÂ vivo</ce:italic> models <ce:cross-refs refid="bib175 bib176" id="crosrefs0135">[175,176]</ce:cross-refs>. In search of selective CDK inhibitors, Liebl etÂ al. identified the role of Cdk5 in endothelial cell migration and angiogenesis and reported that Cdk inhibitor roscovitine blocks angiogenesis <ce:italic>inÂ vitro</ce:italic> as well as <ce:italic>inÂ vivo</ce:italic> and thereby investigated the anti-angiogenic profile of 15 derivatives of roscovitine, which were developed by structurally modifying roscovitine at positions 2 and 6, respectively. The (S)-isomer LGR561 (108) and the respective (R)- and (S)-isomers LGR848 (110) and LGR849 (109) strongly inhibited proliferation and cell cycle progression, induced cell death and reduced migration of endothelial cells <ce:italic>inÂ vitro</ce:italic>. In comparison to roscovitine, these compounds showed an increased potency to inhibit Cdk2, Cdk5, Cdk7, and Cdk9. The two (S)-isomers LGR561 (108) and LGR849 (109) were concluded as highly potent inhibitors of angiogenesis by analyzing their effects on endothelial cell tube formation, mouse aortic ring sprouting, angiogenesis in the chick chorioallantoic membrane and neo-vessel formation in the mouse cornea. In comparison to roscovitine, 108, 110 and 109 more potently inhibited Cdk2, Cdk5, Cdk7, and Cdk9 which all seem to be possible targets of the compounds to inhibit angiogenesis with LGR561 (108) being the most potent anti-angiogenic compound which displayed the strongest inhibition of Cdk5 <ce:cross-ref refid="bib177" id="crosref0530">[177]</ce:cross-ref> (<ce:cross-ref refid="fig32" id="crosref0535">Fig.Â 32</ce:cross-ref>
                        <ce:float-anchor refid="fig32"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0270" view="all">The 2,6,9-trisubstituted purine analogs (olomoucine and roscovitine) and the purvalanols have been shown to selectively inhibit a subset of CDKs <ce:cross-ref refid="bib178" id="crosref0540">[178]</ce:cross-ref>. Purvalanol B targets CDK1 and CDK2 complexes at submicromolar concentrations <ce:cross-ref refid="bib179" id="crosref0545">[179]</ce:cross-ref>. By synthetically coupling the fluorescent compound dansyl-ethylenediamine to purvalanol B, two fluorescent analogs VMY-1-103 (11) and VMY-1-101 (112) were developed by Yenugonda etÂ al. 112 and 111 showed the greatest activity against CDK2/cyclin E (87% and 89% at 100Â nM, respectively). The compounds were also found to be effective in inhibiting other CDK's, such as CDK1/cyclin B, and displayed strong anti-proliferative activity against two human adenocarcinoma cell lines (p53-mutated; estrogen-independent MDA-MB-231Â cells and wild type p53; estrogen dependent MCF-7Â cells), <ce:italic>inÂ vitro</ce:italic>. The potent anti-proliferative activity of synthesized compounds was observed in two breast cancer cell lines (IC<ce:inf loc="post">50</ce:inf> 4.0â4.8Â Î¼M in MDA-MB-231Â cells and 10.0â19.0Â Î¼M in MCF-7Â cells), and was 13 fold more potent in inhibiting MDA-MB-231Â cell growth and 2.8â5.5 folds more potent in inhibiting MCF-7Â cell growth as compared to roscovitine. In contrast to roscovitine, VMY-1-103 (111) showed irreversible anti-proliferative effects. 111 was also moderately active at inhibiting a multidrug resistance (MDR) positive cell line and the synthesized analogs are not substrates for <ce:italic>p</ce:italic>-glycoprotein. Therefore, the designed fluorescent CDK inhibitors (111 and 112) exhibited potent anti-proliferative and pro-apoptotic capabilities in human breast cancer cell lines beyond that seen with the parent compound <ce:cross-ref refid="bib180" id="crosref0550">[180]</ce:cross-ref> (<ce:cross-ref refid="fig33" id="crosref0555">Fig.Â 33</ce:cross-ref>
                        <ce:float-anchor refid="fig33"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0275" view="all">Roscovitine and Flavopiridol were the two CDK inhibitors reached phase II/III clinical trials <ce:cross-ref refid="bib181" id="crosref0560">[181]</ce:cross-ref>. Several optimization studies conducted on Roscovitine, devoted to the selection of the substituent at the position 6 of the purine scaffold, led to the identification of CR8, a potent and selective kinase inhibitor <ce:cross-ref refid="bib182" id="crosref0565">[182]</ce:cross-ref>. To develop less hydrophobic compounds which could be more soluble and display an improved bioavailability, a new series of 2,6,9-trisubstituted purines has been synthesized by N'gompaza-Diarra etÂ al. These compounds mainly differ by the substituent on the C-2 position of the purine scaffold which encompasses a diol group. These compounds were screened for kinase inhibitory activities against a subset of CDKs but also against GSK3-Î±/Î² (Glycogen synthase kinase 3), DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A) and CK1 (casein kinase 1) and anti-proliferative effects against human neuroblastoma SH-SY5Y cells by the MTS reduction assay. They were found to be potent inhibitors of cyclin-dependent kinases. The most potent derivative (113) inhibited SH-SY5Y (neuroblastoma) tumor cell line with an IC<ce:inf loc="post">50</ce:inf>Â <Â 0.5Â Î¼M which means approximately a 30 fold increase compared to Roscovitine. Several valyl esters were previously described to improve bioavailability of the parent compound. The most commonly known is Valacyclovir, the L-valyl ester prodrug of acyclovir (ACV), a valine ester (114) was also prepared from the most potent inhibitor to serve as a prodrug. 114 displayed anti-proliferative activity against cancer cells as the ester may undergo a slow hydrolysis in the culture media. The ester was also found to inhibit kinases unexpectedly, as, up to now, rather small groups have been introduced in position 2 of the purine. For a better understanding of this unexpected activity, a docking analysis was performed with the ester against kinases, using the crystal structure of CR8-CDK9 complex. The binding of ligand 114 was stabilized by various hydrogen bond, ionic bond and van der Waals interactions. To further evaluate the potential interest of 113 several preliminary ADME parameters were determined. Inhibition against a series of CYP 450 enzymes was found higher than 5Â Î¼M and plasma binding protein was also favorable with a moderate binding to serum proteins <ce:cross-ref refid="bib183" id="crosref0570">[183]</ce:cross-ref> (<ce:cross-ref refid="fig34" id="crosref0575">Fig.Â 34</ce:cross-ref>
                        <ce:float-anchor refid="fig34"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0280" view="all">3-Phosphoinositide dependent protein kinase-1 (PDK1) is part of the Akt/PKB pathway which regulates many growth factors and oncogenes. PDK1 signals to a number of proteins shown to be important in cancer, for example, S6K and AKT. PDK1 is reported to phosphorylate Akt on residue Thr308 thereby resulting in its activation <ce:cross-ref refid="bib184" id="crosref0580">[184]</ce:cross-ref>. With an aim of generating potent PDK1 inhibitors, various kinase inhibitors possessing macrocyclic 2-aniline-4-phenyl-pyrimidine scaffold were screened for activity against PDK1 by Poulsen etÂ al. Among these kinase inhibitors, compound 115 having CDK/Flt3/JAK2 inhibitory potential was found to have moderate PDK1 activity. After docking into a PDK1 X-ray structure it was suggested that the pyrimidine ring could be substituted for a purine thereby increasing the number of hydrophobic contacts with the protein and forming an additional hydrogen bond to the kinase hinge. Deletion of the macrocyclic linker allowed a more rapid optimization of the aromatic substituents which further improved binding to the enzyme. As a result of these observations, modification of the macrocycle by fusing an imidazole to the 5 and 6-position of the pyrimidine thereby forming a purine and removal of the macrocyclic linker yielded compound 116 and 117 possessing PDK1/CDK/Flt3/JAK2 and selective PDK1 inhibitory activity, respectively <ce:cross-ref refid="bib185" id="crosref0585">[185]</ce:cross-ref> (<ce:cross-ref refid="fig35" id="crosref0590">Fig.Â 35</ce:cross-ref>
                        <ce:float-anchor refid="fig35"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0285" view="all">With an aim to prepare novel derivatives of roscovitine (trisubstituted purine derivative roscovitine, which inhibits CDK 1, 2, 5, 7 and 9 <ce:cross-refs refid="bib186 bib187 bib188 bib189" id="crosrefs0140">[186â189]</ce:cross-refs>, that possessed enhanced anti-kinase and cytotoxic activities with structural features increasing their elimination half-lives, Zatloukal etÂ al. prepared derivatives of roscovitine, differing in substitutions at positions 2 and 6. With hydroxy group on the benzyl ring enhancing CDK inhibitory activity, the 2-hydroxy-5-chloro derivatives (118â122) and 2-hydroxy-5-fluoro derivatives (123, 124) were found to be potent among the synthesized novel compounds, both in terms of their anti-CDK2 and cytotoxic activity. These inhibitors induced p53-regulated transcription at low micromolar concentrations, as assessed by a cellular reporter assay. Compound 122 was observed to be the most potent inhibitor among the series of compounds with over 13-fold higher activity versus roscovitine in terms of CDK inhibition that corresponds with over 9-fold increase in cytotoxicity on a panel of six cancer cell lines. It potently arrested cells in late S and G2/M phases. This effect was particularly evident in HCT-116Â cells, where about 15% more cells were in the G2/M phase of the cell cycle. Further investigation of the effect of treating colorectal carcinoma HCT-116Â cells with 122 revealed rapid increase in the expression of p53 and p53-regulated p21<ce:sup loc="post">WAF1</ce:sup> at concentrations of 1Â Î¼M and higher. A fluorimetry-based caspase-3/7 activity assay of lysates of HCT-116 and K562Â cells treated with 122 revealed potent dose-dependent activation of the caspase in K562 but only weak activation in HCT-116Â cells. Compound 122 blocked cell cycle progression and induced apoptosis in cells as a result of transcriptional perturbations due to reduced phosphorylation of Ser-2 and Ser-5 in the C-terminal domain of RNAP-II, caused by inhibition of CDK9 and CDK7 <ce:cross-ref refid="bib190" id="crosref0595">[190]</ce:cross-ref> (<ce:cross-ref refid="fig36" id="crosref0600">Fig.Â 36</ce:cross-ref>
                        <ce:float-anchor refid="fig36"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0290" view="all">The vast majority of CDK inhibitors are low molecular weight, flat, hydrophobic heterocyclic molecules that compete with ATP for binding at the kinase ATP-binding site by both hydrophobic interactions and hydrogen bonding <ce:cross-ref refid="bib191" id="crosref0605">[191]</ce:cross-ref>. All potent purine and related CDK inhibitors contain an aromatic amine moiety at position 6, such as benzylamino or phenylamino groups, that (i) binds to the hydrophobic pocket near the active site of CDKs (and thus deliver their selectivity) and (ii) forms an essential H-bond to carbonyl of Leu83 in CDK2 (or to corresponding residues in other CDKs). Doleckova etÂ al. explored the influence of the guanidino group at position C6 of the purine and prepared a library of compounds consisting of 2,9-disubstituted-6-guanidinopurines based on the ability of the guanidino group to form strong non-covalent interactions at the active site of enzymes responsible for their biological activities. The synthesized compounds were screened for CDK inhibitory activities and anti-proliferative effects in the human breast cancer-derived cell line MCF7. Compound 125 was the most active 6-guanidinopurine bearing the same substituent at position C2 as roscovitine (in addition to the roscovitine N9 substituent). This compound was more active in CDKs (2.7 folds for CDK1 and 4.6 folds for CDK2) as well as on MCF7 cells (IC<ce:inf loc="post">50</ce:inf> more than 10 times lower) than roscovitine itself. In contrast to roscovitine, which is a more potent CDK inhibitor as an (R)-enantiomer, (S)-enantiomer (125) seems to be more active than its (R)-counterpart (126). Kinase selectivity profiling of (R)- and (S)-enantiomers, revealed that introduction of a guanidino group at the C6 position of the purine moiety decreased selectivity towards protein kinases compared to roscovitine <ce:cross-ref refid="bib192" id="crosref0610">[192]</ce:cross-ref> (<ce:cross-ref refid="fig37" id="crosref0615">Fig.Â 37</ce:cross-ref>
                        <ce:float-anchor refid="fig37"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0295" view="all">Among the cyclin dependent kinase (CDK) family, the cyclin dependent kinase 5 (CDK5), was discovered in 1992. It is activated by proteins identified as p35, its isoform p39, and their respective proteolytic fragments p25 and p29. CDK5 is involved in numerous neuronal diseases (including Alzheimer's or Parkinson's diseases, stroke, traumatic brain injury), pain signaling and cell migration. Thus, the pharmacological inhibitors of CDK5 have a great potential as new drugs against several major pathologies <ce:cross-refs refid="bib193 bib194 bib195 bib196" id="crosrefs0145">[193â196]</ce:cross-refs>. Demange etÂ al. synthesized and biological evaluated new 2,6,9-trisubstituted purines, structurally related to DRF 53 [IC<ce:inf loc="post">50</ce:inf>Â =Â 220Â nM (CDK1/Cyclin B); 80Â nM (CDK5/p25) and 10Â nM (Casein kinase 1 (CK1), involved in the hyperphosphorylation of the Tau protein and in the amyloid-Î² production, the two major hallmarks of Alzheimer's disease)], a promising kinase inhibitor currently in clinical trials. Among all the synthesized compounds, 127 displayed most potent kinase inhibition against CDK1 and CDK5, but none of the synthesized derivative of DRF 53 showed better potency against CK1 <ce:cross-ref refid="bib197" id="crosref0620">[197]</ce:cross-ref> (<ce:cross-ref refid="fig38" id="crosref0625">Fig.Â 38</ce:cross-ref>
                        <ce:float-anchor refid="fig38"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec3.3" view="all">
                     <ce:label>3.3</ce:label>
                     <ce:section-title id="sectitle0075">Other specific protein kinase inhibitors</ce:section-title>
                     <ce:para id="p0300" view="all">PDK1 has been shown to serve as a master regulator of a group of protein kinases known as the AGC kinase super-family which play important roles in the progression of cancer, such as activation of Akt, S6 kinase (S6K, SGK, and PKA), and protein kinase C (PKC). PDK1 inhibition, might avoid possible adverse effects resulting from inhibiting PI3K which is upstream of a wide range of signaling cascades <ce:cross-ref refid="bib198" id="crosref0630">[198]</ce:cross-ref>. To develop a small molecule selective PDK1 inhibitor suitable for oral administration, focused screening approach was carried out which resulted in the discovery of a compound 128 as a potent inhibitor of PDK1 with an IC<ce:inf loc="post">50</ce:inf> of 0.39Â Î¼M in ATPase assay <ce:cross-ref refid="bib199" id="crosref0635">[199]</ce:cross-ref>. Macrocycle 128 was originally synthesized as part of a cyclin-dependent protein kinase (CDK) inhibitor program where it had been shown to inhibit CDK2 at low micromolar concentrations. In order to identify potentially selective PDK1 inhibitors, various modifications were done which led to the design of novel 4-aryl purines (129). Blanchard etÂ al. prepared a series of 4-aryl-8<ce:italic>H</ce:italic>-purines and applied optimization strategy applied to this scaffold leading to potent PDK1 inhibitors with good physicochemical and pharmacological properties and devoid of CDK activity. It was clear from initial SAR, and supported by modeling studies, that substitutions on either 9-N or C-8 were not tolerated so attention was focused on the 2-position where <ce:italic>meta</ce:italic>-substituted anilines were preferred. Thus the strategy focused on development of 2-anilinophenyl side-chains and parallel optimization of the 4-aryl group. To guide the optimization, modeling studies were carried out on compound 130 having good initial potency towards PDK1, using published X-ray structures of PDK1 while achieving excellent selectivity over CDK2. To guide the optimization, modeling studies were carried out using published X-ray structures of PDK1. To simplify the SAR, 4-aryl group was fixed to 3,4-dimethoxyphenyl or 4-methoxyphenyl group and modification of 2-anilinophenyl side-chains was investigated with a view to increasing potency as well as improving the solubility of the compounds. Although improved potency and solubility were achieved permeability was seriously compromised rendering these compounds useful only as <ce:italic>inÂ vitro</ce:italic> ligands with negligible utility in cells. Further, selected compounds were evaluated in cellular proliferation assays, metabolic stability in mouse and human liver microsomes and Caco-2 permeability. All compounds had very good <ce:italic>inÂ vitro</ce:italic> metabolic stability (t<ce:inf loc="post">1/2</ce:inf>) as assessed in human and mouse liver microsomes. Compounds 130 and 131 showed encouraging activity against human tumor cell lines sensitive to the PI3K/Akt pathway, such as the prostate cancer cell line PC3. However an additional hydrogen bond and high polar surface area (128Â Ã2) rendered 132 much less active than 130 or 131 in PC3 cells. Compound 130 was also potent in another prostate cell line, DU 145, and in a breast cancer cell line, MDA-MB468, therefore it was selected for pharmacokinetic studies in the mouse <ce:cross-ref refid="bib200" id="crosref0640">[200]</ce:cross-ref> (<ce:cross-ref refid="fig39" id="crosref0645">Fig.Â 39</ce:cross-ref>
                        <ce:float-anchor refid="fig39"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0305" view="all">Choline (Cho) is phosphorylated by choline kinase (ChoK) to generate phosphocholine (PCho), which represents the first step in the biosynthesis of a membrane phospholipid, phosphatidylcholine <ce:cross-ref refid="bib201" id="crosref0650">[201]</ce:cross-ref>. Inhibition of Choline Kinase (ChoK) has been reported as a therapeutical target in the treatment of some kinds of tumor. Docking in the homology model of the human choline kinase isoform ChoKÎ± <ce:cross-ref refid="bib202" id="crosref0655">[202]</ce:cross-ref> based on the 3D structure of <ce:italic>Caenorhabditiselegans</ce:italic> choline kinase revealed that size of symmetrical biscationic inhibitors is appropriated to bind simultaneously in both the ATP and choline putative binding sites of the protein model <ce:cross-ref refid="bib203" id="crosref0660">[203]</ce:cross-ref>. The nature of the residues that constitute the ATP binding site is quite different to those residues that form the Cho binding site. Non-symmetric monocationic inhibitors should conserve one cationic head that could be inserted into the Cho binding site, but the second cationic head will be substituted by another fragment that could mimic the ATP adenine moiety. Rubio-RuÃ­z etÂ al presented the first family of these new inhibitors. In these compounds, adenine itself was used to mimic the ATP adenine moiety, and 4-dimethylamino- or 4-pyrrolidino-pyridinium salts were used as cationic head. Both fragments are separated by several linkers that have been chosen to study the influence of the linker size in the inhibition of ChoK. Designed compounds were synthesized and tested at two different concentrations: 10 and 50 Î¼Min an <ce:italic>inÂ vitro</ce:italic> system using human ChoK as a target. The effects on cell proliferation by the ChoK inhibitors were also investigated on the human hepatoma HepG2 cell line. Compounds 133 (N-9 series) (IC<ce:inf loc="post">50</ce:inf>Â =Â 10.70Â Î¼M) and 134 (N-3 series) (IC<ce:inf loc="post">50</ce:inf>Â =Â 6.21Â Î¼M) were the most potent ChoK inhibitors. The anti-proliferative IC<ce:inf loc="post">50</ce:inf> of 134 measured on HepG2 cell line gives a value of 49.70Â Î¼M. Whereas, compound 135 was the most potent structure as anti-proliferative agent of N-3 series that presents an IC<ce:inf loc="post">50</ce:inf> value of 38.9Â Î¼M. A trisubstituted purine derivative roscovitine, which inhibits CDK 1, 2, 5, 7, and 9 is in clinical trials <ce:cross-ref refid="bib204" id="crosref0665">[204]</ce:cross-ref> (<ce:cross-ref refid="fig40" id="crosref0670">Fig.Â 40</ce:cross-ref>
                        <ce:float-anchor refid="fig40"/></ce:float-anchor>).</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0080">Dual specificity (tyrosine/specific protein) protein kinase inhibitors</ce:section-title>
                  <ce:para id="p0310" view="all">Mps1 (also known as TTK) is a dual specificity serine/threonine and tyrosine protein kinase and is essential for the proper attachment of chromosomes to the mitotic spindle <ce:cross-ref refid="bib205" id="crosref0675">[205]</ce:cross-ref>. Inhibiting Mps1 has been shown to cause chromosomal miss-aggregations followed by cell death <ce:cross-ref refid="bib206" id="crosref0680">[206]</ce:cross-ref>. Kumar etÂ al. made efforts to optimize biological activity, novelty, selectivity and oral bioavailability of Mps1 inhibitors, from a purine based lead MPI-0479605 (136) having potent activity against the Mps1 enzyme (IC<ce:inf loc="post">50</ce:inf>Â =Â 0.004Â Î¼M) and good cytotoxicity (HCT-116; IC<ce:inf loc="post">50</ce:inf>Â =Â 0.1Â Î¼M). Activity in the mechanism based G2/M escape assay (EC<ce:inf loc="post">50</ce:inf>Â =Â 0.3Â Î¼M) suggests that cytotoxicity of this compound is due to inhibition of the Mps1 kinase. Compound 136 when dosed intra-peritoneally (IP), demonstrated dose dependent and statistically significant tumor growth inhibition in HCT-116 xenograft studies in mice. Docking of compound 136 in the ATP-binding site of Mps1 crystal structure reveals crucial interactions of two nitrogens of the purine core and C-6 aniline NH that anchor the molecule in the active site. Optimization efforts at C-6 position and keeping the C-2 group constant, reveals that C-6 position was intolerant to significant change. 136 and des-methyl derivative Reversine 137 were assayed against the related mitotic kinases Aurora A and B, and PLK1. Selectivity of compound 136 for Mps1 reveals that the presence of <ce:italic>ortho</ce:italic>-substituted aniline at the purine C-2 position is an essential selectivity element of this class of Mps1 inhibitors which was further rationalized by molecular modeling studies where the aniline ortho group was involved in various van der Waal interactions. Various ortho groups on the aniline moiety were investigated and the <ce:italic>ortho</ce:italic>-methoxy group was deemed optimal, and was therefore held constant during subsequent investigations. To optimize the remaining C-2 aniline substituents, numerous <ce:italic>para</ce:italic>-position modifications were assessed. Replacement of the morpholine group, with a substituted piperazine resulted in a series of promising inhibitors <ce:cross-ref refid="bib207" id="crosref0685">[207]</ce:cross-ref> (<ce:cross-ref refid="fig41" id="crosref0690">Fig.Â 41</ce:cross-ref>
                     <ce:float-anchor refid="fig41"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0315" view="all">In an effort to identify novel compounds for the treatment of cancer, a diverse array of purine-benzimidazole hybrids were synthesized through nucleophilic substitution at C6 position of purine ring with versatile cyclic amines at C2 position. All the newly synthesized hybrids were evaluated against 60 human tumor cell lines at one dose concentration level (10Â Î¼M). Compound 139 exhibited significant growth inhibition and was evaluated as 60Â cell panel at five dose concentration levels. Compound 139 proved to be 1.25 fold more active than the positive control 5-FU, with GI<ce:inf loc="post">50</ce:inf> value of 18.12Â Î¼M (MG-MID) and showed outstanding sensitivity towards colon cancer, CNS cancer and ovarian cancer with GI<ce:inf loc="post">50</ce:inf> values of 3.16, 2.00 and 1.36Â Î¼M respectively at five dose concentration level. Interaction of the compounds with Aurora-A enzyme involved in the process of propagation of cancer, has also been investigated. Compound 139 showed selectivity towards Aurora-A kinase inhibition with IC<ce:inf loc="post">50</ce:inf> value of 0.0Â lÂ Î¼M and ligand efficiency of 0.39 for binding to the enzyme. Molecular docking studies of compound 139 in the active binding site of Aurora-A over Aurora B/C kinase enzyme that also favor the enzyme immunoassay results <ce:cross-ref refid="bib208" id="crosref0695">[208]</ce:cross-ref> (<ce:cross-ref refid="fig42" id="crosref0700">Fig.Â 42</ce:cross-ref>
                     <ce:float-anchor refid="fig42"/></ce:float-anchor>).</ce:para>
               </ce:section>
               <ce:section id="sec5" view="all">
                  <ce:label>5</ce:label>
                  <ce:section-title id="sectitle0085">Miscellaneous kinase inhibitors</ce:section-title>
                  <ce:para id="p0320" view="all">A series of 2- and 6-substituted (RS)-9-(2,3-dihydro-1,4-benzoxathiin-3-ylmethyl)-9<ce:italic>H</ce:italic>-purine derivatives previously synthesized by Conejo-GarcÃ­a etÂ al., with the most active compounds 140 (IC<ce:inf loc="post">50</ce:inf>Â =Â 6.18Â Â±Â 1.70Â Î¼M) and 141 (IC<ce:inf loc="post">50</ce:inf>Â =Â 8.97Â Â±Â 0.83Â Î¼M). Further, the two series of these derivatives were synthesized by changing the position of methylenic linker from 3 to 2 position of six membered ring and by isosteric replacement of S atom with O atom. The resulted two bioisosteric series [substituted (RS)-9-(2,3-dihydro-1,4-benzoxathiin-2-ylmethyl)purines and substituted (RS)-9-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)purines] were thereby screened for their anticancer activity against the MCF-7 cancer cell line. Three compounds exhibited significant activity 142, 143 and 144 with IC<ce:inf loc="post">50</ce:inf>Â =Â 2.75Â Â±Â 0.03, 4.87Â Â±Â 0.02 and 7.64Â Â±Â 0.03Â Î¼M, respectively. Compound 142 was found to be 3.3 fold higher as anti-proliferative agent against the MCF-7Â cell line than the previously reported bioisoster 142. Furthermore To study the mechanisms of the anti-tumor activity of the most active compounds, the effects on the cell cycle distribution were analyzed by flow cytometry. Apoptosis induction in the MCF-7 human breast cancer cell line after treatment for 48Â h with 142 and 141 were observed in the same range [percentage of cells undergoing apoptosis: 70.08% (for 163) and 76.22% (for 162)]. The induction of the G<ce:inf loc="post">2</ce:inf>/M cell cycle arrest and apoptosis by the three most active compounds was found to be associated with increased phosphorylation of eIF2Î± in human breast cancer cells <ce:cross-ref refid="bib209" id="crosref0705">[209]</ce:cross-ref> (<ce:cross-ref refid="fig43" id="crosref0710">Fig.Â 43</ce:cross-ref>
                     <ce:float-anchor refid="fig43"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0325" view="all">Purine derivatives exhibit potent antitumor activity and represent a new generation of anticancer drugs. Bozepinib, a potent antitumor compound, is able to induce apoptosis in breast cancer cells, with IC<ce:inf loc="post">50</ce:inf> ten times smaller than that of 5-fluorouracil in MCF-7 breast cancer cells. The mechanism of induction of cell death via apoptosis by bozepinib is unknown <ce:cross-ref refid="bib210" id="crosref0715">[210]</ce:cross-ref>. Marchal and his co-workers demonstrated that bozepinib (145) has antitumor activity in colon cancer cells also, with IC<ce:inf loc="post">50</ce:inf> values lower than for breast cancer cells, suggesting great potential of this synthetic drug in the treatment of cancer. Bozepinib and IFNÎ± act synergistically to suppress the viability of breast and colon cancer cells to a greater extent than when either agent is used alone, reducing cell viability by more than 20% in all cell lines analyzed. One of the mechanisms by which IFNÎ± improves the cytotoxic effect of bozepinib involves enhancement of apoptosis, and that the synergistic apoptotic effect induced by the bozepinib/IFNÎ± combination is affected by the absence or down-regulation of PKR protein <ce:cross-ref refid="bib211" id="crosref0720">[211]</ce:cross-ref> (<ce:cross-ref refid="fig44" id="crosref0725">Fig.Â 44</ce:cross-ref>
                     <ce:float-anchor refid="fig44"/></ce:float-anchor>).</ce:para>
               </ce:section>
               <ce:section id="sec6" view="all">
                  <ce:label>6</ce:label>
                  <ce:section-title id="sectitle0090">Patent summary</ce:section-title>
                  <ce:para id="p0330" view="all">Several patents have also been published on purine based protein kinase inhibitors in the past and are worth mentioning. Therefore, various purine based structures patented during 2001â2015 are summarized in <ce:cross-ref refid="tbl1" id="crosref0730">TableÂ 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl1"/></ce:float-anchor> 
                     <ce:cross-ref refid="bib212" id="crosref0735">[212]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec7" role="conclusion" view="all">
                  <ce:label>7</ce:label>
                  <ce:section-title id="sectitle0095">Conclusion</ce:section-title>
                  <ce:para id="p0335" view="all">In view of significant number of reports on the promising potential of purine based kinase inhibitors, this review article presents the rational approaches behind the design of purine based molecules exerting inhibitory effects on diverse kinases. The effect of various substituents on the purine scaffold towards the kinase inhibition has been discussed. An overview of various interactions with the amino acid residues of various kinases as indicated by the molecular modeling studies has also been included. The purines have exerted their protein kinase inhibiting potential by inhibiting various types of kinases such as CDK, P13KÎ±, AAK1, ABL1, mTOR selective kinase, LCK, lyn kinase, spleen tyrosine kinase, aurora kinase, JAK etc. Numerous purine based molecules have displayed remarkable kinase inhibition with IC<ce:inf loc="post">50</ce:inf> values in nanomolar range. Their promising kinase inhibiting potential clearly places them ahead as potential future drug candidates. Based on their excellent IC<ce:inf loc="post">50</ce:inf> values and varied mechanisms involved, one can use a variety of these purine scaffolds as an essential tool for targeting protein kinase activities. The present compilation can be extremely beneficial for the medicinal chemists focusing on the kinase inhibiting potential of purine moiety.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="all">
                  <ce:section-title id="sectitle0105">Index of applied abbreviations and acronyms</ce:section-title>
                  <ce:para id="p0345" view="all">
                     <ce:def-list id="dlist0010">
                        <ce:def-term id="d0010">BCR-Abl</ce:def-term>
                        <ce:def-description id="defdis0010">
                           <ce:para id="p0350" view="all">Breakpoint cluster region that juxtaposes the Abl1 gene</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0015">FSBA</ce:def-term>
                        <ce:def-description id="defdis0015">
                           <ce:para id="p0355" view="all">Fluoro sulfonyl benzoyl adenosine</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0020">JAK-STAT</ce:def-term>
                        <ce:def-description id="defdis0020">
                           <ce:para id="p0360" view="all">Janus kinase-signal transducer and activator of transcription</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0025">GM-CSF</ce:def-term>
                        <ce:def-description id="defdis0025">
                           <ce:para id="p0365" view="all">Granulocyte macrophage-colony stimulating factor</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0030">FACS</ce:def-term>
                        <ce:def-description id="defdis0030">
                           <ce:para id="p0370" view="all">Fluorescence activated cell sorting</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0035">TF1</ce:def-term>
                        <ce:def-description id="defdis0035">
                           <ce:para id="p0375" view="all">Human erythroleukemic cell line from blood</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0040">Blk</ce:def-term>
                        <ce:def-description id="defdis0040">
                           <ce:para id="p0380" view="all">B lymphocyte kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0045">Brk</ce:def-term>
                        <ce:def-description id="defdis0045">
                           <ce:para id="p0385" view="all">Breast tumor kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0050">Fgr, Frk, Fyn, Hck, Lck, c-yes</ce:def-term>
                        <ce:def-description id="defdis0050">
                           <ce:para id="p0390" view="all">Proto oncogenes</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0055">c-SRC</ce:def-term>
                        <ce:def-description id="defdis0055">
                           <ce:para id="p0395" view="all">Terminal phosphorylation of SRC</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0060">SRM</ce:def-term>
                        <ce:def-description id="defdis0060">
                           <ce:para id="p0400" view="all">src-related kinase lacking C-terminal regulatory tyrosine</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0065">TAM</ce:def-term>
                        <ce:def-description id="defdis0065">
                           <ce:para id="p0405" view="all">three members of kinase family Tyro3, Axl and Mer</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0070">Caco2</ce:def-term>
                        <ce:def-description id="defdis0070">
                           <ce:para id="p0410" view="all">Cells of heterogeneous human epithelial colorectal adenocarcinoma cells</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0075">Lovo</ce:def-term>
                        <ce:def-description id="defdis0075">
                           <ce:para id="p0415" view="all">olon cancer cell line</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0080">PC3MM2</ce:def-term>
                        <ce:def-description id="defdis0080">
                           <ce:para id="p0420" view="all">Prostate cancer stem cells</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0085">PIP3</ce:def-term>
                        <ce:def-description id="defdis0085">
                           <ce:para id="p0425" view="all">Phosphatidyl inositol-(3,4,5)-trisphosphate</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0090">mTOR</ce:def-term>
                        <ce:def-description id="defdis0090">
                           <ce:para id="p0430" view="all">The mechanistic target of rapamycin</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0095">DELFIA</ce:def-term>
                        <ce:def-description id="defdis0095">
                           <ce:para id="p0435" view="all">Dissociation enhanced lanthanide fluorescent immunoassay</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0100">MDA-361</ce:def-term>
                        <ce:def-description id="defdis0100">
                           <ce:para id="p0440" view="all">Human Caucasian breast adenocarcinoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0105">ATM</ce:def-term>
                        <ce:def-description id="defdis0105">
                           <ce:para id="p0445" view="all">Ataxia telangiectasia mutated</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0110">ATR</ce:def-term>
                        <ce:def-description id="defdis0110">
                           <ce:para id="p0450" view="all">ataxia telangiectasia and Rad3-related protein</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0115">DNA-PK</ce:def-term>
                        <ce:def-description id="defdis0115">
                           <ce:para id="p0455" view="all">DNA dependent protein kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0120">CD86</ce:def-term>
                        <ce:def-description id="defdis0120">
                           <ce:para id="p0460" view="all">Cluster of differentiation 86</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0125">IgD stimulation</ce:def-term>
                        <ce:def-description id="defdis0125">
                           <ce:para id="p0465" view="all">Immunoglobulin D stimulation</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0130">HC-MNT assay</ce:def-term>
                        <ce:def-description id="defdis0130">
                           <ce:para id="p0470" view="all">Human cell micronucleus test</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0135">HCA</ce:def-term>
                        <ce:def-description id="defdis0135">
                           <ce:para id="p0475" view="all">High content analysis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0140">MCF-7</ce:def-term>
                        <ce:def-description id="defdis0140">
                           <ce:para id="p0480" view="all">Michigan Cancer Foundation-7 (human breast adenocarcinoma cell line)</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0145">HCC827 and H1975</ce:def-term>
                        <ce:def-description id="defdis0145">
                           <ce:para id="p0485" view="all">Lung cancer cell lines</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0150">CDK5/p25</ce:def-term>
                        <ce:def-description id="defdis0150">
                           <ce:para id="p0490" view="all">Cyclin-dependent kinase 5</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0155">MAPKAPK2</ce:def-term>
                        <ce:def-description id="defdis0155">
                           <ce:para id="p0495" view="all">Mitogen activated protein kinase activated protein kinase 2</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0160">Ras/Raf/MEK/ERK</ce:def-term>
                        <ce:def-description id="defdis0160">
                           <ce:para id="p0500" view="all">Mitogen activated protein kinase/extracellular signal regulated kinase pathway</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0165">POC</ce:def-term>
                        <ce:def-description id="defdis0165">
                           <ce:para id="p0505" view="all">Percent of control</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0170">PBS</ce:def-term>
                        <ce:def-description id="defdis0170">
                           <ce:para id="p0510" view="all">Phosphate buffered saline</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0175">DMPK assay</ce:def-term>
                        <ce:def-description id="defdis0175">
                           <ce:para id="p0515" view="all">Drug metabolism and pharmacokinetics assay</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0180">Drak</ce:def-term>
                        <ce:def-description id="defdis0180">
                           <ce:para id="p0520" view="all">Death associated protein kinase related apoptosis inducing protein kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0185">IKKb</ce:def-term>
                        <ce:def-description id="defdis0185">
                           <ce:para id="p0525" view="all">Nuclear factor kappa-B kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0190">GSK3b</ce:def-term>
                        <ce:def-description id="defdis0190">
                           <ce:para id="p0530" view="all">Glycogen synthase kinase 3 beta</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0195">SYK</ce:def-term>
                        <ce:def-description id="defdis0195">
                           <ce:para id="p0535" view="all">Spleen tyrosine kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0200">QSAR</ce:def-term>
                        <ce:def-description id="defdis0200">
                           <ce:para id="p0540" view="all">Quantitative structure activity relationship</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0205">NCI</ce:def-term>
                        <ce:def-description id="defdis0205">
                           <ce:para id="p0545" view="all">National cancer institute</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0210">Flt3</ce:def-term>
                        <ce:def-description id="defdis0210">
                           <ce:para id="p0550" view="all">FMS (oncogene responsible for Feline McDonough Sarcoma) like tyrosine kinase-3</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0215">HCT116</ce:def-term>
                        <ce:def-description id="defdis0215">
                           <ce:para id="p0555" view="all">Human colon cancer cell line</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0220">k562</ce:def-term>
                        <ce:def-description id="defdis0220">
                           <ce:para id="p0560" view="all">Human immortalisedmyelogenous leukemia line</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0225">RNAP2</ce:def-term>
                        <ce:def-description id="defdis0225">
                           <ce:para id="p0565" view="all">Ribose nucleic acid polymerase II</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0230">AGC kinase</ce:def-term>
                        <ce:def-description id="defdis0230">
                           <ce:para id="p0570" view="all">Protein kinase A (cAMP), G (cGMP) and C</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0235">HepG2</ce:def-term>
                        <ce:def-description id="defdis0235">
                           <ce:para id="p0575" view="all">Human liver carcinoma cells</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0240">Mps1</ce:def-term>
                        <ce:def-description id="defdis0240">
                           <ce:para id="p0580" view="all">Also known as TTK (threonine and tyrosine kinase)</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0245">PLK1</ce:def-term>
                        <ce:def-description id="defdis0245">
                           <ce:para id="p0585" view="all">Polo like kinase 1</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0250">IFNÎ±</ce:def-term>
                        <ce:def-description id="defdis0250">
                           <ce:para id="p0590" view="all">Type I interferon</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0255">AAK1</ce:def-term>
                        <ce:def-description id="defdis0255">
                           <ce:para id="p0595" view="all">Adapter associated protein kinase 1</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0260">LCK</ce:def-term>
                        <ce:def-description id="defdis0260">
                           <ce:para id="p0600" view="all">Lymphocyte-specific protein tyrosine kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0265">VEGR</ce:def-term>
                        <ce:def-description id="defdis0265">
                           <ce:para id="p0605" view="all">Vascular endothelial growth receptors</ce:para>
                        </ce:def-description>
                     </ce:def-list>
                  </ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0110">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinases â the major drug targets of the twenty-first century?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>309</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Grant</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic protein kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Mol. Life Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1163</sb:first-page>
                              <sb:last-page>1177</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Knockaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Greengard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacological inhibitors of cyclin-dependent kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>417</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Daub</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Specht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ullrich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strategies to overcome resistance to targeted protein kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1001</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Dar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Shokat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The evolution of protein kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>769</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.E.M.</ce:given-name>
                                 <ce:surname>Noble</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Endicott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.N.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase inhibitors: insights into drug design from structure</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>303</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1800</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.A.</ce:given-name>
                                 <ce:surname>Knight</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Shokat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Features of selective kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>621</sb:first-page>
                              <sb:last-page>637</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Raymond</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Accounts Chem. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>417</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wodicka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.W.H.</ce:given-name>
                                 <ce:surname>Thunnissen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Norman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.H.</ce:given-name>
                                 <ce:surname>Espinoza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.O.</ce:given-name>
                                 <ce:surname>Morgan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Barnes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>LeClerc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Lockhart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Schultz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>281</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>533</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Sorbera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Serradell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bolos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Rosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bozzo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK3 inhibitor, immunosuppressant, treatment of rheumatoid arthritis, treatment of transplant rejection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drugs Future</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>674</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Ledeboer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Duffy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Pierce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Zuccola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Block</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Shlyakter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Hogan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Bennani</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ novel chemotype of kinase inhibitors: discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>153</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Aligayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Boyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Heiss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.K.</ce:given-name>
                                 <ce:surname>Abdalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Curley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Gallick</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Increases in c-src expression level and activity do not promote the growth ofÂ human colorectal carcinoma cells inÂ vitro and inÂ vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>94</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>344</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Belsches-Jablonski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Biscardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Peavy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Tice</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Romney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src family kinases and HER2 interactions in human breast cancer cell growth and survival</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1465</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>MacMillan-Crow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Greendorfer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Vickers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine nitration of c-Src tyrosine kinase in human pancreatic duetal adrenocarcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Archives Biochem. Biophys.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>377</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>350</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Rucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Susa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Teti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anti-Cancer Agents Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>342</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Missbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Attman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Susa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase inhibition in bone metabolism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Drug Discov. Dev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>541</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Azam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Nardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Shakespeare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Metcalf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Bohacek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sundaramoorthi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sliz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Veach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Bornmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Clarkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Dalgarno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Q.</ce:given-name>
                                 <ce:surname>Daley</ce:surname>
                              </sb:author>
                           </sb:authors>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9244</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Verones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Flouquet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Farce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Carato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Leonce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pfeiffer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Berthelot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Lebegue</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, biological evaluation and docking studies of 4-aminotetrahydroquinazolino[3,2-e]purine derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5678</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The hunting of the Src</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>467</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Yeatman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ renaissance for Src</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>470</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Finn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targetting Src in breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1379</sb:first-page>
                              <sb:last-page>1386</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Summy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Gallick</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src family kinases in tumor progression and metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Metastasis Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>337</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Frame</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src in cancer: deregulation and consequences for cell behavior</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1602</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>114</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Summy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Gallick</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Treatment for advanced tumors: SRC reclaims center stage</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1398</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Rucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Susa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Teti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anti-Cancer Agents Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>342</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hilbig</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src kinase and pancreatic cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Recent Results Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>177</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>179</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.F.</ce:given-name>
                                 <ce:surname>Boyce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yamashita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Shakespeare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Metcalf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sundaramoorthi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Dalgarno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Iuliucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SRC inhibitors in metastatic bone diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6291</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.Y.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Norris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Barrish</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Behnia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Castaneda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Cornelius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Doweyko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Fairchild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Hunt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Inigo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Johnston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Klei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Marathe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Peterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Schieven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Schmidt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wityak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Borzilleri</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6658</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Norris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Padmanabha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.V.</ce:given-name>
                                 <ce:surname>Moquin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Cook</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Doweyko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.F.</ce:given-name>
                                 <ce:surname>de Fex</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>McIntyre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Shuster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Gillooly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Behnia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Schieven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wityak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Barrish</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>49</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6819</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Serrels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Serrels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Mason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Baldeschi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.H.</ce:given-name>
                                 <ce:surname>Ashton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Canel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Mackintosh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Doyle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Frame</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.J.</ce:given-name>
                                 <ce:surname>Sansom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.</ce:given-name>
                                 <ce:surname>Brunton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Carcinogenesis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>249</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Azam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sundaramoorthi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Banda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Lentini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Keats</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wardwell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Snodgrass</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Broudy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Russian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Q.</ce:given-name>
                                 <ce:surname>Daley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Iuliucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Dalgarno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Clackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Shakespeare</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4743</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Dalgarno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Stehle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Narula</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Schelling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>van Schravendijk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Andrade</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Keats</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Grossman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>MacNeil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Metcalf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Shakespeare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Keenan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sundaramoorthi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bohacek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Weigele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>67</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>46</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Metcalf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Shakespeare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sundaramoorthi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Keenan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Bohacek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>van Schravendijk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Violette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Narula</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Dalgarno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Haraldson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Keats</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Mani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pradeepan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Weigele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3067</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Legraverend</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Grierson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The purines: potent and versatile small molecule inhibitors and modulators of key biological targets</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3987</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.T.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Wignall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Rosania</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Hanson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.I.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>John</ce:given-name>
                                 <ce:surname>Merlie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Moon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Sangankar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Perez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Heald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Schultz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4497</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4615</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Cheson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New antimetabolites in the treatment of human malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Seminars Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>1992</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>695</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Elgemeie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Pharm. Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2627</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Galmarini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Mackey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dumontet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nucleoside analogues and nucleobases in cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>415</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.G.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bentley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Arris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.T.</ce:given-name>
                                 <ce:surname>Boyle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Curtin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Endicott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Gibson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.T.</ce:given-name>
                                 <ce:surname>Golding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.R.</ce:given-name>
                                 <ce:surname>Hardcastle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jewsbury</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.N.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Mesguiche</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Newell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.M.</ce:given-name>
                                 <ce:surname>Noble</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Tucker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Whitfield</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Struct. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>745</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Burnstock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pathophysiology and therapeutic potential of purinergic signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>58</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Wrzeszczynska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Devgan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Pestell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Albanese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 as an oncogene</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>295</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Drewry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.G.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular disruption of signal transducer and activator of transcription 3 (stat3) oncogenic activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>825</sb:first-page>
                              <sb:last-page>833</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Berta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shuai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Specific inhibition of Stat3 signal transduction by PIAS3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>278</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1803</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kaluarachchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structureâactivity studies of phosphopeptidomimetic prodrugs targeting the src homology 2 (SH2) domain of signal transducer and activator of transcription 3 (stat3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Peptide Res. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Ramos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Spagnuolo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Schimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Trudel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5618</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mohamed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>BÃ¤ckesjÃ¶</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Vargas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Faryal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aints</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Christensson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>BerglÃ¶f</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vihinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.F.</ce:given-name>
                                 <ce:surname>Nore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.I.E.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunol. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>228</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>58</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tebben</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Dyckman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Spergel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>McIntyre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Olini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Surti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Muckelbauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>An</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Ruan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Leftheris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.V.</ce:given-name>
                                 <ce:surname>De Lucca</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2206</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cappellen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>De Oliveira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ricol</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>de Medina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bourdin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Sastre-Garau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chopin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Thiery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Radvanyi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>18</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chesi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Nardini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Brents</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Schrock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ried</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Kuehl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.L.</ce:given-name>
                                 <ce:surname>Bergsagel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Frequent translocation t(4,14)(p16.3,q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>260</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>de Muga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Agell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Juanpere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Esgueva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Lorente</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mojal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Serrano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lloreta</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FGFR3 mutations in prostate cancer: association with low-grade tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mod. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>848</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sonvilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Allerstorfer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Heinzle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>StÃ¤ttner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Karner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Klimpfinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wrba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gauglhofer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Spiegl-Kreinecker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Grasl-Kraupp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Holzmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Grusch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.Br</ce:given-name>
                                 <ce:surname>Marian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1145</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Traxler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>195</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Legraverend</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Grierson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The purines: potent and versatile small molecule inhibitors and modulators of key biological targets</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3987</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tak-Tak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Barbault</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Maurel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Busca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Merrer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of purin-2-yl and purin-6-yl-aminoglucitols as C-nucleosidic ATP mimics and biological evaluation as FGFR3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1254</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.F.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The protein tyrosine kinase family of the human genome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5548</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.A.</ce:given-name>
                                 <ce:surname>Linger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Keating</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Earp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Adv. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>35</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rational design of inhibitors that bind to inactive kinase conformations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>358</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.G.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>Adrian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tuntland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Warmuth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Manley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mestan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ type-II kinase inhibitor capable of inhibiting the T315I âgatekeeperâ mutant of Bcr-AblJ</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5439</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Okram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Nagle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>Adrian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Spraggon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Warmuth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ general strategy for creating âinactive-conformationâ abl inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>779</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>SuÃ¡rez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Chevot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cavagnino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Saettel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Radvanyi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Piguel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Bernard-Pierrot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Stoven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Legraverend</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vanhaesebroeck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Leevers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ahmadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Timms</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Katso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Driscoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Woscholski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Parker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Waterfield</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and function of 3-phosphorylated inositol lipids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>535</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targetting the phosphoinositide 3-kinase pathway in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>627</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Saal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Holm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Maurer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Memeo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.O.</ce:given-name>
                                 <ce:surname>Malmstrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mansukhani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Enoksson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hibshoosh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Borg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2554</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.B.</ce:given-name>
                                 <ce:surname>She</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Solit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Basso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Moasser</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4340</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Ameriks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Venable</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Top. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>738</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Nowak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Brooijmans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Bursavich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dehnhardt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Delos Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Feldberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Hollander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lombardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Venkatesan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mallon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-a: hit to lead studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>636</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the phosphoinositide 3-kinase pathway in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>627</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Yap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Garrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Walton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Raynand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>deBono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Workman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>393</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bellacosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Di cristofano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Testa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of AKT kinases in cancer: implications for therapeutic targeting</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Adv. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>94</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>29</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Manning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Cantley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AKT/PKB signaling: navigating downstream</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>129</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1261</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Engelman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Cantley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>606</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref73">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.T.</ce:given-name>
                                 <ce:surname>Hennessy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Ram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.B.</ce:given-name>
                                 <ce:surname>Mills</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploiting the PI3K/AKT pathway for cancer drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>988</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref74">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Venkatesan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Dehnhardt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Delos Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Dos Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bursavich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Ellingboe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ayral-Kaloustian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Khafizova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Brooijmans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mallon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Hollander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Feldberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lucas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gibbons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Abraham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Mansour</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>653</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref75">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vanhaesebroeck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Leevers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Khatereh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Timms</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Katso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Driscoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Woscholski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Parker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Waterfield</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and function of 3-phosphorylated inositolipids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>535</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib76">
                     <ce:label>[76]</ce:label>
                     <sb:reference id="sref76">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of new azaindole-based PI3KÎ± inhibitors: apoptotic and antiangiogenic effect on cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7212</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib77">
                     <ce:label>[77]</ce:label>
                     <sb:reference id="sref77">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>O'Brien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Wallin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sampath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Guhathakurta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Savage</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Punnoose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Berry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Prior</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Amler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Belvin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lackner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3670</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib78">
                     <ce:label>[78]</ce:label>
                     <sb:reference id="sref78">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fluorescent phosphoinositide 3-kinase inhibitors suitable for monitoring of intracellular distribution</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2508</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib79">
                     <ce:label>[79]</ce:label>
                     <sb:reference id="sref79">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Okkenhaug</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vanhaesebroeck</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PI3K-signalling in B- and Tcells: insights from gene-targeted mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Soc. Trans.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>270</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib80">
                     <ce:label>[80]</ce:label>
                     <sb:reference id="sref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Okkenhaug</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vanhaesebroeck</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PI3K in lymphocyte development, differentiation and activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>317</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib81">
                     <ce:label>[81]</ce:label>
                     <sb:reference id="sref81">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sadhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Masinovsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Sowell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Staunton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>170</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2647</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib82">
                     <ce:label>[82]</ce:label>
                     <sb:reference id="sref82">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.K.</ce:given-name>
                                 <ce:surname>Sweeney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Balazs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Bradley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Castanedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chabot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chantry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Flagella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Goldstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kondru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lesnick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Lucas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nonomiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Price</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Salphati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Safina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.A.</ce:given-name>
                                 <ce:surname>Savy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Seward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ultsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Sutherlin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent and highly selective benzimidazole inhibitors of pi3-kinase delta</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7686</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib83">
                     <ce:label>[83]</ce:label>
                     <sb:reference id="sref83">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rommel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Camps</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>191</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib84">
                     <ce:label>[84]</ce:label>
                     <sb:reference id="sref84">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Herzog</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Reth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jumaa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>195</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib85">
                     <ce:label>[85]</ce:label>
                     <sb:reference id="sref85">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bilancio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Pearce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilfillan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tkaczyk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kuehn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Giddings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Peskett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Bruce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Okkenhaug</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Finan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vanhaesebroeck</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Essential role for the p110delta phosphoinositide 3-kinase in the allergic response</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>431</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1007</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib86">
                     <ce:label>[86]</ce:label>
                     <sb:reference id="sref86">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Safina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Baumgardner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Blaney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Cartwright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Castanedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chabot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Cheguillaume</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Goldsmith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Goldstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Goyal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hancox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Handa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Iyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kaur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kondru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Kenny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Krintel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lesnick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Lucas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Reif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Salphati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Savy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Seward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shuttleworth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sohal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.K.</ce:given-name>
                                 <ce:surname>Sweeney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Tivitmahaisoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Waszkowycz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Sutherlin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel PI3-kinase Î´ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5887</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib87">
                     <ce:label>[87]</ce:label>
                     <sb:reference id="sref87">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.K.</ce:given-name>
                                 <ce:surname>Sweeney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Balazs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Bradley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Castanedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chabot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chantry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Flagella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Goldstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kondru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lesnick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Lucas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nonomiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Price</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Salphati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Safina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.A.</ce:given-name>
                                 <ce:surname>Savy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Seward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ultsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Sutherlin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent and highly selective benzimidazole inhibitors of PI3-kinase delta</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7686</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib88">
                     <ce:label>[88]</ce:label>
                     <sb:reference id="sref88">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Safina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.K.</ce:given-name>
                                 <ce:surname>Sweeney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bisconte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Carrera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Castanedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Flagella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Heald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nonomiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Price</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Reif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Salphati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Seward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Sutherlin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of GNE-293, a potent and selective PI3<ce:italic>Kd</ce:italic> inhibitor: navigating inÂ vitro genotoxicity while improving potency and selectivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4953</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib89">
                     <ce:label>[89]</ce:label>
                     <sb:reference id="sref89">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.B.</ce:given-name>
                                 <ce:surname>Elion</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Furman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Fyfe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>de Miranda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Beauchamp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Schaeffer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selectivity of action of an antiherpetic agent, 9-[[1',2'-bis(hydroxymethyl)-(cycloprop-1'-yl]methyl]guanine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>74</sb:volume-nr>
                              </sb:series>
                              <sb:date>1977</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5716</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib90">
                     <ce:label>[90]</ce:label>
                     <sb:reference id="sref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Visse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sandhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structures of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Struct. Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>876</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib91">
                     <ce:label>[91]</ce:label>
                     <sb:reference id="sref91">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Benci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Suhina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mandic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Pavelic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tomljenovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Pavelic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Balzarini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wittine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mintas</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel 1,2,4-triazole and purine acyclic cyclopropane nucleoside analogues, synthesis, antiviral and cytostatic activity evaluations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Antivir. Chem. Chemother.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>221</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib92">
                     <ce:label>[92]</ce:label>
                     <sb:reference id="bib92a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Connolly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Wetter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Binnun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.V.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.V.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.B.</ce:given-name>
                                 <ce:surname>Pandey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Morreno-Mazza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Fuentes-Pesquera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Middleton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d]pyrimidine analogues as antitumor epidermal growth factor receptor tyrosine kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2333</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <sb:reference id="bib92b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.L.</ce:given-name>
                                 <ce:surname>Gaikwad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Gandhi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Jagdale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.J.</ce:given-name>
                                 <ce:surname>Kadam</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The use of bioisosterism in drug design and molecular modification</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. PharmTech Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib93">
                     <ce:label>[93]</ce:label>
                     <sb:reference id="sref92">
                        <sb:host>
                           <sb:book>
                              <sb:title>
                                 <sb:maintitle>Adis International Ltd. Erlotinib: CP358774, NSC718781, OSI774, R1415, Drugs R & D 4</sb:maintitle>
                              </sb:title>
                              <sb:date>2003</sb:date>
                           </sb:book>
                           <sb:pages>
                              <sb:first-page>243</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib94">
                     <ce:label>[94]</ce:label>
                     <sb:reference id="sref93">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Erlotinib: small-molecule targeted therapy in the treatment of non small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1513</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib95">
                     <ce:label>[95]</ce:label>
                     <sb:reference id="sref94">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Amine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Georgey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Awadallah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EGFR tyrosine kinase targeted compounds: synthesis, docking study, and in-vitro antitumor activity of some new quinazoline and benzo[d]isothiazole derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Chem. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1042</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib96">
                     <ce:label>[96]</ce:label>
                     <sb:reference id="sref95">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Burchat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Calderwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Hirst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rafferty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ritter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Skinner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pyrazolo[3,4-d]pyrimidines containing an extented 3- subsitutent as potant inhibitors of Lck-a selectivity insight</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1687</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib97">
                     <ce:label>[97]</ce:label>
                     <sb:reference id="sref96">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Borhani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Calderwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Hirst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>McRae</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ratnofsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ritter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Waegell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A-420983: a potant, orally active inhibitors of LCK with efficacy in model of transplant rejection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2613</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib98">
                     <ce:label>[98]</ce:label>
                     <sb:reference id="sref97">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Peat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Garrido</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Boucheron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Schweiker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Dickerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Thomson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel GSK-3 inhibitors with improved cellular activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2127</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib99">
                     <ce:label>[99]</ce:label>
                     <sb:reference id="sref98">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Revesz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Blum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.E.</ce:given-name>
                                 <ce:surname>Di Padova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Buhl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Feifel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Hiestand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Manning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Neumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Rucklin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pyrazoloheteroaryls: novell p38Î± MAP kinase inhibiting scaffolds with oral activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>262</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib100">
                     <ce:label>[100]</ce:label>
                     <sb:reference id="sref99">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Angelucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schenone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Gravina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Muzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Festuccia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Vicentini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Botta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bologna</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pyrazolo[3,4-d] pyrimidines C-Src inhibitors reduce epidermal growth factor-induced migeration in prostate cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>42</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2838</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib101">
                     <ce:label>[101]</ce:label>
                     <sb:reference id="sref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Nowak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Brooijmans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Bursavich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dehnhardt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.D.</ce:given-name>
                                 <ce:surname>Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Feldberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Hollander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lombardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Venkatesan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mallon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel purine and pyrazolo[3,4-d]pyrimidne inhibitors of p13 kinaseâÎ±: Hitto & lea studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>636</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib102">
                     <ce:label>[102]</ce:label>
                     <sb:reference id="sref101">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Curran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Verheijen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kaplan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Richard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Toral-Barza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Hollander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lucas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Aryal-Kaloustian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zask</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pyrazolopyrimidines as highly potant and selective ATP competative inhibitors of the mammalian target of rapamycin (mTOR) optimization of 1- subsitutent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1440</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib103">
                     <ce:label>[103]</ce:label>
                     <sb:reference id="sref102">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Bakr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.K.A.</ce:given-name>
                                 <ce:surname>Abdelall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Abdel-Hamid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Manal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Kandeel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of new egfr- tyrosine kinase inhibitors containing pyrazolo[3,4-d]pyrimidine cores as anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bull. Pharm. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>27</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib104">
                     <ce:label>[104]</ce:label>
                     <sb:reference id="sref103">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Siegel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Naishadham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jemal</ce:surname>
                              </sb:author>
                           </sb:authors>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Stat. Cancer J. Clin.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10</sb:first-page>
                              <sb:last-page>29</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib105">
                     <ce:label>[105]</ce:label>
                     <sb:reference id="sref104">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kobayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Boggon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Dayaram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>JÃ¤nne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Kocher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Meyerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Eck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Tenen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Halmos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N.Â Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>352</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>786</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib106">
                     <ce:label>[106]</ce:label>
                     <sb:reference id="sref105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Pao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.A.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Politi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Riely</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Somwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Zakowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Kris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Varmus</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLOS Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>73</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib107">
                     <ce:label>[107]</ce:label>
                     <sb:reference id="sref106">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Kwak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sordella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Godin-Heymann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Okimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Brannigan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.L.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Driscoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Fidias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Lynch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Rabindran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>McGinnis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wissner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Isselbacher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Settleman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Haber</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7665</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib108">
                     <ce:label>[108]</ce:label>
                     <sb:reference id="sref107">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Mengwasser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Toms</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Woo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Greulich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Meyerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Eck</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Nat. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>105</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2070</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib109">
                     <ce:label>[109]</ce:label>
                     <sb:reference id="sref108">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.D.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Q.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10685</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib110">
                     <ce:label>[110]</ce:label>
                     <sb:reference id="sref109">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bacterial signalling involving eukaryotic-type protein kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Microbiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib111">
                     <ce:label>[111]</ce:label>
                     <sb:reference id="sref110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Bakal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>No longer an exclusive club: eukaryotic signalling domains in bacteria</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>32</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib112">
                     <ce:label>[112]</ce:label>
                     <sb:reference id="sref111">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Ulrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.V.</ce:given-name>
                                 <ce:surname>Koonin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.B.</ce:given-name>
                                 <ce:surname>Zhulin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>One-component systems dominate signal transduction in prokaryotes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Microbiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>52</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib113">
                     <ce:label>[113]</ce:label>
                     <sb:reference id="sref112">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>SzÃ©kely</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>WÃ¡czek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Szabadkai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>NÃ©meth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hegymegi-Barakonyi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Eros</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Szokol</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>PatÃ³</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hafenbradl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Satchell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Saint-Joanis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Cole</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Orfi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Klebl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>KÃ©ri</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunol. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>116</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>225</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib114">
                     <ce:label>[114]</ce:label>
                     <sb:reference id="sref113">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Donat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Streker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Schirmeister</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rakette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Stehle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liebeke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lalk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ohlsen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcriptome and functional analysis of the eukaryotic-type serine/threonine kinase PknB in <ce:italic>Staphylococcus aureus</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Bacteriol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>191</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4056</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib115">
                     <ce:label>[115]</ce:label>
                     <sb:reference id="sref114">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>DÃ©barbouillÃ©</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dramsi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Dussurget</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Nahori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Vaganay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Jouvion</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cozzone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Msadek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Duclos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of a serine/threonine kinase involved in virulence of <ce:italic>Staphylococcus aureus</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Bacteriol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>191</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4070</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib116">
                     <ce:label>[116]</ce:label>
                     <sb:reference id="sref115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Beltramini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Mukhopadhyay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Pancholi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Modulation of cell wall structure and antimicrobial susceptibility by a <ce:italic>Staphylococcus aureus</ce:italic> eukaryote-like serine/threonine kinase and phosphatase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Infect. Immun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1406</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib117">
                     <ce:label>[117]</ce:label>
                     <sb:reference id="sref116">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Kristich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Wells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Dunny</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ eukaryotic-type Ser/Thr kinase in <ce:italic>Enterococcus faecalis</ce:italic> mediates antimicrobial resistance and intestinal persistence</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3508</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib118">
                     <ce:label>[118]</ce:label>
                     <sb:reference id="sref117">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hong Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Pancholi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification and biochemical characterization of a eukaryotic-type serine/threonine kinase and its cognate phosphatase in <ce:italic>Streptococcus pyogenes</ce:italic>: their biological functions and substrate identification</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>357</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1351</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib119">
                     <ce:label>[119]</ce:label>
                     <sb:reference id="sref118">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rajagopal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Vo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Silvestroni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Rubens</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of purine biosynthesis by a eukaryotic-type kinase in <ce:italic>Streptococcus agalactiae</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Microbiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1329</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib120">
                     <ce:label>[120]</ce:label>
                     <sb:reference id="sref119">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Nowak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Brooijmans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Bursavich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dehnhardt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.D.</ce:given-name>
                                 <ce:surname>Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Feldberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Hollander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lombardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Venkatesan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mallon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-Î±: hit to lead studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>636</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib121">
                     <ce:label>[121]</ce:label>
                     <sb:reference id="sref120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Oxoby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Moreau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Durant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Denis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Genevard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Vongsouthi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Escaich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gerusz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Towards Gram-positive antivirulence drugs: new inhibitors of <ce:italic>Streptococcus agalactiae</ce:italic> StkL</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3486</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib122">
                     <ce:label>[122]</ce:label>
                     <sb:reference id="sref121">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Goeder</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel 8-arylated purines as inhibitors of glycogen synthase kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>479</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib123">
                     <ce:label>[123]</ce:label>
                     <sb:reference id="sref122">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ibrahim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mouawad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Legraverend</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel 8-arylated purines as inhibitors of glycogen synthase kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3389</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib124">
                     <ce:label>[124]</ce:label>
                     <sb:reference id="sref123">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.T.</ce:given-name>
                                 <ce:surname>Flaherty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Puzanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.B.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ribas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>McArthur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Sosman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>O' Dwyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Grippo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nolop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Chapman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of mutated, activated BRAF in metastatic melanoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N.Â Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>363</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>809</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib125">
                     <ce:label>[125]</ce:label>
                     <sb:reference id="sref124">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Singer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Oldt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.G.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sidransky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Kurman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.M.</ce:given-name>
                                 <ce:surname>Shih</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Natl. Cancer Inst.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>95</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>484</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib126">
                     <ce:label>[126]</ce:label>
                     <sb:reference id="sref125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tol</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.D.</ce:given-name>
                                 <ce:surname>Nagtegaal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Punt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BRAF mutation in metastatic colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N.Â Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>361</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>98</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib127">
                     <ce:label>[127]</ce:label>
                     <sb:reference id="sref126">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Mambo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Trink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Beller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Westra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Ladenson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sidransky</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BRAF mutation in papillary thyroid carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Natl. Cancer Inst.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>95</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>625</sb:first-page>
                              <sb:last-page>627</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib128">
                     <ce:label>[128]</ce:label>
                     <sb:reference id="sref127">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of novel BRAF kinase inhibitors with structure-based virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5753</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib129">
                     <ce:label>[129]</ce:label>
                     <sb:reference id="sref128">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.T.</ce:given-name>
                                 <ce:surname>Flaherty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Puzanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.B.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ribas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>McArthur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Sosman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>O' Dwyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Grippo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nolop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Chapman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of mutated, activated BRAF in metastatic melanoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N.Â Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>363</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>809</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib130">
                     <ce:label>[130]</ce:label>
                     <sb:reference id="sref129">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jeong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1027</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib131">
                     <ce:label>[131]</ce:label>
                     <sb:reference id="sref130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>Hauber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Blaukovitsch</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Current and future treatment options in idiopathic pulmonary fibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Inflamm. Allergy Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>158</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib132">
                     <ce:label>[132]</ce:label>
                     <sb:reference id="sref131">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.P.</ce:given-name>
                                 <ce:surname>Krenitsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Nadolny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sahasrabudhe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ayala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Delgado</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Clareen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hilgraf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Albers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kois</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sudbeck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ghosh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nowakowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Muir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Cathers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Giegel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Celeridad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Moghaddam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Khatsenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Omholt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Shirley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Benis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Blease</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Raymon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bhagwat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Henderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Cole</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Bennett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Satoh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1427</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib133">
                     <ce:label>[133]</ce:label>
                     <sb:reference id="sref132">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.P.</ce:given-name>
                                 <ce:surname>Krenitsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Nadolny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Delgado</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ayala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Clareen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hilgraf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Albers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hegde</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>D' Sidocky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sapienza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>McCarrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bahmanyar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chamberlain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Delker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Muir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Giegel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Celeridad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lachowitzer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Bennett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Moghaddam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Khatsenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Katz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Shirley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Benish</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bodine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Blease</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Raymon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Cathers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Satoh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1433</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib134">
                     <ce:label>[134]</ce:label>
                     <sb:reference id="sref133">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Bogoyevitch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Ngoei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Yeap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Ng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1804</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>463</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib135">
                     <ce:label>[135]</ce:label>
                     <sb:reference id="sref134">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Siddiqui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule JNK (c-Jun N-terminal kinase) inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3005</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib136">
                     <ce:label>[136]</ce:label>
                     <sb:reference id="sref135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.P.</ce:given-name>
                                 <ce:surname>Krenitsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Delgado</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Nadolny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sahasrabudhe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ayala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Clareen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hilgraf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Albers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kois</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nowakowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sudbeck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ghosh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bahmanyar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chamberlain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Muir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Cathers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Giegel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Celeridad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Moghaddam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Khatsenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Omholt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Katz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Shirley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Benish</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Blease</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Raymon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bhagwat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Henderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Cole</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Bennett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Satoh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1427</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib137">
                     <ce:label>[137]</ce:label>
                     <sb:reference id="sref136">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Cheong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Virshup</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Casein kinase 1: complexity in the family</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Biochem. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>465</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib138">
                     <ce:label>[138]</ce:label>
                     <sb:reference id="sref137">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gallego</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Virshup</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Post-translational modifications regulate the ticking of the circadian clock</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>139</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib139">
                     <ce:label>[139]</ce:label>
                     <sb:reference id="sref138">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Rebholz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Brocia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Warner-Schmidt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Fienberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Nairn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Greengard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Flajolet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Forebrain overexpression of CK1delta leads to down-regulation of dopamine receptors and altered locomotor activity reminiscent of ADHD</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4401</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib140">
                     <ce:label>[140]</ce:label>
                     <sb:reference id="sref139">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Knippschild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gocht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wolff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Huber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lohler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Stoter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The casein kinase 1 family: participation in multiple cellular processes in eukaryotes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>675</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib141">
                     <ce:label>[141]</ce:label>
                     <sb:reference id="sref140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Flajolet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Heiman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Nairn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Greengard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4159</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib142">
                     <ce:label>[142]</ce:label>
                     <sb:reference id="sref141">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Knippschild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wolff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Giamas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Brockschmidt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wittau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.U.</ce:given-name>
                                 <ce:surname>Wurl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Eismann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Stoter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Onkologie</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>508</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib143">
                     <ce:label>[143]</ce:label>
                     <sb:reference id="sref142">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bibian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Rahaim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Noguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>SchÃ¼rer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nakanishi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Licht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Rosenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Cameron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Duckett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Cleveland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.R.</ce:given-name>
                                 <ce:surname>Roush</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development of highly selective casein kinase 1d/1e (CK1d/e) inhibitors with potent antiproliferative properties</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4374</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib144">
                     <ce:label>[144]</ce:label>
                     <sb:reference id="sref143">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wangc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wene</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation, part III</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1487</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib145">
                     <ce:label>[145]</ce:label>
                     <sb:reference id="sref144">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Staal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular cloning of the Akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>84</sb:volume-nr>
                              </sb:series>
                              <sb:date>1987</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5034</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib146">
                     <ce:label>[146]</ce:label>
                     <sb:reference id="sref145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Q.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ruggeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Klein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sonoda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Altomare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Watson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Testa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>93</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3636</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib147">
                     <ce:label>[147]</ce:label>
                     <sb:reference id="sref146">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.T.</ce:given-name>
                                 <ce:surname>Joseph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Alfonso</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AKT plays a central role in tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10983</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib148">
                     <ce:label>[148]</ce:label>
                     <sb:reference id="sref147">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Cantley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The phosphoinositide 3-kinase pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>296</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1655</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib149">
                     <ce:label>[149]</ce:label>
                     <sb:reference id="sref148">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Nicholson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.G.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The protein kinase B/Akt signalling pathway in human malignancy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Signal</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>381</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib150">
                     <ce:label>[150]</ce:label>
                     <sb:reference id="sref149">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Q.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Lindsley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Z.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Nicosia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Akt/PKB pathway: molecular target for cancer drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7482</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib151">
                     <ce:label>[151]</ce:label>
                     <sb:reference id="sref150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>167</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib152">
                     <ce:label>[152]</ce:label>
                     <sb:reference id="sref151">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.W.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recycling the cell cycle: cyclins revisited</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>116</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib153">
                     <ce:label>[153]</ce:label>
                     <sb:reference id="sref152">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Mader</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Cell, Biology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:edition>fourth ed.</sb:edition>
                              <sb:date>1993</sb:date>
                              <sb:publisher>
                                 <sb:name>WCB Publisher</sb:name>
                                 <sb:location>New York (</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib154">
                     <ce:label>[154]</ce:label>
                     <sb:reference id="sref153">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.T.</ce:given-name>
                                 <ce:surname>Le</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sidduri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Lou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Michoud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Portland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Konzelmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Chi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tovar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Xiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.T.</ce:given-name>
                                 <ce:surname>Vassilevet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2134</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib155">
                     <ce:label>[155]</ce:label>
                     <sb:reference id="sref154">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Al-Sha'er</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.O.</ce:given-name>
                                 <ce:surname>Taha</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by inÂ vitro bioassay</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4316</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib156">
                     <ce:label>[156]</ce:label>
                     <sb:reference id="sref155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Plant Hormones</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:edition>third ed</sb:edition>
                              <sb:date>1997</sb:date>
                              <sb:publisher>
                                 <sb:name>Springer</sb:name>
                                 <sb:location>Dordrecht</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib157">
                     <ce:label>[157]</ce:label>
                     <sb:reference id="sref156">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Borgne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Mulner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.J.</ce:given-name>
                                 <ce:surname>Chong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Blow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Inagaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Inagaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Delcros</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Moulinoux</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>243</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>527</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib158">
                     <ce:label>[158]</ce:label>
                     <sb:reference id="sref157">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Benson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kaye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Workman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Garret</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Walton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>de Bono</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinical anticancer drug development: targeting the cyclin-dependent kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>92</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib159">
                     <ce:label>[159]</ce:label>
                     <sb:reference id="sref158">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>TrÃ¡vnÃ­cek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Starha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Popa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Vrzal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>DvorÃ¡k</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Roscovitine-based CDK inhibitors acting as N-donor ligands in the platinum(II) oxalato complexes: preparation, characterization and inÂ vitro cytotoxicity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4609</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib160">
                     <ce:label>[160]</ce:label>
                     <sb:reference id="sref159">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Castanedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Tsui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nicholas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wickramasinghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Marsters</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sutherlina</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CDK2/cyclinA inhibitors: targeting the cyclin A recruitment site with small molecules derived from peptide leads</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1716</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib161">
                     <ce:label>[161]</ce:label>
                     <sb:reference id="sref160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Shewchuk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hasegawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Washio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nishigaki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2985</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib162">
                     <ce:label>[162]</ce:label>
                     <sb:reference id="sref161">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Senderowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Headlee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.F.</ce:given-name>
                                 <ce:surname>Stinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Lush</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kalil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Villalba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Steinberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.D.</ce:given-name>
                                 <ce:surname>Figg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tompkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Arbuck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Sausville</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2986</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib163">
                     <ce:label>[163]</ce:label>
                     <sb:reference id="sref162">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.S.H.</ce:given-name>
                                 <ce:surname>Elgazwy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.M.</ce:given-name>
                                 <ce:surname>Ismail</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.A.</ce:given-name>
                                 <ce:surname>Elzahabi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7639</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib164">
                     <ce:label>[164]</ce:label>
                     <sb:reference id="sref163">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dehay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kennedy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cell cycle control and cortical development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>438</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib165">
                     <ce:label>[165]</ce:label>
                     <sb:reference id="sref164">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Malumbres</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Barbacid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mammalian cyclin dependent kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Biochem. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>630</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib166">
                     <ce:label>[166]</ce:label>
                     <sb:reference id="sref165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Sielecki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Boylan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Benfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Trainor</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib167">
                     <ce:label>[167]</ce:label>
                     <sb:reference id="sref166">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Knockaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Greengard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacological inhibitors of cyclin-dependent kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>417</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib168">
                     <ce:label>[168]</ce:label>
                     <sb:reference id="sref167">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Senderowicz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The first cyclin dependent kinase inhibitor in human clinical trials</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Investig. New Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>313</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib169">
                     <ce:label>[169]</ce:label>
                     <sb:reference id="sref168">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.F.</ce:given-name>
                                 <ce:surname>De Azevedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Leclerc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Havlicek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>243</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>51</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib170">
                     <ce:label>[170]</ce:label>
                     <sb:reference id="sref169">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Wyatt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Woodhead</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Berdini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Boulstridge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Carr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Cross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Davis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Devin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.R.</ce:given-name>
                                 <ce:surname>Early</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Feltell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>McMenamin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Navarro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>O' Brien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>O' Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Reule</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Saxty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.A.</ce:given-name>
                                 <ce:surname>Seavers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Squires</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Trewartha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.A.</ce:given-name>
                                 <ce:surname>Woolford</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4986</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib171">
                     <ce:label>[171]</ce:label>
                     <sb:reference id="sref170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.R.</ce:given-name>
                                 <ce:surname>Hardcastle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Northen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.T.</ce:given-name>
                                 <ce:surname>Golding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Org. Biomol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2457</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib172">
                     <ce:label>[172]</ce:label>
                     <sb:reference id="sref171">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Golsteyn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>217</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>129</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib173">
                     <ce:label>[173]</ce:label>
                     <sb:reference id="sref172">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rudolph</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>202</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib174">
                     <ce:label>[174]</ce:label>
                     <sb:reference id="sref173">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Atrash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Barlow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Eccles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hayes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kelland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jarman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mirza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Moreno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.P.</ce:given-name>
                                 <ce:surname>Nutley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.I.</ce:given-name>
                                 <ce:surname>Raynaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sheldrake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Walton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Westwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Whittaker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Workman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>McDonald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6949</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib175">
                     <ce:label>[175]</ce:label>
                     <sb:reference id="sref174">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.T.</ce:given-name>
                                 <ce:surname>Aldoss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Ganti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Seliciclib in malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Investig. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1957</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib176">
                     <ce:label>[176]</ce:label>
                     <sb:reference id="sref175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Guzi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CYC-202 cyclacel</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Investig. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1311</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib177">
                     <ce:label>[177]</ce:label>
                     <sb:reference id="sref176">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liebl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Krystof</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Vereb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Takacs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Pechan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Havlicek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zatloukal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Furst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Vollmar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zahler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angiogenesis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>281</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib178">
                     <ce:label>[178]</ce:label>
                     <sb:reference id="sref177">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wodicka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Thunnissen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Norman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.H.</ce:given-name>
                                 <ce:surname>Espinoza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.O.</ce:given-name>
                                 <ce:surname>Morgan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Barnes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>LeClerc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Lockhart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Schultz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>281</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>533</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib179">
                     <ce:label>[179]</ce:label>
                     <sb:reference id="sref178">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Senderowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Sausville</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preclinical and clinical development of cyclin-dependent kinase modulators</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Natl. Cancer Inst.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>92</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>376</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib180">
                     <ce:label>[180]</ce:label>
                     <sb:reference id="sref179">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Yenugonda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.B.</ce:given-name>
                                 <ce:surname>Deb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Grindrod</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dakshanamurthy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Paige</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2714</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib181">
                     <ce:label>[181]</ce:label>
                     <sb:reference id="sref180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Christian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Blum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Andritsos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Moran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Brooker-McEldowney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Phelps</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Dalton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Colevas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Byrd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Grever</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Flavopiridol in the treatment of chronic lymphocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>573</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib182">
                     <ce:label>[182]</ce:label>
                     <sb:reference id="sref181">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bettayeb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Oumata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Echalier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ferandin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Endicott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Galons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5797</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib183">
                     <ce:label>[183]</ce:label>
                     <sb:reference id="sref182">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>N' gompaza-Diarra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bettayeb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gresh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Oumata</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>210</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib184">
                     <ce:label>[184]</ce:label>
                     <sb:reference id="sref183">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Granville</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Memmott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Gills</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Dennis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>679</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib185">
                     <ce:label>[185]</ce:label>
                     <sb:reference id="sref184">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Poulsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Blanchard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.K.</ce:given-name>
                                 <ce:surname>Soh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Dymock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of PDK1 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>305</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib186">
                     <ce:label>[186]</ce:label>
                     <sb:reference id="sref185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Havlicek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hanus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Vesely</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>LeClerc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Shaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>40</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>408</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib187">
                     <ce:label>[187]</ce:label>
                     <sb:reference id="sref186">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>McClue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Blake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Clarke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cowan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cummings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>MacKenzie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Melville</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Stewart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Zhelev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zheleva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Lane</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>InÂ vitro and inÂ vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>463</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib188">
                     <ce:label>[188]</ce:label>
                     <sb:reference id="sref187">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Le</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Faivre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Laurence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Delbaldo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Vera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Girre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Armour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Frame</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gianella-Borradori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Dieras</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Raymond</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3243</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib189">
                     <ce:label>[189]</ce:label>
                     <sb:reference id="sref188">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mahadevan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Plummer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Squires</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Rensvold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kurtin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Pretzinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Dragovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Lock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.D.</ce:given-name>
                                 <ce:surname>Von</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Calvert</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2137</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib190">
                     <ce:label>[190]</ce:label>
                     <sb:reference id="sref189">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zatloukal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jorda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>GuckÃ½</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>ReznÃ­ckovÃ¡</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Voller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>PospÃ­sil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>MalÃ­nkovÃ¡</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>AdamcovÃ¡</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Krystof</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and inÂ vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>61</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib191">
                     <ce:label>[191]</ce:label>
                     <sb:reference id="sref190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Knockaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Greengard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacological inhibitors of cyclindependent kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>417</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib192">
                     <ce:label>[192]</ce:label>
                     <sb:reference id="sref191">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>DoleckovÃ¡</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cesnek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>DracinskÃ½</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Brynda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Voller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Janeba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Krystof</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of guanidino analogues of roscovitine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>443</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib193">
                     <ce:label>[193]</ce:label>
                     <sb:reference id="sref192">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Knockaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Reinhardt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Lozach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schmitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Baratte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Koken</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Coburn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Galons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Dierick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Pinna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Meggio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Totzke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schaechtele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Lerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Carnero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Roscovitine targets, protein kinases and pyridoxal kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>280</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>31208</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib194">
                     <ce:label>[194]</ce:label>
                     <sb:reference id="sref193">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Sippli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation, regulation, and inhibition of DYRK1A</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Fed. Eur. Biochem. Soc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>278</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>246</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib195">
                     <ce:label>[195]</ce:label>
                     <sb:reference id="sref194">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bettayeb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Oumata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Echalier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ferandin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Endicott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Galons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5797</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib196">
                     <ce:label>[196]</ce:label>
                     <sb:reference id="sref195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bischof</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Leban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zaja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Grothey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Radunsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Othersen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Strobl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Vitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Knippschild</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2-Benzamido-N-(1Hbenzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1d/e</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Amino Acids</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1577</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib197">
                     <ce:label>[197]</ce:label>
                     <sb:reference id="sref196">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Demange</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Lozach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ferandin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.T.</ce:given-name>
                                 <ce:surname>Hoang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Galons</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of new potent inhibitors of CK1 and CDK5, two kinases involved in Alzheimer's disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Chem. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3247</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib198">
                     <ce:label>[198]</ce:label>
                     <sb:reference id="sref197">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Engelman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting PI3K signalling in cancer: opportunities, challenges and limitations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>550</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib199">
                     <ce:label>[199]</ce:label>
                     <sb:reference id="sref198">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Ramanujulu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Poulsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Blanchard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Bonday</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Dymock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDK1 inhibitors discovered by fragment-based screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4023</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib200">
                     <ce:label>[200]</ce:label>
                     <sb:reference id="sref199">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Blanchard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.K.</ce:given-name>
                                 <ce:surname>Soh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.P.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Poulsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Bonday</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Pasha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ethirajulu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Dymock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2-Anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2880</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib201">
                     <ce:label>[201]</ce:label>
                     <sb:reference id="sref200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Aoyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ishidate</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure and function of choline kinase isoforms in mammalian cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Prog. Lipid Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>266</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib202">
                     <ce:label>[202]</ce:label>
                     <sb:reference id="sref201">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Milanese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Espinosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Campos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Gallo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Entrena</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Insight into the inhibition of human choline kinase: homology modelling and molecular dynamics simulations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1216</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib203">
                     <ce:label>[203]</ce:label>
                     <sb:reference id="sref202">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Peisach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Kent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The crystal structure of choline kinase reveals a eukaryotic protein kinase fold</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Structure</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>703</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib204">
                     <ce:label>[204]</ce:label>
                     <sb:reference id="sref203">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Rubio-RuÃ­z</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Conejo-GarcÃ­a</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>RÃ­os-Marco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Carrasco-JimÃ©nez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Segovia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Marco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Gallo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Espinosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Entrena</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, theoretical calculations and biological evaluation of new non-symmetrical choline kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>154</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib205">
                     <ce:label>[205]</ce:label>
                     <sb:reference id="sref204">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase signaling in the spindle checkpoint</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>284</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15359</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib206">
                     <ce:label>[206]</ce:label>
                     <sb:reference id="sref205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.D.</ce:given-name>
                                 <ce:surname>Tardiff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Roger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cassiano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.L.</ce:given-name>
                                 <ce:surname>Roth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Cimbora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>McKinnon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Peterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Douce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Dorweiler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Davis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Hess</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ostanin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.I.</ce:given-name>
                                 <ce:surname>Papac</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Baichwal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>McAlexander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Willardsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Saunders</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hoarau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.V.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Wettstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.O.</ce:given-name>
                                 <ce:surname>Carlson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.L.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2267</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib207">
                     <ce:label>[207]</ce:label>
                     <sb:reference id="sref206">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.V.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hoarau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bursavich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Slattum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gerrish</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yager</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Saunders</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shenderovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.L.</ce:given-name>
                                 <ce:surname>Roth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>McKinnon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Cimbora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Bradford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Reeves</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Patton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.I.</ce:given-name>
                                 <ce:surname>Papac</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.L.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.O.</ce:given-name>
                                 <ce:surname>Carlson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4377</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib208">
                     <ce:label>[208]</ce:label>
                     <sb:reference id="sref207">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Luxami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Paul</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Purine-benzimidazole hybrids: Synthesis, single crystal determination and inÂ vitro evaluation of antitumor activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>93</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>414</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib209">
                     <ce:label>[209]</ce:label>
                     <sb:reference id="sref208">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Conejo-GarcÃ­a</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>GarcÃ­a-RubiÃ±o</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Marchal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>NÃºÃ±ez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>RamÃ­rez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Cimino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>GarcÃ­a</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>ArÃ¡nega</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Gallo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Campos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and anticancer activity of (RS)-9-(2,3-dihydro-1,4-benzoxaheteroin-2- ylmethyl)-9H-purines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3795</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib210">
                     <ce:label>[210]</ce:label>
                     <sb:reference id="sref209">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>NÃºÃ±ez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>DÃ­az-GavilÃ¡n</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Conejo-GarcÃ­a</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2614</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib211">
                     <ce:label>[211]</ce:label>
                     <sb:reference id="sref210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Marchal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Carrasco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ramirez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>JimÃ©nez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Olmedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Peran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Agil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Conejo-GarcÃ­a</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Cruz-LÃ³pez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Campos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>GarcÃ­a</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNÎ± triggering apoptosis, autophagy and senescence</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Des. Dev. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1301</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib212">
                     <ce:label>[212]</ce:label>
                     <sb:reference id="sref211">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mehndiratta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yadav</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.S.</ce:given-name>
                                 <ce:surname>Bedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nepali</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Purine analogues as kinase inhibitors: a review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Recent Pat. Anti-Cancer Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>308</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>